cancer.type	eQTL.type	tagSNP	LD	SNP.ID	SNP.position.hg19	Gene.symbol	Gene.position.hg19	Beta	t-stat	P-value	GWAS-Traits	
OV	cis	1	rs10008757	chr4:76903036	NAAA	chr4:76831809-76862166:-	-0.28	-4.8	2.61E-6	Longevity	
OV	cis	1	rs10009541	chr4:17682218	LAP3	chr4:17578927-17609590:+	0.25	4.16	4.25E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10011865	chr4:17645710	LAP3	chr4:17578927-17609590:+	-0.26	-4.59	6.73E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10012335	chr4:17628630	LAP3	chr4:17578927-17609590:+	-0.25	-4.26	2.76E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1001373	chr1:171684506	VAMP4	chr1:171669298-171711214:-	0.38	4.67	4.66E-6	Hippocampal atrophy	
OV	cis	1	rs10019856	chr4:17615742	LAP3	chr4:17578927-17609590:+	-0.24	-3.98	8.66E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10021364	chr4:310691	ZNF718	chr4:53272-156488:+	-0.41	-3.98	8.82E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs1002676	chr3:38444932	LOC100128640	chr3:38492524-38496311:-	-0.24	-3.98	8.77E-5	Electrocardiographic conduction measures	
OV	cis	1	rs10027325	chr4:282608	ZNF718	chr4:53272-156488:+	0.41	4.7	4.14E-6	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs10032326	chr4:17630717	LAP3	chr4:17578927-17609590:+	-0.25	-4.22	3.25E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1003719	chr21:38491095	PIGP	chr21:38437664-38445458:-	-0.32	-5.79	1.93E-8	Eye color traits	
OV	cis	1	rs10051747	chr5:56083289	C5orf35	chr5:56205103-56213010:+	0.71	8.99	3.86E-17	Type 2 diabetes	
OV	cis	1	rs10069964	chr5:101947692	C5orf30	chr5:102594442-102614361:+	-0.42	-3.9	0.000119	Crohn's disease	
OV	cis	1	rs10069964	chr5:101947692	GIN1	chr5:102421704-102455842:-	-0.52	-5.63	4.39E-8	Crohn's disease	
OV	cis	1	rs10069964	chr5:101947692	NUDT12	chr5:102884557-102898490:-	-0.52	-5.25	3.0E-7	Crohn's disease	
OV	cis	1	rs10069964	chr5:101947692	PPIP5K2	chr5:102455958-102538907:+	-0.45	-4.77	2.92E-6	Crohn's disease	
OV	cis	1	rs1008374	chr4:17683219	LAP3	chr4:17578927-17609590:+	-0.24	-4.08	5.94E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1008375	chr4:17682834	LAP3	chr4:17578927-17609590:+	-0.23	-3.99	8.37E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10097215	chr8:2506899	ARHGEF10	chr8:1772149-1906806:+	0.38	4.86	1.96E-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	
OV	cis	1	rs10097215	chr8:2506899	CLN8	chr8:1711870-1734735:+	0.38	4.35	1.95E-5	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	
OV	cis	1	rs1011054	chr4:120202387	METTL14	chr4:119606574-119632075:+	0.33	4.54	8.25E-6	Corneal astigmatism	
OV	cis	1	rs10117059	chr9:123653477	LOC253039	chr9:123605320-123616644:+	-0.27	-3.94	0.000102	Rheumatoid arthritis	
OV	cis	1	rs10134944	chr14:58119196	EXOC5	chr14:57669196-57735617:-	-0.37	-4.16	4.21E-5	Bipolar disorder	
OV	cis	1	rs10140433	chr14:74659989	LIN52	chr14:74551656-74667117:+	-0.24	-3.86	0.000142	Common traits (Other)	
OV	cis	1	rs10157597	chr1:45990278	CCDC163P	chr1:45960581-45965646:-	-0.98	-16.51	4.3E-43	Homocysteine levels	
OV	cis	1	rs10157597	chr1:45990278	MMACHC	chr1:45965856-45976737:+	-0.3	-4.15	4.38E-5	Homocysteine levels	
OV	cis	1	rs10164319	chr19:18569833	SSBP4	chr19:18530221-18545371:+	-0.31	-3.99	8.44E-5	Breast cancer	
OV	cis	1	rs10164323	chr19:18569492	SSBP4	chr19:18530221-18545371:+	-0.35	-4.47	1.15E-5	Breast cancer	
OV	cis	1	rs1016669	chr3:41894440	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs10169714	chr2:73808773	ALMS1P	chr2:73872046-73912692:+	0.37	5.8	1.84E-8	Metabolite levels	
OV	cis	1	rs10177607	chr2:240226439	MGC16025	chr2:240115027-240117153:-	0.45	4.17	4.11E-5	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs10177970	chr2:37512968	CEBPZ	chr2:37428778-37458740:-	0.28	4.51	9.68E-6	Chronic lymphocytic leukemia	
OV	cis	1	rs10178409	chr2:73855507	ALMS1P	chr2:73872046-73912692:+	0.36	5.14	5.08E-7	Urinary metabolites	
OV	cis	1	rs10178975	chr2:37514564	CEBPZ	chr2:37428778-37458740:-	-0.28	-4.41	1.51E-5	Chronic lymphocytic leukemia	
OV	cis	1	rs10179134	chr2:73637519	ALMS1P	chr2:73872046-73912692:+	0.39	5.84	1.46E-8	Metabolite levels	
OV	cis	1	rs1018184	chr6:86648475	SNHG5	chr6:86386726-86388451:-	0.65	10.99	1.49E-23	Response to antipsychotic treatment	
OV	cis	1	rs10183592	chr2:240230769	MGC16025	chr2:240115027-240117153:-	0.56	4.79	2.75E-6	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs10184268	chr2:73627044	ALMS1P	chr2:73872046-73912692:+	0.4	6.17	2.4E-9	Metabolite levels	
OV	cis	1	rs10187192	chr2:73713500	ALMS1P	chr2:73872046-73912692:+	0.36	5.32	2.12E-7	Metabolite levels	
OV	cis	1	rs10187458	chr2:5975242	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs10187762	chr2:5975505	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs10190219	chr2:73658331	ALMS1P	chr2:73872046-73912692:+	0.4	6	6.14E-9	Metabolite levels	
OV	cis	1	rs1019217	chr11:22842622	SVIP	chr11:22843600-22851382:-	0.26	3.91	0.000117	Dialysis-related mortality	
OV	cis	1	rs10193373	chr2:281886	SH3YL1	chr2:218138-264810:-	-0.53	-7.49	9.14E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs10200850	chr2:240234901	MGC16025	chr2:240115027-240117153:-	0.57	4.5	9.96E-6	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs10204505	chr2:240225455	MGC16025	chr2:240115027-240117153:-	0.64	4.99	1.05E-6	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs10207220	chr2:73785046	ALMS1P	chr2:73872046-73912692:+	0.37	5.82	1.59E-8	Metabolite levels	
OV	cis	1	rs10212536	chr3:41827026	ULK4	chr3:41288091-42003660:-	0.6	7.68	2.8E-13	Diastolic blood pressure	
OV	cis	1	rs10216533	chr8:143763690	LY6K	chr8:143781529-143785582:+	0.29	4.03	7.33E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs10216533	chr8:143763690	PSCA	chr8:143761875-143764142:+	0.28	4.42	1.42E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs10218795	chr1:145416056	NOTCH2NL	chr1:145209111-145295525:+	1.03	6.41	6.26E-10	Coronary heart disease	
OV	cis	1	rs10222496	chr3:114694757	ZNF80	chr3:113953478-113956425:-	0.4	4.36	1.81E-5	Type 2 diabetes	
OV	cis	1	rs10234309	chr7:135311167	PL-5283	chr7:135347221-135378160:+	0.57	8.01	3.13E-14	Paget's disease	
OV	cis	1	rs10234309	chr7:135311167	SLC13A4	chr7:135365993-135412933:-	-0.44	-5.8	1.81E-8	Paget's disease	
OV	cis	1	rs10241783	chr7:27857520	TAX1BP1	chr7:27778992-27869384:+	0.39	4.71	3.91E-6	Hypospadias	
OV	cis	1	rs10247856	chr7:36400826	KIAA0895	chr7:36363759-36429734:-	0.41	4.55	8.15E-6	Systolic blood pressure	
OV	cis	1	rs1025646	chr3:41754422	ULK4	chr3:41288091-42003660:-	0.56	7.2	5.78E-12	Diastolic blood pressure	
OV	cis	1	rs10256972	chr7:1039003	ZFAND2A	chr7:1192544-1199855:-	0.37	5.93	9.13E-9	Longevity;Endometriosis	
OV	cis	1	rs1028449	chr14:35512995	KIAA0391	chr14:35591776-35786673:+	0.37	4.07	6.14E-5	Atopic dermatitis	
OV	cis	1	rs1036554	chr2:86236099	LOC90784	chr2:86247339-86250991:-	-0.65	-4.95	1.28E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs1039664	chr7:65449716	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.77E-6	Diabetic kidney disease	
OV	cis	1	rs10403249	chr19:18604942	SSBP4	chr19:18530221-18545371:+	-0.32	-4.16	4.2E-5	Breast cancer	
OV	cis	1	rs10405636	chr19:18538742	SSBP4	chr19:18530221-18545371:+	-0.34	-4.38	1.69E-5	Breast cancer	
OV	cis	1	rs10409483	chr19:18590223	SSBP4	chr19:18530221-18545371:+	-0.34	-4.39	1.58E-5	Breast cancer	
OV	cis	1	rs10409505	chr19:18590251	SSBP4	chr19:18530221-18545371:+	-0.34	-4.39	1.58E-5	Breast cancer	
OV	cis	1	rs10411009	chr19:18606266	SSBP4	chr19:18530221-18545371:+	-0.3	-3.87	0.000138	Breast cancer	
OV	cis	1	rs10413237	chr19:18548249	SSBP4	chr19:18530221-18545371:+	-0.34	-4.23	3.24E-5	Breast cancer	
OV	cis	1	rs10421887	chr19:44294849	LYPD5	chr19:44300080-44324808:-	0.28	4.2	3.59E-5	Breast cancer	
OV	cis	1	rs10421887	chr19:44294849	ZNF155	chr19:44488355-44502477:+	0.26	3.87	0.000134	Breast cancer	
OV	cis	1	rs10425982	chr19:18586519	SSBP4	chr19:18530221-18545371:+	-0.32	-4.03	7.32E-5	Breast cancer	
OV	cis	1	rs10427083	chr19:18550276	SSBP4	chr19:18530221-18545371:+	-0.34	-4.32	2.14E-5	Breast cancer	
OV	cis	1	rs10431505	chr12:58178589	FAM119B	chr12:58166383-58176323:+	0.34	4.95	1.3E-6	Multiple sclerosis	
OV	cis	1	rs10431505	chr12:58178589	TSFM	chr12:58176536-58191367:+	-0.33	-5.79	1.94E-8	Multiple sclerosis	
OV	cis	1	rs1043806	chr1:147229299	ACP6	chr1:147119168-147142634:-	-0.36	-4.02	7.43E-5	Cognitive performance	
OV	cis	1	rs10440301	chr4:17663199	LAP3	chr4:17578927-17609590:+	-0.27	-4.64	5.42E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10442	chr19:18545341	SSBP4	chr19:18530221-18545371:+	-0.34	-4.32	2.14E-5	Breast cancer	
OV	cis	1	rs1044717	chr1:45976587	CCDC163P	chr1:45960581-45965646:-	-1.01	-17.37	3.28E-46	Homocysteine levels	
OV	cis	1	rs1044717	chr1:45976587	MMACHC	chr1:45965856-45976737:+	-0.32	-4.29	2.47E-5	Homocysteine levels	
OV	cis	1	rs10454142	chr2:48646399	KLRAQ1	chr2:48667908-48742524:+	0.31	4.42	1.43E-5	Sex hormone-binding globulin levels	
OV	cis	1	rs10455158	chr6:86672825	SNHG5	chr6:86386726-86388451:-	-0.65	-10.9	2.92E-23	Response to antipsychotic treatment	
OV	cis	1	rs1045531	chr8:143763547	LY6K	chr8:143781529-143785582:+	0.29	3.96	9.46E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs1045531	chr8:143763547	PSCA	chr8:143761875-143764142:+	0.28	4.33	2.09E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs10455449	chr6:86592226	SNHG5	chr6:86386726-86388451:-	-0.67	-10.76	8.69E-23	Response to antipsychotic treatment	
OV	cis	1	rs10455455	chr6:86670214	SNHG5	chr6:86386726-86388451:-	-0.69	-11.46	3.7E-25	Response to antipsychotic treatment	
OV	cis	1	rs10455456	chr6:86670322	SNHG5	chr6:86386726-86388451:-	-0.66	-11	1.35E-23	Response to antipsychotic treatment	
OV	cis	1	rs1045547	chr8:143763757	LY6K	chr8:143781529-143785582:+	0.29	3.96	9.46E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs1045547	chr8:143763757	PSCA	chr8:143761875-143764142:+	0.28	4.33	2.09E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs1045574	chr8:143763958	LY6K	chr8:143781529-143785582:+	0.32	4.33	2.07E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs1045605	chr8:143764101	LY6K	chr8:143781529-143785582:+	0.3	4.16	4.28E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs1045605	chr8:143764101	PSCA	chr8:143761875-143764142:+	0.28	4.45	1.23E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs10456622	chr6:49396453	MUT	chr6:49398994-49431031:-	0.3	4.59	6.58E-6	Folate pathway vitamin levels	
OV	cis	1	rs1046073	chr20:25281333	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1046073	chr20:25281333	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs10461617	chr5:56104308	C5orf35	chr5:56205103-56213010:+	0.68	9.12	1.57E-17	Type 2 diabetes	
OV	cis	1	rs10470686	chr3:48449956	TREX1	chr3:48501186-48509043:+	-0.28	-5.38	1.62E-7	Longevity	
OV	cis	1	rs1047171	chr20:25428786	ABHD12	chr20:25275380-25371477:-	0.41	6.1	3.53E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1047171	chr20:25428786	FAM182B	chr20:25744102-25848786:-	0.33	5.1	6.36E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs10489249	chr1:171714521	VAMP4	chr1:171669298-171711214:-	0.41	5.12	5.71E-7	Hippocampal atrophy	
OV	cis	1	rs10489251	chr1:171717534	VAMP4	chr1:171669298-171711214:-	0.42	5.14	5.21E-7	Hippocampal atrophy	
OV	cis	1	rs10494874	chr1:205754688	PM20D1	chr1:205797154-205819245:-	-0.32	-3.95	0.000101	Prostate-specific antigen levels	
OV	cis	1	rs10498958	chr6:86649705	SNHG5	chr6:86386726-86388451:-	0.69	11.36	8.08E-25	Response to antipsychotic treatment	
OV	cis	1	rs10509744	chr10:102271579	SEC31B	chr10:102246403-102289636:-	-0.3	-4.52	9.11E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10510761	chr3:52965255	SFMBT1	chr3:52938628-53080070:-	0.56	5.34	1.98E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs10514604	chr16:84446384	CRISPLD2	chr16:84853587-84943116:+	-0.18	-4.09	5.62E-5	Attention deficit hyperactivity disorder	
OV	cis	1	rs1052501	chr3:41925398	ULK4	chr3:41288091-42003660:-	-0.61	-8.09	1.89E-14	Diastolic blood pressure	
OV	cis	1	rs1052676	chr1:171673054	VAMP4	chr1:171669298-171711214:-	0.38	4.65	5.23E-6	Hippocampal atrophy	
OV	cis	1	rs1054399	chr10:102312565	SEC31B	chr10:102246403-102289636:-	-0.28	-4.03	7.1E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs1055583	chr10:50226334	PARG	chr10:51026327-51729967:-	-0.32	-3.93	0.000109	Migraine with aura	
OV	cis	1	rs10736426	chr1:45984353	CCDC163P	chr1:45960581-45965646:-	0.89	14.89	3.1E-37	Homocysteine levels	
OV	cis	1	rs10736426	chr1:45984353	MMACHC	chr1:45965856-45976737:+	0.3	4.33	2.05E-5	Homocysteine levels	
OV	cis	1	rs10747783	chr12:58176614	FAM119B	chr12:58166383-58176323:+	0.35	5.13	5.4E-7	Multiple sclerosis	
OV	cis	1	rs10747783	chr12:58176614	TSFM	chr12:58176536-58191367:+	-0.35	-6.03	5.18E-9	Multiple sclerosis	
OV	cis	1	rs10749860	chr1:46328210	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.93	2.94E-11	Body mass index	
OV	cis	1	rs10758892	chr9:7734250	C9orf123	chr9:7796493-7799799:-	-0.33	-3.86	0.000144	Myopia (pathological)	
OV	cis	1	rs10760118	chr9:123641616	LOC253039	chr9:123605320-123616644:+	-0.29	-4.3	2.37E-5	Rheumatoid arthritis	
OV	cis	1	rs10766969	chr11:22849952	SVIP	chr11:22843600-22851382:-	-0.29	-4.38	1.69E-5	Dialysis-related mortality	
OV	cis	1	rs1077889	chr20:25267893	ABHD12	chr20:25275380-25371477:-	0.41	5.98	7.02E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1077889	chr20:25267893	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.89E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs10783847	chr12:58196447	FAM119B	chr12:58166383-58176323:+	0.35	5.16	4.69E-7	Multiple sclerosis	
OV	cis	1	rs10783847	chr12:58196447	TSFM	chr12:58176536-58191367:+	-0.35	-5.99	6.48E-9	Multiple sclerosis	
OV	cis	1	rs10783848	chr12:58196528	FAM119B	chr12:58166383-58176323:+	0.35	5.16	4.69E-7	Multiple sclerosis	
OV	cis	1	rs10783848	chr12:58196528	TSFM	chr12:58176536-58191367:+	-0.35	-5.99	6.48E-9	Multiple sclerosis	
OV	cis	1	rs10786596	chr10:102282126	SEC31B	chr10:102246403-102289636:-	-0.3	-4.51	9.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10786597	chr10:102291287	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10786598	chr10:102291579	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10789475	chr1:46304177	CCDC163P	chr1:45960581-45965646:-	-0.47	-7.02	1.75E-11	Body mass index	
OV	cis	1	rs10789481	chr1:46383583	CCDC163P	chr1:45960581-45965646:-	-0.47	-6.97	2.25E-11	Body mass index	
OV	cis	1	rs10789487	chr1:46420221	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs1078968	chr3:53123486	RFT1	chr3:53122503-53164470:-	-0.34	-4.77	3.0E-6	Height	
OV	cis	1	rs1080267	chr1:169176469	C1orf156	chr1:169761675-169764031:-	0.5	4.18	3.99E-5	QT interval	
OV	cis	1	rs10804632	chr3:134294501	ANAPC13	chr3:134196547-134204865:-	0.39	5.34	1.93E-7	Height	
OV	cis	1	rs10805357	chr4:17652352	LAP3	chr4:17578927-17609590:+	-0.26	-4.6	6.54E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10805358	chr4:17652450	LAP3	chr4:17578927-17609590:+	-0.25	-4.27	2.63E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1080698	chr10:102295114	SEC31B	chr10:102246403-102289636:-	-0.28	-4.21	3.39E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10818480	chr9:123643170	LOC253039	chr9:123605320-123616644:+	-0.27	-3.98	8.75E-5	Rheumatoid arthritis	
OV	cis	1	rs10833824	chr11:22847485	SVIP	chr11:22843600-22851382:-	-0.33	-5.16	4.78E-7	Dialysis-related mortality	
OV	cis	1	rs10833825	chr11:22850753	SVIP	chr11:22843600-22851382:-	-0.27	-3.98	8.79E-5	Dialysis-related mortality	
OV	cis	1	rs1085243	chr1:46544768	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.16	7.23E-12	Body mass index	
OV	cis	1	rs1085244	chr1:46563680	CCDC163P	chr1:45960581-45965646:-	-0.47	-7.07	1.28E-11	Body mass index	
OV	cis	1	rs10865914	chr3:41919499	ULK4	chr3:41288091-42003660:-	-0.61	-8.06	2.38E-14	Diastolic blood pressure	
OV	cis	1	rs10877012	chr12:58162085	FAM119B	chr12:58166383-58176323:+	0.36	5.23	3.42E-7	Multiple sclerosis	
OV	cis	1	rs10877012	chr12:58162085	TSFM	chr12:58176536-58191367:+	-0.35	-5.98	6.69E-9	Multiple sclerosis	
OV	cis	1	rs10877013	chr12:58165085	FAM119B	chr12:58166383-58176323:+	0.33	4.88	1.8E-6	Multiple sclerosis	
OV	cis	1	rs10877013	chr12:58165085	TSFM	chr12:58176536-58191367:+	-0.32	-5.49	8.86E-8	Multiple sclerosis	
OV	cis	1	rs10877014	chr12:58167661	FAM119B	chr12:58166383-58176323:+	0.32	4.74	3.5E-6	Multiple sclerosis	
OV	cis	1	rs10877014	chr12:58167661	TSFM	chr12:58176536-58191367:+	-0.33	-5.73	2.57E-8	Multiple sclerosis	
OV	cis	1	rs10877015	chr12:58167788	FAM119B	chr12:58166383-58176323:+	0.35	5.11	5.89E-7	Multiple sclerosis	
OV	cis	1	rs10877015	chr12:58167788	TSFM	chr12:58176536-58191367:+	-0.36	-6.2	2.08E-9	Multiple sclerosis	
OV	cis	1	rs10877019	chr12:58172929	FAM119B	chr12:58166383-58176323:+	-0.4	-5.7	3.1E-8	Multiple sclerosis	
OV	cis	1	rs10877019	chr12:58172929	TSFM	chr12:58176536-58191367:+	0.34	5.61	4.93E-8	Multiple sclerosis	
OV	cis	1	rs10883503	chr10:102275504	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.21E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883504	chr10:102280687	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.21E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883505	chr10:102280772	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883506	chr10:102289743	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883507	chr10:102291275	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883508	chr10:102294413	SEC31B	chr10:102246403-102289636:-	-0.28	-4.21	3.51E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883509	chr10:102296461	SEC31B	chr10:102246403-102289636:-	-0.26	-3.96	9.71E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883510	chr10:102297018	SEC31B	chr10:102246403-102289636:-	-0.27	-3.89	0.000126	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883511	chr10:102299407	SEC31B	chr10:102246403-102289636:-	-0.27	-3.97	9.18E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10883512	chr10:102308516	SEC31B	chr10:102246403-102289636:-	-0.28	-4.12	4.98E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs10890352	chr1:46283628	CCDC163P	chr1:45960581-45965646:-	-0.47	-7	1.97E-11	Body mass index	
OV	cis	1	rs10890354	chr1:46305347	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.37E-11	Body mass index	
OV	cis	1	rs10890361	chr1:46346234	CCDC163P	chr1:45960581-45965646:-	-0.38	-5.76	2.29E-8	Body mass index	
OV	cis	1	rs10890363	chr1:46356148	CCDC163P	chr1:45960581-45965646:-	0.44	6.64	1.61E-10	Body mass index	
OV	cis	1	rs10890383	chr1:46588503	CCDC163P	chr1:45960581-45965646:-	-0.47	-6.76	8.35E-11	Body mass index	
OV	cis	1	rs10903	chr1:171673236	VAMP4	chr1:171669298-171711214:-	0.39	4.75	3.28E-6	Hippocampal atrophy	
OV	cis	1	rs10913475	chr1:171650139	VAMP4	chr1:171669298-171711214:-	0.37	4.55	7.87E-6	Hippocampal atrophy	
OV	cis	1	rs10913489	chr1:171653384	VAMP4	chr1:171669298-171711214:-	0.35	4.22	3.3E-5	Hippocampal atrophy	
OV	cis	1	rs10913490	chr1:171653401	VAMP4	chr1:171669298-171711214:-	0.35	4.22	3.3E-5	Hippocampal atrophy	
OV	cis	1	rs10913511	chr1:171668951	VAMP4	chr1:171669298-171711214:-	0.38	4.91	1.55E-6	Hippocampal atrophy	
OV	cis	1	rs10913514	chr1:171670823	VAMP4	chr1:171669298-171711214:-	0.38	4.65	5.23E-6	Hippocampal atrophy	
OV	cis	1	rs10913529	chr1:171679465	VAMP4	chr1:171669298-171711214:-	0.39	4.7	4.07E-6	Hippocampal atrophy	
OV	cis	1	rs10913565	chr1:171706706	VAMP4	chr1:171669298-171711214:-	0.38	4.64	5.47E-6	Hippocampal atrophy	
OV	cis	1	rs10913582	chr1:171715585	VAMP4	chr1:171669298-171711214:-	0.41	5.46	1.06E-7	Hippocampal atrophy	
OV	cis	1	rs10935120	chr3:134233092	ANAPC13	chr3:134196547-134204865:-	-0.37	-5.34	1.9E-7	Height	
OV	cis	1	rs10938353	chr4:44582487	GUF1	chr4:44680433-44702696:+	-0.36	-3.96	9.53E-5	Body mass index	
OV	cis	1	rs10939740	chr4:17617490	LAP3	chr4:17578927-17609590:+	-0.24	-4.14	4.6E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10939742	chr4:17659936	LAP3	chr4:17578927-17609590:+	-0.27	-4.71	3.99E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10939743	chr4:17662731	LAP3	chr4:17578927-17609590:+	-0.26	-4.56	7.62E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10939744	chr4:17664473	LAP3	chr4:17578927-17609590:+	-0.26	-4.55	8.16E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs10944161	chr6:86630376	SNHG5	chr6:86386726-86388451:-	-0.65	-11.02	1.16E-23	Response to antipsychotic treatment	
OV	cis	1	rs10944169	chr6:86683036	SNHG5	chr6:86386726-86388451:-	-0.66	-10.52	5.36E-22	Response to antipsychotic treatment	
OV	cis	1	rs10944170	chr6:86685469	SNHG5	chr6:86386726-86388451:-	-0.66	-11.11	5.77E-24	Response to antipsychotic treatment	
OV	cis	1	rs10966	chr20:25282944	ABHD12	chr20:25275380-25371477:-	0.41	5.99	6.6E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs10966	chr20:25282944	FAM182B	chr20:25744102-25848786:-	0.33	5.13	5.53E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs10972341	chr9:35141705	ATP8B5P	chr9:35406752-35483026:+	-0.27	-3.99	8.51E-5	Weight	
OV	cis	1	rs11000019	chr10:73591530	ANAPC16	chr10:73975806-73995616:+	0.56	4.94	1.37E-6	Asthma (childhood onset)	
OV	cis	1	rs11000019	chr10:73591530	ASCC1	chr10:73856278-73976892:-	0.59	4.94	1.36E-6	Asthma (childhood onset)	
OV	cis	1	rs11000019	chr10:73591530	CBARA1	chr10:74127098-74385899:-	0.58	4.43	1.33E-5	Asthma (childhood onset)	
OV	cis	1	rs11000019	chr10:73591530	DNAJB12	chr10:74092588-74114907:-	0.57	4.66	5.01E-6	Asthma (childhood onset)	
OV	cis	1	rs11000019	chr10:73591530	PCBD1	chr10:72643267-72648541:-	0.43	4.94	1.35E-6	Asthma (childhood onset)	
OV	cis	1	rs11000019	chr10:73591530	PSAP	chr10:73576056-73611082:-	0.53	5.13	5.53E-7	Asthma (childhood onset)	
OV	cis	1	rs11026804	chr11:22841582	SVIP	chr11:22843600-22851382:-	0.33	5.08	7.09E-7	Dialysis-related mortality	
OV	cis	1	rs11062040	chr12:2091257	ERC1	chr12:1100404-1605099:+	0.25	4.51	9.48E-6	Response to gemcitabine in pancreatic cancer	
OV	cis	1	rs11087520	chr20:25436827	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs11087520	chr20:25436827	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs11087521	chr20:25440648	ABHD12	chr20:25275380-25371477:-	0.39	5.67	3.68E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs11087521	chr20:25440648	FAM182B	chr20:25744102-25848786:-	0.33	5.11	6.03E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1109227	chr3:48479207	TREX1	chr3:48501186-48509043:+	-0.27	-5.12	5.65E-7	Longevity	
OV	cis	1	rs11100	chr20:25281184	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs11100	chr20:25281184	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1112137	chr1:247215375	ZNF670	chr1:247200087-247242069:-	-0.32	-4.4	1.53E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs11121533	chr1:10292888	PGD	chr1:10459085-10480200:+	0.27	3.98	8.64E-5	Hepatocellular carcinoma	
OV	cis	1	rs11123170	chr2:113978940	LOC654433	chr2:113993107-114024579:+	-0.39	-5.77	2.17E-8	Renal function-related traits (BUN)	
OV	cis	1	rs11125529	chr2:54475866	C2orf73	chr2:54558071-54588714:+	-0.32	-4.48	1.1E-5	Telomere length	
OV	cis	1	rs11127188	chr2:28972852	TRMT61B	chr2:29072690-29093175:-	-0.32	-4.28	2.57E-5	Body mass index	
OV	cis	1	rs11130170	chr3:48449897	TREX1	chr3:48501186-48509043:+	-0.28	-5.38	1.62E-7	Longevity	
OV	cis	1	rs11130171	chr3:48462461	TREX1	chr3:48501186-48509043:+	-0.27	-5.06	7.56E-7	Longevity	
OV	cis	1	rs11130338	chr3:53120924	RFT1	chr3:53122503-53164470:-	-0.33	-4.62	5.86E-6	Height	
OV	cis	1	rs111315781	chr2:201738724	PPIL3	chr2:201735680-201753999:-	-0.64	-8.34	3.43E-15	Triptolide cytotoxicity	
OV	cis	1	rs1114380	chr2:73804708	ALMS1P	chr2:73872046-73912692:+	0.37	5.8	1.84E-8	Metabolite levels	
OV	cis	1	rs11156875	chr14:35619816	KIAA0391	chr14:35591776-35786673:+	0.4	4.52	9.26E-6	Atopic dermatitis	
OV	cis	1	rs11156875	chr14:35619816	PPP2R3C	chr14:35554679-35591679:-	0.39	4.68	4.56E-6	Atopic dermatitis	
OV	cis	1	rs111641740	chr20:33707177	CPNE1	chr20:34213968-34262539:-	0.43	3.98	8.81E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs11172333	chr12:58170335	FAM119B	chr12:58166383-58176323:+	0.34	5	1.01E-6	Multiple sclerosis	
OV	cis	1	rs11172333	chr12:58170335	TSFM	chr12:58176536-58191367:+	-0.37	-6.42	5.85E-10	Multiple sclerosis	
OV	cis	1	rs11172335	chr12:58175201	FAM119B	chr12:58166383-58176323:+	0.37	5.41	1.36E-7	Multiple sclerosis	
OV	cis	1	rs11172335	chr12:58175201	TSFM	chr12:58176536-58191367:+	-0.37	-6.32	1.05E-9	Multiple sclerosis	
OV	cis	1	rs11172342	chr12:58187758	FAM119B	chr12:58166383-58176323:+	0.37	5.41	1.36E-7	Multiple sclerosis	
OV	cis	1	rs11172342	chr12:58187758	TSFM	chr12:58176536-58191367:+	-0.37	-6.32	1.05E-9	Multiple sclerosis	
OV	cis	1	rs11172343	chr12:58188157	FAM119B	chr12:58166383-58176323:+	0.37	5.41	1.36E-7	Multiple sclerosis	
OV	cis	1	rs11172343	chr12:58188157	TSFM	chr12:58176536-58191367:+	-0.37	-6.32	1.05E-9	Multiple sclerosis	
OV	cis	1	rs11172344	chr12:58193448	FAM119B	chr12:58166383-58176323:+	0.35	5.16	4.69E-7	Multiple sclerosis	
OV	cis	1	rs11172344	chr12:58193448	TSFM	chr12:58176536-58191367:+	-0.35	-5.99	6.48E-9	Multiple sclerosis	
OV	cis	1	rs11172349	chr12:58212528	FAM119B	chr12:58166383-58176323:+	0.37	5.34	1.94E-7	Multiple sclerosis	
OV	cis	1	rs11172349	chr12:58212528	TSFM	chr12:58176536-58191367:+	-0.36	-6.19	2.12E-9	Multiple sclerosis	
OV	cis	1	rs11172351	chr12:58213485	FAM119B	chr12:58166383-58176323:+	0.37	5.29	2.53E-7	Multiple sclerosis	
OV	cis	1	rs11172351	chr12:58213485	TSFM	chr12:58176536-58191367:+	-0.36	-6.06	4.51E-9	Multiple sclerosis	
OV	cis	1	rs11190466	chr10:102061908	SLC25A28	chr10:101370275-101418994:-	0.49	4.59	6.69E-6	Obesity-related traits	
OV	cis	1	rs11190569	chr10:102227409	SEC31B	chr10:102246403-102289636:-	-0.25	-4.01	7.7E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190587	chr10:102266638	SEC31B	chr10:102246403-102289636:-	-0.29	-4.21	3.41E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190589	chr10:102275471	SEC31B	chr10:102246403-102289636:-	-0.26	-3.96	9.41E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190592	chr10:102291059	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190595	chr10:102291761	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190596	chr10:102293238	SEC31B	chr10:102246403-102289636:-	-0.26	-3.87	0.000135	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190597	chr10:102293676	SEC31B	chr10:102246403-102289636:-	-0.27	-4.12	5.03E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190599	chr10:102295420	SEC31B	chr10:102246403-102289636:-	-0.27	-4.12	5.03E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190601	chr10:102296730	SEC31B	chr10:102246403-102289636:-	-0.26	-3.97	9.01E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190602	chr10:102297256	SEC31B	chr10:102246403-102289636:-	-0.26	-3.96	9.48E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11190607	chr10:102303614	SEC31B	chr10:102246403-102289636:-	-0.28	-4.18	3.95E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs11191419	chr10:104612335	C10orf32	chr10:104613967-104624718:+	-0.27	-3.88	0.000133	Schizophrenia	
OV	cis	1	rs11201660	chr10:81854531	LOC219347	chr10:81805991-81838949:-	-0.41	-4.49	1.03E-5	Chronic obstructive pulmonary disease-related biomarkers	
OV	cis	1	rs11201799	chr10:81881954	LOC219347	chr10:81805991-81838949:-	-0.41	-4.27	2.74E-5	Chronic obstructive pulmonary disease-related biomarkers	
OV	cis	1	rs1121089	chr4:17676476	LAP3	chr4:17578927-17609590:+	-0.24	-4.09	5.76E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1121090	chr4:17676437	LAP3	chr4:17578927-17609590:+	-0.24	-4.09	5.76E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1121091	chr4:17676386	LAP3	chr4:17578927-17609590:+	-0.24	-4.09	5.76E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs11211132	chr1:45990516	CCDC163P	chr1:45960581-45965646:-	-0.98	-16.51	4.3E-43	Homocysteine levels	
OV	cis	1	rs11211132	chr1:45990516	MMACHC	chr1:45965856-45976737:+	-0.3	-4.15	4.38E-5	Homocysteine levels	
OV	cis	1	rs11211199	chr1:46287869	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.37E-11	Body mass index	
OV	cis	1	rs11211208	chr1:46334256	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.78	7.38E-11	Body mass index	
OV	cis	1	rs11211230	chr1:46406767	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs11211234	chr1:46438787	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs11211241	chr1:46452683	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs11223996	chr11:134626887	ACAD8	chr11:134123434-134135744:+	0.37	4.11	5.23E-5	Myopia (pathological)	
OV	cis	1	rs11223996	chr11:134626887	THYN1	chr11:134118175-134123260:-	0.32	4.04	7.04E-5	Myopia (pathological)	
OV	cis	1	rs112293138	chr1:171714002	VAMP4	chr1:171669298-171711214:-	0.4	5.02	9.42E-7	Hippocampal atrophy	
OV	cis	1	rs11242	chr3:53125922	RFT1	chr3:53122503-53164470:-	0.31	4.47	1.12E-5	Height	
OV	cis	1	rs11248009	chr4:220149	ZNF718	chr4:53272-156488:+	0.42	4.1	5.42E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11248013	chr4:311425	ZNF718	chr4:53272-156488:+	0.42	4.09	5.74E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs1125203	chr3:41760895	ULK4	chr3:41288091-42003660:-	0.61	8.21	8.56E-15	Diastolic blood pressure	
OV	cis	1	rs11292	chr10:102313607	SEC31B	chr10:102246403-102289636:-	-0.26	-3.91	0.000115	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs1133146	chr19:53666660	ZNF665	chr19:53666552-53696619:-	0.28	4.39	1.65E-5	Yu-Zhi constitution type in type 2 diabetes	
OV	cis	1	rs113347819	chr5:158240047	RNF145	chr5:158584419-158637061:-	0.41	3.99	8.4E-5	Hip circumference (psychosocial stress interaction)	
OV	cis	1	rs11344	chr16:29910518	LOC440356	chr16:29875004-29879374:+	-0.29	-4.22	3.29E-5	Response to taxane treatment (placlitaxel)	
OV	cis	1	rs1138273	chr3:134261437	ANAPC13	chr3:134196547-134204865:-	0.41	5.77	2.17E-8	Height	
OV	cis	1	rs113995589	chr3:53132372	SFMBT1	chr3:52938628-53080070:-	-0.42	-4.23	3.18E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs114031213	chr2:207619463	MDH1B	chr2:207598943-207630050:-	0.44	4.12	4.92E-5	Episodic memory	
OV	cis	1	rs114200987	chr14:35586916	KIAA0391	chr14:35591776-35786673:+	0.42	4.54	8.56E-6	Atopic dermatitis	
OV	cis	1	rs114200987	chr14:35586916	PPP2R3C	chr14:35554679-35591679:-	0.38	4.32	2.21E-5	Atopic dermatitis	
OV	cis	1	rs114490726	chr4:17680898	LAP3	chr4:17578927-17609590:+	-0.23	-3.95	9.8E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs114562844	chr3:52991584	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.31	2.24E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs1148004	chr12:75978677	GLIPR1L2	chr12:75784889-75825591:+	-0.31	-4.2	3.62E-5	Polycystic ovary syndrome	
OV	cis	1	rs114960066	chr3:41882323	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs114976176	chr2:264621	SH3YL1	chr2:218138-264810:-	-0.52	-7.33	2.6E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs11538349	chr7:65421871	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.17E-5	Diabetic kidney disease	
OV	cis	1	rs1154513	chr12:122391963	WDR66	chr12:122356480-122441830:+	-0.43	-4.34	1.99E-5	Urinary metabolites	
OV	cis	1	rs11553746	chr2:272203	SH3YL1	chr2:218138-264810:-	-0.55	-7.77	1.57E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs1157164	chr2:5974838	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs11576221	chr1:171653696	VAMP4	chr1:171669298-171711214:-	0.35	4.22	3.3E-5	Hippocampal atrophy	
OV	cis	1	rs11577073	chr1:171716724	VAMP4	chr1:171669298-171711214:-	-0.37	-4.86	1.94E-6	Hippocampal atrophy	
OV	cis	1	rs11577745	chr1:171720909	VAMP4	chr1:171669298-171711214:-	0.41	5.24	3.23E-7	Hippocampal atrophy	
OV	cis	1	rs11578699	chr1:171719769	VAMP4	chr1:171669298-171711214:-	0.42	5.14	5.21E-7	Hippocampal atrophy	
OV	cis	1	rs11579634	chr1:46466391	CCDC163P	chr1:45960581-45965646:-	0.47	6.97	2.33E-11	Body mass index	
OV	cis	1	rs11579698	chr1:171666922	VAMP4	chr1:171669298-171711214:-	0.32	3.95	9.93E-5	Hippocampal atrophy	
OV	cis	1	rs11580415	chr1:171666832	VAMP4	chr1:171669298-171711214:-	0.37	4.51	9.56E-6	Hippocampal atrophy	
OV	cis	1	rs11580522	chr1:171720978	VAMP4	chr1:171669298-171711214:-	-0.42	-5.3	2.35E-7	Hippocampal atrophy	
OV	cis	1	rs11583920	chr1:171683611	VAMP4	chr1:171669298-171711214:-	0.38	4.67	4.66E-6	Hippocampal atrophy	
OV	cis	1	rs115889150	chr2:207597807	MDH1B	chr2:207598943-207630050:-	0.44	3.89	0.000125	Episodic memory	
OV	cis	1	rs11589562	chr1:46466721	CCDC163P	chr1:45960581-45965646:-	0.34	5.06	7.71E-7	Body mass index	
OV	cis	1	rs11590680	chr1:171716574	VAMP4	chr1:171669298-171711214:-	0.41	5.12	5.71E-7	Hippocampal atrophy	
OV	cis	1	rs11590714	chr1:171716779	VAMP4	chr1:171669298-171711214:-	0.38	4.64	5.32E-6	Hippocampal atrophy	
OV	cis	1	rs11591579	chr10:45203117	ZNF22	chr10:45496273-45500776:+	0.38	5.41	1.38E-7	Parkinson's disease	
OV	cis	1	rs11625697	chr14:104464800	TDRD9	chr14:104394817-104519002:+	0.4	5.29	2.43E-7	Bipolar disorder	
OV	cis	1	rs11631963	chr15:83318202	AP3B2	chr15:83328034-83378635:-	0.24	4.03	7.25E-5	Schizophrenia	
OV	cis	1	rs11635252	chr15:91071774	FES	chr15:91427665-91439004:+	0.48	4.02	7.46E-5	Response to exercise (triglyceride levels)	
OV	cis	1	rs11637433	chr15:83321336	AP3B2	chr15:83328034-83378635:-	0.24	3.95	0.000101	Schizophrenia	
OV	cis	1	rs11645033	chr16:86485261	MAP1LC3B	chr16:87425801-87438379:+	0.6	4	8.02E-5	Corneal astigmatism	
OV	cis	1	rs116616340	chr3:53132371	SFMBT1	chr3:52938628-53080070:-	-0.42	-4.23	3.18E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11668269	chr19:22513960	ZNF98	chr19:22573899-22605148:-	0.26	3.86	0.000141	Telomere length	
OV	cis	1	rs11674602	chr2:73723185	ALMS1P	chr2:73872046-73912692:+	0.34	5.33	2.05E-7	Metabolite levels	
OV	cis	1	rs1167613	chr7:65487439	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs1167827	chr7:75163169	STAG3L1	chr7:74988447-75026250:+	-0.3	-4.58	7.12E-6	Body mass index	
OV	cis	1	rs11681497	chr2:242344333	SEPT2	chr2:242254723-242293439:+	0.67	5.77	2.15E-8	Chronic lymphocytic leukemia	
OV	cis	1	rs11688129	chr2:28952581	TRMT61B	chr2:29072690-29093175:-	0.3	3.94	0.000104	Body mass index	
OV	cis	1	rs11706035	chr3:53011868	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.29	2.47E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11706117	chr3:134212526	ANAPC13	chr3:134196547-134204865:-	0.4	5.5	8.48E-8	Height	
OV	cis	1	rs11707575	chr3:53113762	SFMBT1	chr3:52938628-53080070:-	-0.46	-4.74	3.49E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11707780	chr3:53084326	SFMBT1	chr3:52938628-53080070:-	0.46	5	1.01E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11708531	chr3:134224902	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs11710292	chr3:53117798	SFMBT1	chr3:52938628-53080070:-	-0.55	-5.11	6.14E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11710707	chr3:52975916	SFMBT1	chr3:52938628-53080070:-	-0.54	-4.9	1.6E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11712111	chr3:156608940	LEKR1	chr3:156544076-156763918:+	0.36	5.93	9.2E-9	Multiple sclerosis (severity)	
OV	cis	1	rs11712561	chr3:48435272	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs11712587	chr3:114952404	ZNF80	chr3:113953478-113956425:-	-0.35	-3.86	0.000144	Type 2 diabetes	
OV	cis	1	rs11712653	chr3:53070875	SFMBT1	chr3:52938628-53080070:-	0.51	5.04	8.52E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11713206	chr3:52999243	SFMBT1	chr3:52938628-53080070:-	-0.59	-5.38	1.59E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11713290	chr3:52971579	SFMBT1	chr3:52938628-53080070:-	-0.54	-5.05	7.9E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11713859	chr3:53042080	SFMBT1	chr3:52938628-53080070:-	-0.6	-5.82	1.6E-8	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11714876	chr3:53101640	SFMBT1	chr3:52938628-53080070:-	0.56	5.44	1.14E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11715767	chr3:126795125	SEC61A1	chr3:127771212-127790525:+	0.3	4.06	6.39E-5	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs11717619	chr3:53003179	SFMBT1	chr3:52938628-53080070:-	-0.55	-5.21	3.73E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11718538	chr3:52975987	SFMBT1	chr3:52938628-53080070:-	-0.54	-5.05	7.9E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11718752	chr3:53130745	SFMBT1	chr3:52938628-53080070:-	-0.43	-4.28	2.57E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11718834	chr3:52963668	SFMBT1	chr3:52938628-53080070:-	-0.56	-5.32	2.18E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11720191	chr3:53013839	SFMBT1	chr3:52938628-53080070:-	-0.56	-5.22	3.56E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs11722197	chr4:281707	ZNF718	chr4:53272-156488:+	0.38	3.86	0.000141	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11722521	chr4:276765	ZNF718	chr4:53272-156488:+	0.4	4.21	3.48E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11723261	chr4:282499	ZNF718	chr4:53272-156488:+	0.38	3.86	0.000141	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11723615	chr4:276983	ZNF718	chr4:53272-156488:+	0.39	4.19	3.76E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11723803	chr4:292369	ZNF718	chr4:53272-156488:+	0.36	4.56	7.81E-6	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11724176	chr4:224901	ZNF718	chr4:53272-156488:+	0.42	4.08	5.85E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11724417	chr4:223352	ZNF718	chr4:53272-156488:+	0.42	4.08	5.85E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11724495	chr4:17621310	LAP3	chr4:17578927-17609590:+	-0.25	-4.31	2.23E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs11726829	chr4:224948	ZNF718	chr4:53272-156488:+	0.43	4.93	1.44E-6	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11727312	chr4:17669185	LAP3	chr4:17578927-17609590:+	-0.28	-4.9	1.62E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs11729365	chr4:272524	ZNF718	chr4:53272-156488:+	0.39	4.01	7.71E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11733284	chr4:48028097	CNGA1	chr4:47937996-48018610:-	0.3	3.95	9.9E-5	Renal underexcretion gout;Gout	
OV	cis	1	rs11733284	chr4:48028097	NIPAL1	chr4:48018791-48039078:+	0.52	7.78	1.47E-13	Renal underexcretion gout;Gout	
OV	cis	1	rs11737138	chr4:17657986	LAP3	chr4:17578927-17609590:+	-0.26	-4.5	9.95E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs11737268	chr4:224452	ZNF718	chr4:53272-156488:+	0.43	4.93	1.44E-6	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs11739344	chr5:56111087	C5orf35	chr5:56205103-56213010:+	0.71	8.97	4.52E-17	Type 2 diabetes	
OV	cis	1	rs11759855	chr6:86610841	SNHG5	chr6:86386726-86388451:-	-0.69	-11.6	1.23E-25	Response to antipsychotic treatment	
OV	cis	1	rs11764561	chr7:156022102	RBM33	chr7:155437203-155574179:+	-0.21	-4.12	4.95E-5	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
OV	cis	1	rs11782652	chr8:82653644	CHMP4C	chr8:82644688-82671746:+	-0.83	-7.8	1.23E-13	Epithelial ovarian cancer;Ovarian cancer	
OV	cis	1	rs117907570	chr6:86601283	SNHG5	chr6:86386726-86388451:-	-0.65	-11.27	1.68E-24	Response to antipsychotic treatment	
OV	cis	1	rs11799420	chr1:171652978	VAMP4	chr1:171669298-171711214:-	-0.37	-4.48	1.07E-5	Hippocampal atrophy	
OV	cis	1	rs11801846	chr1:171674241	VAMP4	chr1:171669298-171711214:-	0.39	4.7	4.07E-6	Hippocampal atrophy	
OV	cis	1	rs11802265	chr1:171649936	VAMP4	chr1:171669298-171711214:-	0.36	4.37	1.76E-5	Hippocampal atrophy	
OV	cis	1	rs11803174	chr1:171674338	VAMP4	chr1:171669298-171711214:-	0.39	4.7	4.07E-6	Hippocampal atrophy	
OV	cis	1	rs11810993	chr1:46478793	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.96	2.4E-11	Body mass index	
OV	cis	1	rs11811780	chr1:171652759	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.37E-6	Hippocampal atrophy	
OV	cis	1	rs11816840	chr10:102309220	SEC31B	chr10:102246403-102289636:-	-0.28	-4.06	6.52E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs1185260	chr12:122389248	WDR66	chr12:122356480-122441830:+	-0.43	-4.29	2.49E-5	Urinary metabolites	
OV	cis	1	rs11862744	chr16:31057800	HSD3B7	chr16:30996519-31000473:+	0.31	4.99	1.08E-6	Response to metformin (IC50)	
OV	cis	1	rs11862744	chr16:31057800	STX1B	chr16:31000577-31021829:-	0.25	3.93	0.000109	Response to metformin (IC50)	
OV	cis	1	rs1187446	chr14:104409896	TDRD9	chr14:104394817-104519002:+	0.4	5.42	1.32E-7	Bipolar disorder	
OV	cis	1	rs1187448	chr14:104406627	TDRD9	chr14:104394817-104519002:+	0.41	5.48	9.42E-8	Bipolar disorder	
OV	cis	1	rs11882144	chr19:42072602	CEACAM21	chr19:42055886-42093196:+	0.41	6.48	4.14E-10	Schizophrenia	
OV	cis	1	rs11893832	chr2:88507537	THNSL2	chr2:88469835-88486145:+	-0.82	-7.32	2.68E-12	Plasma clusterin levels	
OV	cis	1	rs11893881	chr2:73824373	ALMS1P	chr2:73872046-73912692:+	0.38	5.8	1.81E-8	Metabolite levels	
OV	cis	1	rs11896604	chr2:54479199	C2orf73	chr2:54558071-54588714:+	-0.29	-3.99	8.63E-5	Telomere length	
OV	cis	1	rs11899576	chr2:86256193	LOC90784	chr2:86247339-86250991:-	-0.62	-4.74	3.5E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs11899740	chr2:73631212	ALMS1P	chr2:73872046-73912692:+	0.39	5.54	7.03E-8	Metabolite levels	
OV	cis	1	rs11899902	chr2:73631564	ALMS1P	chr2:73872046-73912692:+	0.38	5.84	1.43E-8	Metabolite levels	
OV	cis	1	rs11908683	chr20:33720920	CPNE1	chr20:34213968-34262539:-	0.44	4.01	7.93E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs11919350	chr3:134235970	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.53	7.44E-8	Height	
OV	cis	1	rs11921451	chr3:126787159	SEC61A1	chr3:127771212-127790525:+	0.3	4.02	7.45E-5	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs11923562	chr3:41760331	ULK4	chr3:41288091-42003660:-	0.54	6.99	2.07E-11	Diastolic blood pressure	
OV	cis	1	rs11927068	chr3:134266321	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs11928499	chr3:134232350	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.5	8.48E-8	Height	
OV	cis	1	rs11928580	chr3:41885722	ULK4	chr3:41288091-42003660:-	0.64	8.48	1.32E-15	Diastolic blood pressure	
OV	cis	1	rs11947645	chr4:151101672	DCLK2	chr4:151000080-151178606:+	-0.6	-3.9	0.000122	Social autistic-like traits	
OV	cis	1	rs11975942	chr7:143740580	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.73	2.66E-8	Obesity-related traits	
OV	cis	1	rs11975942	chr7:143740580	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.16	4.3E-5	Obesity-related traits	
OV	cis	1	rs11975942	chr7:143740580	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.3	2.33E-5	Obesity-related traits	
OV	cis	1	rs11976020	chr7:72247800	TYW1B	chr7:72023729-72298813:-	0.9	12	5.38E-27	Educational attainment (years of education)	
OV	cis	1	rs11976037	chr7:143741024	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.73	2.66E-8	Obesity-related traits	
OV	cis	1	rs11976037	chr7:143741024	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.16	4.3E-5	Obesity-related traits	
OV	cis	1	rs11976037	chr7:143741024	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.3	2.33E-5	Obesity-related traits	
OV	cis	1	rs11976180	chr7:143741580	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.71	2.96E-8	Obesity-related traits	
OV	cis	1	rs11976180	chr7:143741580	CTAGE6	chr7:143452184-143454843:-	-0.34	-4.25	2.99E-5	Obesity-related traits	
OV	cis	1	rs11976180	chr7:143741580	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.28	2.58E-5	Obesity-related traits	
OV	cis	1	rs12021587	chr1:46472759	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.96	2.4E-11	Body mass index	
OV	cis	1	rs12049588	chr1:46472422	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.96	2.4E-11	Body mass index	
OV	cis	1	rs12091564	chr1:145395604	NOTCH2NL	chr1:145209111-145295525:+	-0.88	-6.13	3.04E-9	Coronary heart disease	
OV	cis	1	rs12118323	chr1:10469641	PGD	chr1:10459085-10480200:+	0.35	5.05	7.99E-7	Hepatocellular carcinoma	
OV	cis	1	rs12122290	chr1:247215810	ZNF670	chr1:247200087-247242069:-	-0.32	-4.4	1.53E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs12125429	chr1:171651153	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.37E-6	Hippocampal atrophy	
OV	cis	1	rs12128536	chr1:171674607	VAMP4	chr1:171669298-171711214:-	0.39	4.7	4.07E-6	Hippocampal atrophy	
OV	cis	1	rs12129035	chr1:10291166	PGD	chr1:10459085-10480200:+	0.27	3.98	8.64E-5	Hepatocellular carcinoma	
OV	cis	1	rs12130075	chr1:247218491	ZNF670	chr1:247200087-247242069:-	-0.3	-4.18	3.85E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs12132221	chr1:171685694	VAMP4	chr1:171669298-171711214:-	0.38	4.67	4.66E-6	Hippocampal atrophy	
OV	cis	1	rs12134493	chr1:115677946	TRIM33	chr1:114935401-115053781:-	-0.39	-4.05	6.77E-5	Migraine;Migraine without aura	
OV	cis	1	rs12136376	chr1:10296452	PGD	chr1:10459085-10480200:+	0.27	3.98	8.64E-5	Hepatocellular carcinoma	
OV	cis	1	rs12139630	chr1:46350935	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.93	2.94E-11	Body mass index	
OV	cis	1	rs12141416	chr1:10327867	PGD	chr1:10459085-10480200:+	0.3	4.69	4.21E-6	Hepatocellular carcinoma	
OV	cis	1	rs12144263	chr1:46352446	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.93	2.94E-11	Body mass index	
OV	cis	1	rs12154056	chr6:86634094	SNHG5	chr6:86386726-86388451:-	-0.65	-11.02	1.16E-23	Response to antipsychotic treatment	
OV	cis	1	rs12185764	chr20:44550020	WFDC3	chr20:44402847-44420547:-	-0.39	-4	8.26E-5	HDL cholesterol;Triglycerides;Gut microbiota (functional units)	
OV	cis	1	rs12188300	chr5:158829527	PWWP2A	chr5:159502894-159546452:-	-0.51	-5.22	3.57E-7	Psoriatic arthritis	
OV	cis	1	rs12189725	chr6:33703394	IP6K3	chr6:33689443-33714762:-	0.43	4.89	1.69E-6	Obesity (extreme)	
OV	cis	1	rs12190598	chr6:86686074	SNHG5	chr6:86386726-86388451:-	-0.65	-10.86	3.95E-23	Response to antipsychotic treatment	
OV	cis	1	rs12190604	chr6:86716215	SNHG5	chr6:86386726-86388451:-	-0.69	-11.59	1.39E-25	Response to antipsychotic treatment	
OV	cis	1	rs12192992	chr6:86609915	SNHG5	chr6:86386726-86388451:-	-0.69	-11.47	3.45E-25	Response to antipsychotic treatment	
OV	cis	1	rs12193658	chr6:33705528	IP6K3	chr6:33689443-33714762:-	0.47	5.1	6.17E-7	Obesity (extreme)	
OV	cis	1	rs12196937	chr6:49382808	MUT	chr6:49398994-49431031:-	0.27	4.17	4.05E-5	Folate pathway vitamin levels	
OV	cis	1	rs12199132	chr6:33708250	IP6K3	chr6:33689443-33714762:-	0.47	5.13	5.42E-7	Obesity (extreme)	
OV	cis	1	rs12199516	chr6:86726221	SNHG5	chr6:86386726-86388451:-	-0.68	-11.41	5.87E-25	Response to antipsychotic treatment	
OV	cis	1	rs12199784	chr6:86726808	SNHG5	chr6:86386726-86388451:-	-0.67	-11.23	2.23E-24	Response to antipsychotic treatment	
OV	cis	1	rs12200330	chr6:86656653	SNHG5	chr6:86386726-86388451:-	-0.69	-11.42	5.12E-25	Response to antipsychotic treatment	
OV	cis	1	rs12201571	chr6:86609750	SNHG5	chr6:86386726-86388451:-	-0.69	-11.6	1.23E-25	Response to antipsychotic treatment	
OV	cis	1	rs12201735	chr6:86656939	SNHG5	chr6:86386726-86388451:-	-0.66	-10.97	1.73E-23	Response to antipsychotic treatment	
OV	cis	1	rs12201741	chr6:86602619	SNHG5	chr6:86386726-86388451:-	-0.63	-10.5	6.1E-22	Response to antipsychotic treatment	
OV	cis	1	rs12201880	chr6:86627007	SNHG5	chr6:86386726-86388451:-	-0.65	-11.02	1.16E-23	Response to antipsychotic treatment	
OV	cis	1	rs12202075	chr6:49427655	MUT	chr6:49398994-49431031:-	0.27	4.17	4.03E-5	Folate pathway vitamin levels	
OV	cis	1	rs12203493	chr6:86758642	SNHG5	chr6:86386726-86388451:-	-0.71	-11.55	1.95E-25	Response to antipsychotic treatment	
OV	cis	1	rs12203924	chr6:86776412	SNHG5	chr6:86386726-86388451:-	-0.71	-11.55	1.95E-25	Response to antipsychotic treatment	
OV	cis	1	rs12204015	chr6:86598334	SNHG5	chr6:86386726-86388451:-	-0.67	-11.62	1.13E-25	Response to antipsychotic treatment	
OV	cis	1	rs12205336	chr6:86722367	SNHG5	chr6:86386726-86388451:-	-0.69	-11.51	2.65E-25	Response to antipsychotic treatment	
OV	cis	1	rs12205548	chr6:86759770	SNHG5	chr6:86386726-86388451:-	-0.7	-11.48	3.14E-25	Response to antipsychotic treatment	
OV	cis	1	rs12207305	chr6:86723502	SNHG5	chr6:86386726-86388451:-	-0.67	-11.33	1.04E-24	Response to antipsychotic treatment	
OV	cis	1	rs12207610	chr6:86688016	SNHG5	chr6:86386726-86388451:-	-0.65	-10.96	1.84E-23	Response to antipsychotic treatment	
OV	cis	1	rs12208493	chr6:86662267	SNHG5	chr6:86386726-86388451:-	-0.69	-11.46	3.87E-25	Response to antipsychotic treatment	
OV	cis	1	rs12209127	chr6:86724427	SNHG5	chr6:86386726-86388451:-	-0.69	-11.51	2.65E-25	Response to antipsychotic treatment	
OV	cis	1	rs12211490	chr6:33725528	IP6K3	chr6:33689443-33714762:-	0.52	5.5	8.79E-8	Obesity (extreme)	
OV	cis	1	rs12211554	chr6:33725788	IP6K3	chr6:33689443-33714762:-	0.52	5.5	8.79E-8	Obesity (extreme)	
OV	cis	1	rs12211565	chr6:33725852	IP6K3	chr6:33689443-33714762:-	0.52	5.5	8.79E-8	Obesity (extreme)	
OV	cis	1	rs12212733	chr6:86726013	SNHG5	chr6:86386726-86388451:-	-0.7	-11.64	9.59E-26	Response to antipsychotic treatment	
OV	cis	1	rs12213149	chr6:86668644	SNHG5	chr6:86386726-86388451:-	-0.69	-11.46	3.87E-25	Response to antipsychotic treatment	
OV	cis	1	rs12213740	chr6:86656733	SNHG5	chr6:86386726-86388451:-	-0.65	-10.98	1.6E-23	Response to antipsychotic treatment	
OV	cis	1	rs12215037	chr6:86727631	SNHG5	chr6:86386726-86388451:-	-0.69	-11.42	5.32E-25	Response to antipsychotic treatment	
OV	cis	1	rs12215903	chr6:86675028	SNHG5	chr6:86386726-86388451:-	-0.65	-10.9	2.92E-23	Response to antipsychotic treatment	
OV	cis	1	rs12216203	chr6:86675301	SNHG5	chr6:86386726-86388451:-	-0.69	-11.49	2.96E-25	Response to antipsychotic treatment	
OV	cis	1	rs12216328	chr6:86703418	SNHG5	chr6:86386726-86388451:-	-0.7	-11.86	1.66E-26	Response to antipsychotic treatment	
OV	cis	1	rs12219158	chr10:102302923	SEC31B	chr10:102246403-102289636:-	-0.28	-4.12	4.98E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs12260159	chr10:100702737	PYROXD2	chr10:100143323-100174978:-	-0.45	-4.31	2.28E-5	Migraine	
OV	cis	1	rs12294479	chr11:110395207	ZC3H12C	chr11:109963926-110042564:+	0.44	4.05	6.67E-5	Renal sinus fat	
OV	cis	1	rs12328085	chr2:86262009	LOC90784	chr2:86247339-86250991:-	-0.6	-4.53	8.74E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs12354411	chr10:102294537	SEC31B	chr10:102246403-102289636:-	-0.27	-4.12	5.03E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs12358187	chr10:102284449	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs12405451	chr1:46384326	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs12409773	chr1:46358831	CCDC163P	chr1:45960581-45965646:-	-0.45	-6.66	1.5E-10	Body mass index	
OV	cis	1	rs12410071	chr1:46358886	CCDC163P	chr1:45960581-45965646:-	-0.45	-6.66	1.5E-10	Body mass index	
OV	cis	1	rs12411269	chr1:46271052	CCDC163P	chr1:45960581-45965646:-	-0.47	-7	1.97E-11	Body mass index	
OV	cis	1	rs12416687	chr10:104629011	C10orf32	chr10:104613967-104624718:+	-0.4	-5.22	3.55E-7	Arsenic metabolism	
OV	cis	1	rs12428	chr20:25433821	ABHD12	chr20:25275380-25371477:-	-0.42	-6.17	2.44E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs12428	chr20:25433821	FAM182B	chr20:25744102-25848786:-	-0.32	-4.93	1.41E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs12429165	chr13:23135984	EFHA1	chr13:22066840-22178307:-	-0.3	-4.16	4.21E-5	Idiopathic osteonecrosis of the femoral head	
OV	cis	1	rs12434746	chr14:78026650	SPTLC2	chr14:77973272-78083110:-	0.27	4.13	4.81E-5	Gut microbiome composition (winter)	
OV	cis	1	rs12445650	chr16:31044897	HSD3B7	chr16:30996519-31000473:+	0.3	4.84	2.18E-6	Response to metformin (IC50)	
OV	cis	1	rs12473740	chr2:88527647	THNSL2	chr2:88469835-88486145:+	-0.78	-7.95	4.78E-14	Plasma clusterin levels	
OV	cis	1	rs12478819	chr2:207645078	MDH1B	chr2:207598943-207630050:-	0.44	4.13	4.81E-5	Episodic memory	
OV	cis	1	rs12483517	chr21:42691920	FAM3B	chr21:42676177-42729654:+	0.39	4.93	1.43E-6	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
OV	cis	1	rs12487542	chr3:48426076	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs12488768	chr3:53086234	ITIH4	chr3:52847007-52866554:-	0.2	4.06	6.52E-5	Ulcerative colitis	
OV	cis	1	rs12490835	chr3:134223730	ANAPC13	chr3:134196547-134204865:-	0.41	5.85	1.4E-8	Height	
OV	cis	1	rs12495617	chr3:126797796	SEC61A1	chr3:127771212-127790525:+	0.29	3.94	0.000102	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs12505835	chr4:297525	ZNF718	chr4:53272-156488:+	0.4	3.9	0.000118	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs12507142	chr4:17656103	LAP3	chr4:17578927-17609590:+	-0.28	-4.94	1.33E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs12534899	chr7:26877189	CBX3	chr7:26241099-26252974:+	0.34	4.5	1.0E-5	Type 1 diabetes	
OV	cis	1	rs12534899	chr7:26877189	HIBADH	chr7:27565063-27702602:-	0.31	4.04	6.94E-5	Type 1 diabetes	
OV	cis	1	rs12534899	chr7:26877189	HNRNPA2B1	chr7:26229557-26240413:-	0.29	4.12	5.05E-5	Type 1 diabetes	
OV	cis	1	rs12534899	chr7:26877189	TAX1BP1	chr7:27778992-27869384:+	0.35	4.53	8.66E-6	Type 1 diabetes	
OV	cis	1	rs12561806	chr1:46396776	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs12564541	chr1:46380237	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs12577464	chr11:43662440	HSD17B12	chr11:43702143-43878160:+	-0.41	-6.01	5.95E-9	Forced vital capacity	
OV	cis	1	rs1259180	chr15:83244680	AP3B2	chr15:83328034-83378635:-	-0.25	-4.24	2.99E-5	Schizophrenia	
OV	cis	1	rs12615749	chr2:54475885	C2orf73	chr2:54558071-54588714:+	0.28	3.86	0.000139	Telomere length	
OV	cis	1	rs12615793	chr2:54475914	C2orf73	chr2:54558071-54588714:+	-0.29	-4.01	7.82E-5	Telomere length	
OV	cis	1	rs12622009	chr2:86248325	LOC90784	chr2:86247339-86250991:-	-0.61	-4.65	5.05E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs12623489	chr2:240222564	MGC16025	chr2:240115027-240117153:-	0.56	4.74	3.49E-6	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs12637751	chr3:134266124	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs12638253	chr3:156626091	LEKR1	chr3:156544076-156763918:+	-0.35	-5.81	1.73E-8	Multiple sclerosis (severity)	
OV	cis	1	rs12639255	chr3:41861738	ULK4	chr3:41288091-42003660:-	0.59	7.52	7.85E-13	Diastolic blood pressure	
OV	cis	1	rs12661204	chr6:86678586	SNHG5	chr6:86386726-86388451:-	-0.67	-10.9	2.87E-23	Response to antipsychotic treatment	
OV	cis	1	rs12662447	chr6:33714673	IP6K3	chr6:33689443-33714762:-	0.5	5.35	1.8E-7	Obesity (extreme)	
OV	cis	1	rs12663690	chr6:86640162	SNHG5	chr6:86386726-86388451:-	0.64	10.66	1.86E-22	Response to antipsychotic treatment	
OV	cis	1	rs12664335	chr6:86597774	SNHG5	chr6:86386726-86388451:-	0.69	11.6	1.27E-25	Response to antipsychotic treatment	
OV	cis	1	rs12665321	chr6:86769289	SNHG5	chr6:86386726-86388451:-	-0.7	-11.48	3.14E-25	Response to antipsychotic treatment	
OV	cis	1	rs12669434	chr7:156018000	RBM33	chr7:155437203-155574179:+	-0.23	-4.25	2.93E-5	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
OV	cis	1	rs12675542	chr8:29986454	MBOAT4	chr8:29989188-30002200:-	-0.45	-4.23	3.2E-5	Migraine	
OV	cis	1	rs1267817	chr7:66110040	CCT6P1	chr7:65216092-65228661:+	0.36	4.28	2.57E-5	Gout	
OV	cis	1	rs1267818	chr7:66107024	CCT6P1	chr7:65216092-65228661:+	0.37	4.43	1.34E-5	Gout	
OV	cis	1	rs1267820	chr7:66050295	CCT6P1	chr7:65216092-65228661:+	0.34	4.16	4.29E-5	Diabetic kidney disease	
OV	cis	1	rs12698509	chr7:65418876	CCT6P1	chr7:65216092-65228661:+	0.33	4.16	4.33E-5	Diabetic kidney disease	
OV	cis	1	rs12712530	chr2:37505561	CEBPZ	chr2:37428778-37458740:-	-0.26	-4.09	5.57E-5	Chronic lymphocytic leukemia	
OV	cis	1	rs12740374	chr1:109817590	PSRC1	chr1:109822179-109825808:-	0.36	5.09	6.56E-7	Cholesterol, total;Myocardial infarction;Coronary artery disease;Lipoprotein-associated phospholipase A2 activity and mass	
OV	cis	1	rs12755094	chr1:10305711	PGD	chr1:10459085-10480200:+	0.26	3.88	0.00013	Hepatocellular carcinoma	
OV	cis	1	rs12760175	chr1:46447840	CCDC163P	chr1:45960581-45965646:-	-0.44	-6.41	6.09E-10	Body mass index	
OV	cis	1	rs12767633	chr10:102056440	SLC25A28	chr10:101370275-101418994:-	-0.42	-4.03	7.19E-5	Obesity-related traits	
OV	cis	1	rs12781019	chr10:102057568	SLC25A28	chr10:101370275-101418994:-	0.48	4.54	8.51E-6	Obesity-related traits	
OV	cis	1	rs12787909	chr11:117546482	PCSK7	chr11:117075789-117102811:-	0.55	4.84	2.15E-6	Lipoprotein (a) - cholesterol levels	
OV	cis	1	rs12787909	chr11:117546482	PHLDB1	chr11:118477213-118528741:+	0.43	3.85	0.000144	Lipoprotein (a) - cholesterol levels	
OV	cis	1	rs12787909	chr11:117546482	SIK3	chr11:116714120-116968993:-	0.46	3.98	8.81E-5	Lipoprotein (a) - cholesterol levels	
OV	cis	1	rs12889168	chr14:104481957	TDRD9	chr14:104394817-104519002:+	0.38	5.09	6.55E-7	Bipolar disorder	
OV	cis	1	rs12930239	chr16:29908777	LOC440356	chr16:29875004-29879374:+	-0.29	-4.26	2.79E-5	Response to taxane treatment (placlitaxel)	
OV	cis	1	rs12995491	chr2:88527414	THNSL2	chr2:88469835-88486145:+	-0.35	-4.76	3.14E-6	Response to metformin (IC50)	
OV	cis	1	rs13003464	chr2:61186829	C2orf74	chr2:61372243-61391964:+	0.37	4.73	3.65E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
OV	cis	1	rs13033143	chr2:61161095	C2orf74	chr2:61372243-61391964:+	0.36	4.12	5.02E-5	Inflammatory skin disease	
OV	cis	1	rs13038834	chr20:25441433	ABHD12	chr20:25275380-25371477:-	0.39	5.67	3.68E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs13038834	chr20:25441433	FAM182B	chr20:25744102-25848786:-	0.33	5.11	6.03E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs13058817	chr3:53024139	SFMBT1	chr3:52938628-53080070:-	-0.59	-5.62	4.62E-8	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13059720	chr3:134242021	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.53	7.44E-8	Height	
OV	cis	1	rs13069006	chr3:52973305	SFMBT1	chr3:52938628-53080070:-	-0.54	-4.9	1.6E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13069724	chr3:48478039	TREX1	chr3:48501186-48509043:+	-0.27	-5.17	4.49E-7	Longevity	
OV	cis	1	rs13071337	chr3:48438189	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs13071551	chr3:134310867	ANAPC13	chr3:134196547-134204865:-	-0.41	-5.59	5.49E-8	Height	
OV	cis	1	rs13072395	chr3:52980573	SFMBT1	chr3:52938628-53080070:-	-0.58	-5.28	2.64E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13072457	chr3:53102389	SFMBT1	chr3:52938628-53080070:-	-0.56	-5.08	6.81E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13072818	chr3:53074263	SFMBT1	chr3:52938628-53080070:-	-0.5	-4.62	5.97E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13074524	chr3:52974184	SFMBT1	chr3:52938628-53080070:-	-0.55	-5.13	5.59E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13076033	chr3:52898427	SFMBT1	chr3:52938628-53080070:-	-0.53	-4.91	1.59E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13076076	chr3:48479039	NME6	chr3:48335591-48342886:-	-0.28	-3.92	0.00011	Longevity	
OV	cis	1	rs13076076	chr3:48479039	TREX1	chr3:48501186-48509043:+	-0.26	-4.93	1.39E-6	Longevity	
OV	cis	1	rs13078971	chr3:53103645	SFMBT1	chr3:52938628-53080070:-	-0.55	-5.04	8.26E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13081177	chr3:134289860	ANAPC13	chr3:134196547-134204865:-	-0.41	-5.59	5.49E-8	Height	
OV	cis	1	rs13081688	chr3:134259954	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs13087719	chr3:41951576	ULK4	chr3:41288091-42003660:-	-0.68	-9.08	2.12E-17	Diastolic blood pressure	
OV	cis	1	rs13087875	chr3:134261123	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs13088281	chr3:53147576	SFMBT1	chr3:52938628-53080070:-	0.58	5.19	4.04E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13088455	chr3:53087482	ITIH4	chr3:52847007-52866554:-	0.2	4.06	6.52E-5	Ulcerative colitis	
OV	cis	1	rs13089966	chr3:134279197	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs13090969	chr3:134307257	ANAPC13	chr3:134196547-134204865:-	-0.41	-5.59	5.49E-8	Height	
OV	cis	1	rs13091785	chr3:48494098	TREX1	chr3:48501186-48509043:+	-0.28	-5.2	3.93E-7	Longevity	
OV	cis	1	rs13091844	chr3:53010271	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.29	2.47E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13092160	chr3:46254791	LARS2	chr3:45430075-45590328:+	-0.45	-3.91	0.000115	Celiac disease	
OV	cis	1	rs13092352	chr3:52969697	SFMBT1	chr3:52938628-53080070:-	-0.54	-5.03	8.69E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs13096604	chr3:134250099	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs13106338	chr4:17676871	LAP3	chr4:17578927-17609590:+	0.27	4.58	7.1E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs13120847	chr4:48030036	NIPAL1	chr4:48018791-48039078:+	0.54	8.11	1.67E-14	Renal underexcretion gout;Gout	
OV	cis	1	rs13125949	chr4:48026560	CNGA1	chr4:47937996-48018610:-	0.3	3.94	0.000103	Renal underexcretion gout;Gout	
OV	cis	1	rs13125949	chr4:48026560	NIPAL1	chr4:48018791-48039078:+	0.51	7.76	1.68E-13	Renal underexcretion gout;Gout	
OV	cis	1	rs13140968	chr4:48025095	NIPAL1	chr4:48018791-48039078:+	0.48	7.21	5.5E-12	Renal underexcretion gout;Gout	
OV	cis	1	rs13142905	chr4:48025298	CNGA1	chr4:47937996-48018610:-	0.3	3.94	0.000103	Renal underexcretion gout;Gout	
OV	cis	1	rs13142905	chr4:48025298	NIPAL1	chr4:48018791-48039078:+	0.51	7.76	1.68E-13	Renal underexcretion gout;Gout	
OV	cis	1	rs13146880	chr4:48031499	CNGA1	chr4:47937996-48018610:-	0.3	3.97	9.16E-5	Renal underexcretion gout;Gout	
OV	cis	1	rs13146880	chr4:48031499	NIPAL1	chr4:48018791-48039078:+	0.53	7.95	4.89E-14	Renal underexcretion gout;Gout	
OV	cis	1	rs13194429	chr6:86646705	SNHG5	chr6:86386726-86388451:-	-0.69	-11.6	1.23E-25	Response to antipsychotic treatment	
OV	cis	1	rs13195401	chr6:26463574	BTN3A2	chr6:26365398-26378546:+	-0.66	-5.79	1.94E-8	Schizophrenia	
OV	cis	1	rs13195402	chr6:26463575	BTN3A2	chr6:26365398-26378546:+	-0.66	-5.79	1.94E-8	Schizophrenia	
OV	cis	1	rs13196930	chr6:86652245	SNHG5	chr6:86386726-86388451:-	-0.69	-11.48	3.32E-25	Response to antipsychotic treatment	
OV	cis	1	rs13199006	chr6:86608708	SNHG5	chr6:86386726-86388451:-	-0.66	-11.67	7.28E-26	Response to antipsychotic treatment	
OV	cis	1	rs13200063	chr6:33730171	IP6K3	chr6:33689443-33714762:-	0.5	5.34	1.94E-7	Obesity (extreme)	
OV	cis	1	rs13200462	chr6:28218199	ZNF389	chr6:28129551-28137375:+	-0.41	-4.54	8.22E-6	Depression	
OV	cis	1	rs1320893	chr7:143752112	ARHGEF35	chr7:143883677-143892736:-	-0.46	-5.78	2.01E-8	Obesity-related traits	
OV	cis	1	rs1320893	chr7:143752112	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.91	0.000115	Obesity-related traits	
OV	cis	1	rs1320893	chr7:143752112	OR2A9P	chr7:143991573-143997832:+;chr7	-0.37	-4.5	1.01E-5	Obesity-related traits	
OV	cis	1	rs1320894	chr7:143751802	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.66	3.7E-8	Obesity-related traits	
OV	cis	1	rs1320894	chr7:143751802	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.9	0.000121	Obesity-related traits	
OV	cis	1	rs1320894	chr7:143751802	OR2A9P	chr7:143991573-143997832:+;chr7	-0.36	-4.32	2.15E-5	Obesity-related traits	
OV	cis	1	rs13217384	chr6:86720000	SNHG5	chr6:86386726-86388451:-	-0.65	-11.07	8.23E-24	Response to antipsychotic treatment	
OV	cis	1	rs13220495	chr6:26441640	BTN3A2	chr6:26365398-26378546:+	-0.68	-5.8	1.78E-8	Schizophrenia	
OV	cis	1	rs13220979	chr7:65363204	CCT6P1	chr7:65216092-65228661:+	0.36	4.49	1.04E-5	Diabetic kidney disease	
OV	cis	1	rs13226728	chr7:143746578	ARHGEF35	chr7:143883677-143892736:-	-0.44	-5.55	6.57E-8	Obesity-related traits	
OV	cis	1	rs13226728	chr7:143746578	CTAGE6	chr7:143452184-143454843:-	-0.31	-3.9	0.000121	Obesity-related traits	
OV	cis	1	rs13226728	chr7:143746578	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.26	2.78E-5	Obesity-related traits	
OV	cis	1	rs13243677	chr7:143746572	ARHGEF35	chr7:143883677-143892736:-	-0.44	-5.55	6.57E-8	Obesity-related traits	
OV	cis	1	rs13243677	chr7:143746572	CTAGE6	chr7:143452184-143454843:-	-0.31	-3.9	0.000121	Obesity-related traits	
OV	cis	1	rs13243677	chr7:143746572	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.26	2.78E-5	Obesity-related traits	
OV	cis	1	rs13247184	chr7:65358928	CCT6P1	chr7:65216092-65228661:+	0.37	4.57	7.35E-6	Diabetic kidney disease	
OV	cis	1	rs13252719	chr8:71734569	XKR9	chr8:71581600-71648176:+	0.87	18.62	9.82E-51	Bone mineral density	
OV	cis	1	rs13253842	chr8:71625503	XKR9	chr8:71581600-71648176:+	0.87	18.83	1.7E-51	Bone mineral density	
OV	cis	1	rs13267838	chr8:25196710	KCTD9	chr8:25285366-25315920:-	-0.45	-4.77	2.97E-6	Glucose homeostasis traits	
OV	cis	1	rs13267838	chr8:25196710	PPP2R2A	chr8:25230075-26228645:+	-0.45	-4.4	1.58E-5	Glucose homeostasis traits	
OV	cis	1	rs13310597	chr7:65598540	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs13314659	chr3:48449149	TREX1	chr3:48501186-48509043:+	0.28	5.41	1.37E-7	Longevity	
OV	cis	1	rs13322305	chr3:134310791	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs13325965	chr3:41914942	ULK4	chr3:41288091-42003660:-	0.58	7.13	9.01E-12	Diastolic blood pressure	
OV	cis	1	rs13329835	chr16:80650805	ATMIN	chr16:81069458-81080951:+	0.35	4.01	7.94E-5	Breast cancer	
OV	cis	1	rs13331733	chr16:29848417	MVP	chr16:29831787-29859342:+	-0.31	-4.9	1.65E-6	Multiple sclerosis	
OV	cis	1	rs13332078	chr16:29850705	MVP	chr16:29831787-29859342:+	-0.28	-4.21	3.43E-5	Multiple sclerosis	
OV	cis	1	rs1337844	chr6:86677273	SNHG5	chr6:86386726-86388451:-	-0.65	-10.89	3.29E-23	Response to antipsychotic treatment	
OV	cis	1	rs1337850	chr6:86729103	SNHG5	chr6:86386726-86388451:-	-0.69	-11.39	6.56E-25	Response to antipsychotic treatment	
OV	cis	1	rs13383871	chr2:73631779	ALMS1P	chr2:73872046-73912692:+	0.39	5.78	2.05E-8	Metabolite levels	
OV	cis	1	rs13384952	chr2:73723959	ALMS1P	chr2:73872046-73912692:+	-0.34	-4.71	3.93E-6	Metabolite levels	
OV	cis	1	rs1339458	chr1:10328338	PGD	chr1:10459085-10480200:+	0.26	3.88	0.000132	Hepatocellular carcinoma	
OV	cis	1	rs13398075	chr2:202376269	PPIL3	chr2:201735680-201753999:-	0.48	4.73	3.51E-6	Rheumatoid arthritis	
OV	cis	1	rs13398956	chr2:73720258	ALMS1P	chr2:73872046-73912692:+	0.37	5.63	4.52E-8	Metabolite levels	
OV	cis	1	rs13405743	chr2:240231126	MGC16025	chr2:240115027-240117153:-	0.54	4.3	2.41E-5	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs13409250	chr2:37463642	CEBPZ	chr2:37428778-37458740:-	-0.25	-3.97	9.05E-5	Chronic lymphocytic leukemia	
OV	cis	1	rs13421462	chr2:73719875	ALMS1P	chr2:73872046-73912692:+	0.36	5.62	4.57E-8	Metabolite levels	
OV	cis	1	rs13428235	chr2:73633430	ALMS1P	chr2:73872046-73912692:+	0.38	5.73	2.63E-8	Metabolite levels	
OV	cis	1	rs13431267	chr2:73782200	ALMS1P	chr2:73872046-73912692:+	0.37	5.82	1.59E-8	Metabolite levels	
OV	cis	1	rs13432605	chr2:73810981	ALMS1P	chr2:73872046-73912692:+	0.37	5.74	2.45E-8	Metabolite levels	
OV	cis	1	rs1346719	chr3:53077372	SFMBT1	chr3:52938628-53080070:-	-0.46	-4.59	6.7E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs1357762	chr3:134264859	ANAPC13	chr3:134196547-134204865:-	0.38	5.38	1.56E-7	Height	
OV	cis	1	rs1359582	chr10:90330483	LIPF	chr10:90424094-90438572:+	0.26	3.87	0.000135	Depressive and manic episodes in bipolar disorder	
OV	cis	1	rs138712	chr22:39141600	LOC646851	chr22:38974125-39052634:-	0.31	4.83	2.28E-6	Resting heart rate	
OV	cis	1	rs1403284	chr2:73726662	ALMS1P	chr2:73872046-73912692:+	-0.32	-4.54	8.33E-6	Metabolite levels	
OV	cis	1	rs1412444	chr10:91002927	LIPA	chr10:90973328-91174382:-	0.24	4.98	1.11E-6	Fibrinogen levels	
OV	cis	1	rs1414740	chr6:129768483	ARHGAP18	chr6:129898241-130031370:-	0.25	4.82	2.35E-6	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs1415753	chr6:86753074	SNHG5	chr6:86386726-86388451:-	-0.71	-11.55	1.95E-25	Response to antipsychotic treatment	
OV	cis	1	rs1417823	chr10:102227886	SEC31B	chr10:102246403-102289636:-	0.26	4.07	6.15E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs1423620	chr5:56100996	C5orf35	chr5:56205103-56213010:+	0.7	9.35	3.17E-18	Type 2 diabetes	
OV	cis	1	rs1423621	chr5:56101035	C5orf35	chr5:56205103-56213010:+	0.67	9.5	1.03E-18	Type 2 diabetes	
OV	cis	1	rs1459242	chr3:48413537	TREX1	chr3:48501186-48509043:+	0.24	4.51	9.62E-6	Longevity	
OV	cis	1	rs1473580	chr3:114790058	ZNF80	chr3:113953478-113956425:-	-0.37	-4.1	5.33E-5	Type 2 diabetes	
OV	cis	1	rs1480570	chr16:73676742	PSMD7	chr16:74330681-74340184:+	0.35	4.47	1.17E-5	Subjective well-being	
OV	cis	1	rs1498718	chr3:134205920	ANAPC13	chr3:134196547-134204865:-	0.4	5.6	5.21E-8	Height	
OV	cis	1	rs1499614	chr7:65730798	CCT6P1	chr7:65216092-65228661:+	0.31	3.87	0.000137	Diabetic kidney disease	
OV	cis	1	rs1502397	chr15:38146126	FAM98B	chr15:38746328-38777062:+	-0.37	-4.21	3.43E-5	Survival in rectal cancer	
OV	cis	1	rs1533266	chr7:143766714	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.71	2.94E-8	Obesity-related traits	
OV	cis	1	rs1533266	chr7:143766714	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.06	6.34E-5	Obesity-related traits	
OV	cis	1	rs1533266	chr7:143766714	OR2A9P	chr7:143991573-143997832:+;chr7	-0.33	-4	8.09E-5	Obesity-related traits	
OV	cis	1	rs1533267	chr7:143766440	ARHGEF35	chr7:143883677-143892736:-	-0.44	-5.6	5.2E-8	Obesity-related traits	
OV	cis	1	rs1533267	chr7:143766440	CTAGE6	chr7:143452184-143454843:-	-0.31	-3.95	9.84E-5	Obesity-related traits	
OV	cis	1	rs1533268	chr7:143766358	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.71	2.94E-8	Obesity-related traits	
OV	cis	1	rs1533268	chr7:143766358	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.06	6.34E-5	Obesity-related traits	
OV	cis	1	rs1533268	chr7:143766358	OR2A9P	chr7:143991573-143997832:+;chr7	-0.33	-4	8.09E-5	Obesity-related traits	
OV	cis	1	rs1534025	chr3:134313304	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.58	5.62E-8	Height	
OV	cis	1	rs1534026	chr3:134284767	ANAPC13	chr3:134196547-134204865:-	0.41	5.73	2.63E-8	Height	
OV	cis	1	rs1534471	chr2:73647508	ALMS1P	chr2:73872046-73912692:+	0.38	5.96	7.79E-9	Metabolite levels	
OV	cis	1	rs1535500	chr6:39284050	KCNK17	chr6:39266778-39282237:-	0.31	4.49	1.05E-5	Type 2 diabetes	
OV	cis	1	rs1540894	chr7:143767676	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.76	2.19E-8	Obesity-related traits	
OV	cis	1	rs1540894	chr7:143767676	CTAGE6	chr7:143452184-143454843:-	-0.34	-4.2	3.61E-5	Obesity-related traits	
OV	cis	1	rs1546059	chr7:65654709	CCT6P1	chr7:65216092-65228661:+	-0.33	-3.94	0.000104	Diabetic kidney disease	
OV	cis	1	rs1547374	chr21:43778895	ZNF295	chr21:43406941-43430496:-	0.29	4.04	7.02E-5	Pancreatic cancer	
OV	cis	1	rs1547958	chr7:150640285	ATG9B	chr7:150709306-150721586:-	0.31	4.22	3.36E-5	QT interval	
OV	cis	1	rs1558377	chr4:17650758	LAP3	chr4:17578927-17609590:+	-0.3	-5.16	4.72E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1558378	chr4:17650351	LAP3	chr4:17578927-17609590:+	-0.3	-5.16	4.72E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1559282	chr5:56099375	C5orf35	chr5:56205103-56213010:+	0.69	9.24	6.8E-18	Type 2 diabetes	
OV	cis	1	rs1561328	chr2:86272758	LOC90784	chr2:86247339-86250991:-	-0.59	-4.53	8.81E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs1563736	chr3:48436794	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs1564716	chr3:41862613	ULK4	chr3:41288091-42003660:-	0.59	7.52	7.85E-13	Diastolic blood pressure	
OV	cis	1	rs15655	chr1:171673272	VAMP4	chr1:171669298-171711214:-	0.38	4.65	5.23E-6	Hippocampal atrophy	
OV	cis	1	rs15676	chr9:131572027	ENDOG	chr9:131580779-131584954:+	-0.25	-4.09	5.68E-5	Blood metabolite levels	
OV	cis	1	rs1568889	chr11:28009463	CCDC34	chr11:27360061-27384795:-	0.35	4.22	3.26E-5	Bipolar disorder	
OV	cis	1	rs1573897	chr1:247215054	ZNF670	chr1:247200087-247242069:-	-0.31	-4.34	2.03E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs1577919	chr6:86757296	SNHG5	chr6:86386726-86388451:-	-0.71	-11.55	1.95E-25	Response to antipsychotic treatment	
OV	cis	1	rs1599932	chr12:58177943	FAM119B	chr12:58166383-58176323:+	0.37	5.41	1.36E-7	Multiple sclerosis	
OV	cis	1	rs1599932	chr12:58177943	TSFM	chr12:58176536-58191367:+	-0.37	-6.32	1.05E-9	Multiple sclerosis	
OV	cis	1	rs160633	chr7:65528228	CCT6P1	chr7:65216092-65228661:+	0.34	4.17	4.13E-5	Diabetic kidney disease	
OV	cis	1	rs160637	chr7:65584318	CCT6P1	chr7:65216092-65228661:+	0.34	4.23	3.23E-5	Diabetic kidney disease	
OV	cis	1	rs160639	chr7:65579987	CCT6P1	chr7:65216092-65228661:+	0.34	4.23	3.23E-5	Diabetic kidney disease	
OV	cis	1	rs160642	chr7:65558373	CCT6P1	chr7:65216092-65228661:+	0.35	4.24	3.03E-5	Diabetic kidney disease	
OV	cis	1	rs160643	chr7:65558222	CCT6P1	chr7:65216092-65228661:+	0.34	4.34	2.03E-5	Diabetic kidney disease	
OV	cis	1	rs160644	chr7:65558186	CCT6P1	chr7:65216092-65228661:+	0.35	4.24	3.03E-5	Diabetic kidney disease	
OV	cis	1	rs160646	chr7:65556280	CCT6P1	chr7:65216092-65228661:+	0.33	4.08	5.82E-5	Diabetic kidney disease	
OV	cis	1	rs160648	chr7:65543384	CCT6P1	chr7:65216092-65228661:+	0.36	4.36	1.8E-5	Diabetic kidney disease	
OV	cis	1	rs160652	chr7:65538431	CCT6P1	chr7:65216092-65228661:+	0.36	4.36	1.82E-5	Diabetic kidney disease	
OV	cis	1	rs160655	chr7:65533214	CCT6P1	chr7:65216092-65228661:+	0.36	4.36	1.8E-5	Diabetic kidney disease	
OV	cis	1	rs1607908	chr3:41905196	ULK4	chr3:41288091-42003660:-	0.62	8.3	4.51E-15	Diastolic blood pressure	
OV	cis	1	rs1609810	chr9:123642351	LOC253039	chr9:123605320-123616644:+	-0.27	-3.98	8.75E-5	Rheumatoid arthritis	
OV	cis	1	rs1612124	chr3:41967893	ULK4	chr3:41288091-42003660:-	-0.64	-8.17	1.13E-14	Diastolic blood pressure	
OV	cis	1	rs1613759	chr3:41906183	ULK4	chr3:41288091-42003660:-	0.61	8.01	3.13E-14	Diastolic blood pressure	
OV	cis	1	rs1615243	chr3:41965234	ULK4	chr3:41288091-42003660:-	-0.69	-9.21	8.33E-18	Diastolic blood pressure	
OV	cis	1	rs1615543	chr3:41906404	ULK4	chr3:41288091-42003660:-	0.61	8.01	3.13E-14	Diastolic blood pressure	
OV	cis	1	rs1618893	chr7:66096119	CRCP	chr7:65579805-65619551:+	-0.39	-3.89	0.000128	Diabetic kidney disease	
OV	cis	1	rs1628874	chr3:41955714	ULK4	chr3:41288091-42003660:-	-0.68	-9.08	2.12E-17	Diastolic blood pressure	
OV	cis	1	rs1629460	chr3:41927449	ULK4	chr3:41288091-42003660:-	-0.61	-8.09	1.89E-14	Diastolic blood pressure	
OV	cis	1	rs1633360	chr12:58108052	FAM119B	chr12:58166383-58176323:+	-0.28	-4.21	3.39E-5	Rheumatoid arthritis	
OV	cis	1	rs1633360	chr12:58108052	TSFM	chr12:58176536-58191367:+	0.25	4.33	2.05E-5	Rheumatoid arthritis	
OV	cis	1	rs1638734	chr7:66097539	CCT6P1	chr7:65216092-65228661:+	0.36	4.36	1.81E-5	Diabetic kidney disease	
OV	cis	1	rs1679709	chr6:28228342	ZNF389	chr6:28129551-28137375:+	0.35	4	8.11E-5	Depression	
OV	cis	1	rs1679732	chr6:28221264	ZNF389	chr6:28129551-28137375:+	0.38	4.47	1.14E-5	Depression	
OV	cis	1	rs16823443	chr3:114711353	ZNF80	chr3:113953478-113956425:-	0.41	4.4	1.55E-5	Type 2 diabetes	
OV	cis	1	rs16826864	chr3:156580033	LEKR1	chr3:156544076-156763918:+	-0.62	-7.62	4.01E-13	Bone mineral density	
OV	cis	1	rs16837131	chr2:202173812	CFLAR	chr2:201980816-202029001:+	0.36	3.9	0.000121	Rheumatoid arthritis	
OV	cis	1	rs16837131	chr2:202173812	PPIL3	chr2:201735680-201753999:-	0.57	6.45	5.01E-10	Rheumatoid arthritis	
OV	cis	1	rs16876529	chr6:86591202	SNHG5	chr6:86386726-86388451:-	-0.67	-11.64	9.29E-26	Response to antipsychotic treatment	
OV	cis	1	rs16879369	chr7:36437829	KIAA0895	chr7:36363759-36429734:-	0.38	4	8.07E-5	Systolic blood pressure	
OV	cis	1	rs16885771	chr8:36898252	BRF2	chr8:37701402-37707411:-	0.36	3.85	0.000144	Insulin resistance/response	
OV	cis	1	rs16889362	chr6:36965705	FTSJD2	chr6:37400907-37449282:+	-0.37	-3.9	0.000119	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	
OV	cis	1	rs1692141	chr1:147230217	ACP6	chr1:147119168-147142634:-	-0.36	-4.05	6.75E-5	Cognitive performance	
OV	cis	1	rs16928809	chr11:2936952	SLC22A18	chr11:2920951-2946475:+	-0.39	-5.17	4.46E-7	Bilirubin levels	
OV	cis	1	rs16935125	chr8:69733918	C8orf34	chr8:69243457-69731256:+	0.43	4.7	4.02E-6	Obesity-related traits	
OV	cis	1	rs16935130	chr8:69735030	C8orf34	chr8:69243457-69731256:+	0.4	4.25	2.97E-5	Obesity-related traits	
OV	cis	1	rs16945894	chr16:48180110	ITFG1	chr16:47189300-47495135:-	-0.43	-4.89	1.73E-6	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs16945894	chr16:48180110	LONP2	chr16:48278211-48387407:+	-0.36	-4.29	2.44E-5	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs16945894	chr16:48180110	PHKB	chr16:47495210-47735433:+	-0.47	-5.41	1.34E-7	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs16945894	chr16:48180110	SIAH1	chr16:48390277-48482309:-	-0.49	-5.46	1.06E-7	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs16958445	chr15:74176557	ARID3B	chr15:74833548-74890470:+	0.5	4.34	2.02E-5	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	CD276	chr15:73976622-74006859:+	0.53	4.25	2.87E-5	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	CLK3	chr15:74890843-74922541:+	0.58	4.28	2.55E-5	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	CSK	chr15:75074425-75095539:+	0.7	5.89	1.1E-8	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	EDC3	chr15:74922900-74988386:-	0.71	5.03	8.65E-7	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	NPTN	chr15:73852345-73925753:-	0.75	5.66	3.71E-8	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	SCAMP2	chr15:75136073-75165670:-	0.61	5.27	2.78E-7	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	STOML1	chr15:74275561-74286949:-	0.5	3.92	0.00011	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	UBL7	chr15:74738318-74753529:-	0.61	4.85	2.02E-6	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16958445	chr15:74176557	ULK3	chr15:75128459-75135552:-	0.66	5.56	6.5E-8	Exfoliation glaucoma or exfoliation syndrome	
OV	cis	1	rs16974263	chr19:40913539	HIPK4	chr19:40885179-40896094:-	0.39	4.18	3.9E-5	Otitis media (recurrent);Otitis media (chronic);Otitis media	
OV	cis	1	rs16995986	chr4:86693317	WDFY3	chr4:85590697-85887544:-	-0.47	-4.76	3.1E-6	Diisocyanate-induced asthma	
OV	cis	1	rs1701750	chr7:65467145	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs1701758	chr7:65470201	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs17045711	chr2:54476678	C2orf73	chr2:54558071-54588714:+	0.3	4.23	3.21E-5	Telomere length	
OV	cis	1	rs17052727	chr3:53070914	SFMBT1	chr3:52938628-53080070:-	-0.5	-4.85	2.1E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs17056262	chr5:158237493	RNF145	chr5:158584419-158637061:-	0.41	3.99	8.43E-5	Hip circumference (psychosocial stress interaction)	
OV	cis	1	rs17061431	chr3:41792655	ULK4	chr3:41288091-42003660:-	0.66	8.69	3.22E-16	Diastolic blood pressure	
OV	cis	1	rs17062109	chr3:41810364	ULK4	chr3:41288091-42003660:-	0.65	8.66	4.09E-16	Diastolic blood pressure	
OV	cis	1	rs17063584	chr3:41861463	ULK4	chr3:41288091-42003660:-	0.59	7.5	8.81E-13	Diastolic blood pressure	
OV	cis	1	rs17063599	chr3:41861676	ULK4	chr3:41288091-42003660:-	0.59	7.52	7.85E-13	Diastolic blood pressure	
OV	cis	1	rs17063649	chr3:41863406	ULK4	chr3:41288091-42003660:-	0.59	7.52	7.85E-13	Diastolic blood pressure	
OV	cis	1	rs17064124	chr3:41890803	ULK4	chr3:41288091-42003660:-	0.63	8.36	3.05E-15	Diastolic blood pressure	
OV	cis	1	rs17067132	chr3:40002028	ZNF619	chr3:40518633-40530114:+	-0.36	-3.92	0.000113	Information processing speed	
OV	cis	1	rs1707304	chr1:46598269	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.12	9.19E-12	Body mass index	
OV	cis	1	rs1707321	chr1:46505309	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.24E-11	Body mass index	
OV	cis	1	rs1707335	chr1:46571921	CCDC163P	chr1:45960581-45965646:-	-0.47	-7.07	1.28E-11	Body mass index	
OV	cis	1	rs1707336	chr1:46493460	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.96	2.4E-11	Body mass index	
OV	cis	1	rs1707340	chr1:46514942	CCDC163P	chr1:45960581-45965646:-	-0.47	-6.98	2.23E-11	Body mass index	
OV	cis	1	rs17092215	chr20:33595913	CPNE1	chr20:34213968-34262539:-	0.42	4	8.03E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs17151904	chr7:25608409	HNRNPA2B1	chr7:26229557-26240413:-	0.28	4.13	4.75E-5	Carotid atherosclerosis in HIV infection	
OV	cis	1	rs1715235	chr7:65488394	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs17155876	chr7:27851055	TAX1BP1	chr7:27778992-27869384:+	0.36	4.37	1.77E-5	Hypospadias	
OV	cis	1	rs17164747	chr4:260587	ZNF718	chr4:53272-156488:+	0.41	4.18	3.9E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs1716642	chr3:41965865	ULK4	chr3:41288091-42003660:-	-0.69	-9.21	8.33E-18	Diastolic blood pressure	
OV	cis	1	rs1716644	chr3:41968028	ULK4	chr3:41288091-42003660:-	-0.64	-8.17	1.13E-14	Diastolic blood pressure	
OV	cis	1	rs1716651	chr3:41975099	ULK4	chr3:41288091-42003660:-	-0.69	-9.21	8.33E-18	Diastolic blood pressure	
OV	cis	1	rs1716657	chr3:41918456	ULK4	chr3:41288091-42003660:-	-0.61	-8.06	2.38E-14	Diastolic blood pressure	
OV	cis	1	rs1716660	chr3:41929960	ULK4	chr3:41288091-42003660:-	-0.63	-8.38	2.69E-15	Diastolic blood pressure	
OV	cis	1	rs1716661	chr3:41962818	ULK4	chr3:41288091-42003660:-	-0.69	-9.17	1.09E-17	Diastolic blood pressure	
OV	cis	1	rs1716664	chr3:41948378	ULK4	chr3:41288091-42003660:-	-0.68	-9.08	2.12E-17	Diastolic blood pressure	
OV	cis	1	rs1716668	chr3:41907850	ULK4	chr3:41288091-42003660:-	0.61	8.01	3.13E-14	Diastolic blood pressure	
OV	cis	1	rs1716669	chr3:41908681	ULK4	chr3:41288091-42003660:-	0.62	8.3	4.51E-15	Diastolic blood pressure	
OV	cis	1	rs1716676	chr3:41903208	ULK4	chr3:41288091-42003660:-	0.61	8.01	3.13E-14	Diastolic blood pressure	
OV	cis	1	rs1716683	chr3:41923074	ULK4	chr3:41288091-42003660:-	-0.61	-8.06	2.38E-14	Diastolic blood pressure	
OV	cis	1	rs1716685	chr3:41925301	ULK4	chr3:41288091-42003660:-	0.66	8.69	3.24E-16	Diastolic blood pressure	
OV	cis	1	rs1716688	chr3:41926546	ULK4	chr3:41288091-42003660:-	-0.61	-8.09	1.89E-14	Diastolic blood pressure	
OV	cis	1	rs1716690	chr3:41922102	ULK4	chr3:41288091-42003660:-	-0.61	-8.06	2.38E-14	Diastolic blood pressure	
OV	cis	1	rs1716692	chr3:41983786	ULK4	chr3:41288091-42003660:-	-0.68	-9.12	1.59E-17	Diastolic blood pressure	
OV	cis	1	rs1716693	chr3:41985600	ULK4	chr3:41288091-42003660:-	-0.67	-9.11	1.66E-17	Diastolic blood pressure	
OV	cis	1	rs1716696	chr3:41935811	ULK4	chr3:41288091-42003660:-	-0.63	-8.38	2.69E-15	Diastolic blood pressure	
OV	cis	1	rs1716984	chr3:41965532	ULK4	chr3:41288091-42003660:-	-0.69	-9.28	5.2E-18	Diastolic blood pressure	
OV	cis	1	rs1716987	chr3:41970516	ULK4	chr3:41288091-42003660:-	-0.64	-8.18	1.03E-14	Diastolic blood pressure	
OV	cis	1	rs1716993	chr3:41974556	ULK4	chr3:41288091-42003660:-	-0.64	-8.17	1.13E-14	Diastolic blood pressure	
OV	cis	1	rs1716997	chr3:41924333	ULK4	chr3:41288091-42003660:-	-0.61	-8.06	2.31E-14	Diastolic blood pressure	
OV	cis	1	rs1716999	chr3:41930041	ULK4	chr3:41288091-42003660:-	-0.63	-8.38	2.69E-15	Diastolic blood pressure	
OV	cis	1	rs1717000	chr3:41930219	ULK4	chr3:41288091-42003660:-	-0.63	-8.38	2.69E-15	Diastolic blood pressure	
OV	cis	1	rs1717001	chr3:41934949	ULK4	chr3:41288091-42003660:-	-0.61	-8.09	1.89E-14	Diastolic blood pressure	
OV	cis	1	rs1717006	chr3:41940448	ULK4	chr3:41288091-42003660:-	0.63	8.39	2.58E-15	Diastolic blood pressure	
OV	cis	1	rs1717009	chr3:41946308	ULK4	chr3:41288091-42003660:-	-0.68	-9.08	2.12E-17	Diastolic blood pressure	
OV	cis	1	rs1717011	chr3:41980199	ULK4	chr3:41288091-42003660:-	-0.69	-9.21	8.33E-18	Diastolic blood pressure	
OV	cis	1	rs1717014	chr3:41917395	ULK4	chr3:41288091-42003660:-	0.61	8.06	2.38E-14	Diastolic blood pressure	
OV	cis	1	rs1717017	chr3:41915616	ULK4	chr3:41288091-42003660:-	0.61	8.01	3.13E-14	Diastolic blood pressure	
OV	cis	1	rs1717020	chr3:41981490	ULK4	chr3:41288091-42003660:-	0.67	8.96	4.93E-17	Diastolic blood pressure	
OV	cis	1	rs1717021	chr3:41983860	ULK4	chr3:41288091-42003660:-	-0.68	-9.12	1.59E-17	Diastolic blood pressure	
OV	cis	1	rs1717024	chr3:41984888	ULK4	chr3:41288091-42003660:-	-0.68	-9.21	8.65E-18	Diastolic blood pressure	
OV	cis	1	rs1717027	chr3:41987920	ULK4	chr3:41288091-42003660:-	-0.67	-9.11	1.66E-17	Diastolic blood pressure	
OV	cis	1	rs1717031	chr3:41905791	ULK4	chr3:41288091-42003660:-	0.61	8.01	3.13E-14	Diastolic blood pressure	
OV	cis	1	rs1717033	chr3:41910216	ULK4	chr3:41288091-42003660:-	0.62	8.3	4.51E-15	Diastolic blood pressure	
OV	cis	1	rs17170593	chr7:36491811	KIAA0895	chr7:36363759-36429734:-	0.36	3.87	0.000136	Systolic blood pressure	
OV	cis	1	rs17214441	chr2:207683777	MDH1B	chr2:207598943-207630050:-	0.48	4.2	3.53E-5	Episodic memory	
OV	cis	1	rs1723267	chr7:65473314	CCT6P1	chr7:65216092-65228661:+	0.37	4.59	6.59E-6	Diabetic kidney disease	
OV	cis	1	rs1723269	chr7:65472786	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs1723270	chr7:65469830	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs17290922	chr16:57024317	BBS2	chr16:56518259-56554008:-	-0.43	-4.2	3.66E-5	Schizophrenia	
OV	cis	1	rs17290922	chr16:57024317	CIAPIN1	chr16:57462087-57481369:-	-0.47	-4.24	3.0E-5	Schizophrenia	
OV	cis	1	rs17290922	chr16:57024317	COQ9	chr16:57481402-57495178:+	-0.46	-4.63	5.57E-6	Schizophrenia	
OV	cis	1	rs17290922	chr16:57024317	HERPUD1	chr16:56965748-56977793:+	-0.41	-3.98	8.73E-5	Schizophrenia	
OV	cis	1	rs17290922	chr16:57024317	OGFOD1	chr16:56485424-56511406:+	-0.55	-4.8	2.6E-6	Schizophrenia	
OV	cis	1	rs17290922	chr16:57024317	POLR2C	chr16:57496551-57505921:+	-0.42	-4.04	6.88E-5	Schizophrenia	
OV	cis	1	rs17311679	chr19:50521331	SIGLEC16	chr19:50472912-50479075:+	-0.63	-4.7	4.18E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
OV	cis	1	rs17317888	chr20:33594959	CPNE1	chr20:34213968-34262539:-	0.43	3.87	0.000138	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs17412623	chr8:20221586	ATP6V1B2	chr8:20054704-20079205:+	0.37	3.93	0.000109	Preeclampsia	
OV	cis	1	rs17412623	chr8:20221586	INTS10	chr8:19674918-19709584:+	0.43	4.03	7.2E-5	Preeclampsia	
OV	cis	1	rs17433780	chr1:89474818	GBP3	chr1:89472367-89488549:-	0.74	16.25	3.73E-42	Carotid intima media thickness	
OV	cis	1	rs17471911	chr10:100670906	PYROXD2	chr10:100143323-100174978:-	0.7	4.03	7.11E-5	Neuroticism	
OV	cis	1	rs17496332	chr1:107546375	PRMT6	chr1:107599267-107601907:+	0.35	4.6	6.56E-6	Sex hormone-binding globulin levels	
OV	cis	1	rs17507481	chr4:17620066	LAP3	chr4:17578927-17609590:+	-0.25	-4.27	2.73E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs17595424	chr4:99993869	EIF4E	chr4:99799607-99851786:-	-0.37	-4.19	3.71E-5	Smoking initiation	
OV	cis	1	rs17595424	chr4:99993869	METAP1	chr4:99916788-99983959:+	-0.38	-4.05	6.77E-5	Smoking initiation	
OV	cis	1	rs17596617	chr11:43690717	HSD17B12	chr11:43702143-43878160:+	-0.46	-6.84	5.21E-11	Forced vital capacity	
OV	cis	1	rs17608059	chr17:13910549	CDRT15P	chr17:13927815-13928915:+	-0.61	-9.28	5.0E-18	Temperament	
OV	cis	1	rs17649068	chr1:171713893	VAMP4	chr1:171669298-171711214:-	0.41	5.12	5.71E-7	Hippocampal atrophy	
OV	cis	1	rs17649250	chr1:171720586	VAMP4	chr1:171669298-171711214:-	0.43	5.25	2.96E-7	Hippocampal atrophy	
OV	cis	1	rs17661933	chr19:50534520	SIGLEC16	chr19:50472912-50479075:+	-0.59	-4.7	4.01E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
OV	cis	1	rs17669480	chr10:102066065	SLC25A28	chr10:101370275-101418994:-	0.49	4.58	6.89E-6	Obesity-related traits	
OV	cis	1	rs1768803	chr1:46546208	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.16	7.23E-12	Body mass index	
OV	cis	1	rs1768816	chr1:46528599	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.1	1.03E-11	Body mass index	
OV	cis	1	rs17694011	chr3:134213981	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs17713396	chr2:227201	SH3YL1	chr2:218138-264810:-	-0.56	-7.69	2.54E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs17713729	chr2:249092	SH3YL1	chr2:218138-264810:-	-0.5	-7.37	2.0E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs17714252	chr2:285471	SH3YL1	chr2:218138-264810:-	-0.54	-7.57	5.64E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs17746014	chr10:102315354	SEC31B	chr10:102246403-102289636:-	-0.26	-3.93	0.000108	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs1778508	chr6:28229881	ZNF389	chr6:28129551-28137375:+	0.33	3.92	0.000111	Depression	
OV	cis	1	rs1778511	chr6:28229411	ZNF389	chr6:28129551-28137375:+	0.35	4.02	7.39E-5	Depression	
OV	cis	1	rs17839567	chr16:31057945	HSD3B7	chr16:30996519-31000473:+	0.31	5.03	8.79E-7	Response to metformin (IC50)	
OV	cis	1	rs17839567	chr16:31057945	STX1B	chr16:31000577-31021829:-	0.26	3.96	9.4E-5	Response to metformin (IC50)	
OV	cis	1	rs1795967	chr12:122344302	WDR66	chr12:122356480-122441830:+	-0.42	-4.11	5.22E-5	Urinary metabolites	
OV	cis	1	rs1796220	chr7:66062100	CCT6P1	chr7:65216092-65228661:+	0.38	4.55	7.94E-6	Diabetic kidney disease	
OV	cis	1	rs1796228	chr7:66033084	CCT6P1	chr7:65216092-65228661:+	0.34	4.14	4.58E-5	Diabetic kidney disease	
OV	cis	1	rs1800662	chr10:102289078	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs1803037	chr4:99993151	EIF4E	chr4:99799607-99851786:-	-0.34	-4.18	3.99E-5	Smoking initiation	
OV	cis	1	rs1814336	chr3:134200823	ANAPC13	chr3:134196547-134204865:-	0.42	5.98	6.84E-9	Height	
OV	cis	1	rs1814337	chr3:134200682	ANAPC13	chr3:134196547-134204865:-	0.4	5.7	3.05E-8	Height	
OV	cis	1	rs1833896	chr5:56097669	C5orf35	chr5:56205103-56213010:+	0.7	9.56	6.71E-19	Type 2 diabetes	
OV	cis	1	rs1857964	chr6:86635994	SNHG5	chr6:86386726-86388451:-	-0.69	-11.6	1.23E-25	Response to antipsychotic treatment	
OV	cis	1	rs1857965	chr6:86630776	SNHG5	chr6:86386726-86388451:-	-0.65	-11.02	1.16E-23	Response to antipsychotic treatment	
OV	cis	1	rs1860596	chr4:17660082	LAP3	chr4:17578927-17609590:+	-0.27	-4.68	4.52E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1860597	chr4:17657650	LAP3	chr4:17578927-17609590:+	-0.26	-4.6	6.54E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1862619	chr5:56098256	C5orf35	chr5:56205103-56213010:+	0.7	9.56	6.71E-19	Type 2 diabetes	
OV	cis	1	rs186378	chr7:65582058	CCT6P1	chr7:65216092-65228661:+	0.34	4.23	3.23E-5	Diabetic kidney disease	
OV	cis	1	rs1863913	chr3:134200205	ANAPC13	chr3:134196547-134204865:-	0.39	5.5	8.67E-8	Height	
OV	cis	1	rs1864367	chr3:53111704	RFT1	chr3:53122503-53164470:-	-0.36	-5.11	5.91E-7	Height	
OV	cis	1	rs1867486	chr16:86681155	COX4I1	chr16:85833196-85840605:+	0.28	4.26	2.78E-5	IgG glycosylation	
OV	cis	1	rs1867486	chr16:86681155	COX4NB	chr16:85812233-85833148:-	0.33	4.24	3.04E-5	IgG glycosylation	
OV	cis	1	rs1867486	chr16:86681155	MAP1LC3B	chr16:87425801-87438379:+	0.34	3.93	0.000109	IgG glycosylation	
OV	cis	1	rs1867486	chr16:86681155	ZCCHC14	chr16:87439852-87525460:-	0.31	4.23	3.21E-5	IgG glycosylation	
OV	cis	1	rs1872329	chr2:54471823	C2orf73	chr2:54558071-54588714:+	0.32	4.22	3.29E-5	Telomere length	
OV	cis	1	rs1874883	chr3:134205071	ANAPC13	chr3:134196547-134204865:-	0.43	6.14	2.83E-9	Height	
OV	cis	1	rs1875124	chr12:58196802	FAM119B	chr12:58166383-58176323:+	0.37	5.41	1.36E-7	Multiple sclerosis	
OV	cis	1	rs1875124	chr12:58196802	TSFM	chr12:58176536-58191367:+	-0.37	-6.32	1.05E-9	Multiple sclerosis	
OV	cis	1	rs1880376	chr3:134270347	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs1880377	chr3:134270468	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs1881245	chr2:73649928	ALMS1P	chr2:73872046-73912692:+	0.37	5.72	2.77E-8	Metabolite levels	
OV	cis	1	rs1888997	chr20:25298988	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.5E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1888997	chr20:25298988	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1888998	chr20:25291826	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1888998	chr20:25291826	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1888999	chr20:25291848	ABHD12	chr20:25275380-25371477:-	0.38	5.63	4.49E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1888999	chr20:25291848	FAM182B	chr20:25744102-25848786:-	0.33	5.07	7.13E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs1893767	chr11:123956466	ZNF202	chr11:123594997-123612363:-	-0.38	-3.96	9.63E-5	Obesity-related traits	
OV	cis	1	rs190414	chr5:56116772	C5orf35	chr5:56205103-56213010:+	0.67	8.41	2.18E-15	Type 2 diabetes	
OV	cis	1	rs1911552	chr6:86638024	SNHG5	chr6:86386726-86388451:-	-0.66	-11.67	7.28E-26	Response to antipsychotic treatment	
OV	cis	1	rs1911553	chr6:86630892	SNHG5	chr6:86386726-86388451:-	-0.65	-11	1.32E-23	Response to antipsychotic treatment	
OV	cis	1	rs1917130	chr3:134313773	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.51	8.41E-8	Height	
OV	cis	1	rs1919948	chr7:143762843	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.62	4.77E-8	Obesity-related traits	
OV	cis	1	rs1919948	chr7:143762843	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.98	8.85E-5	Obesity-related traits	
OV	cis	1	rs1919948	chr7:143762843	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.24	3.07E-5	Obesity-related traits	
OV	cis	1	rs1919949	chr7:143767723	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.84	1.47E-8	Obesity-related traits	
OV	cis	1	rs1919949	chr7:143767723	CTAGE6	chr7:143452184-143454843:-	-0.34	-4.29	2.43E-5	Obesity-related traits	
OV	cis	1	rs1919949	chr7:143767723	OR2A9P	chr7:143991573-143997832:+;chr7	-0.33	-4	8.22E-5	Obesity-related traits	
OV	cis	1	rs1919950	chr7:143767898	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.75	2.42E-8	Obesity-related traits	
OV	cis	1	rs1919950	chr7:143767898	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.09	5.61E-5	Obesity-related traits	
OV	cis	1	rs1919950	chr7:143767898	OR2A9P	chr7:143991573-143997832:+;chr7	-0.33	-4.03	7.3E-5	Obesity-related traits	
OV	cis	1	rs1919951	chr7:143768891	ARHGEF35	chr7:143883677-143892736:-	-0.48	-6.13	3.03E-9	Obesity-related traits	
OV	cis	1	rs1919951	chr7:143768891	CTAGE6	chr7:143452184-143454843:-	-0.36	-4.5	1.01E-5	Obesity-related traits	
OV	cis	1	rs1919951	chr7:143768891	OR2A9P	chr7:143991573-143997832:+;chr7	-0.33	-3.98	8.93E-5	Obesity-related traits	
OV	cis	1	rs1927726	chr13:99912883	TM9SF2	chr13:100153728-100215276:+	-0.37	-4.69	4.26E-6	Basal cell carcinoma	
OV	cis	1	rs1927726	chr13:99912883	UBAC2	chr13:99852679-100038751:+	-0.34	-4.25	2.87E-5	Basal cell carcinoma	
OV	cis	1	rs1933182	chr1:109999838	MYBPHL	chr1:109834987-109849663:-	-0.58	-8.72	2.6E-16	Chronic kidney disease	
OV	cis	1	rs1953126	chr9:123640500	LOC253039	chr9:123605320-123616644:+	-0.29	-4.16	4.17E-5	Rheumatoid arthritis	
OV	cis	1	rs1962716	chr6:86648436	SNHG5	chr6:86386726-86388451:-	-0.69	-11.74	4.21E-26	Response to antipsychotic treatment	
OV	cis	1	rs1964692	chr7:65454183	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs1974624	chr4:17650281	LAP3	chr4:17578927-17609590:+	-0.28	-4.94	1.33E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs1979755	chr2:42708405	HAAO	chr2:42994230-43019751:-	-0.27	-4.26	2.84E-5	Body mass index	
OV	cis	1	rs1979755	chr2:42708405	OXER1	chr2:42989641-42991401:-	-0.25	-4.5	1.01E-5	Body mass index	
OV	cis	1	rs1979	chr6:26377591	BTN3A2	chr6:26365398-26378546:+	-0.5	-5.05	8.18E-7	Schizophrenia	
OV	cis	1	rs1986557	chr4:283118	ZNF718	chr4:53272-156488:+	0.4	4.51	9.53E-6	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs1994157	chr3:41897482	ULK4	chr3:41288091-42003660:-	0.61	7.51	8.37E-13	Diastolic blood pressure	
OV	cis	1	rs1995688	chr6:86632319	SNHG5	chr6:86386726-86388451:-	-0.65	-11	1.32E-23	Response to antipsychotic treatment	
OV	cis	1	rs2006751	chr11:43670501	HSD17B12	chr11:43702143-43878160:+	-0.41	-6.02	5.6E-9	Forced vital capacity	
OV	cis	1	rs2007981	chr19:18567555	SSBP4	chr19:18530221-18545371:+	-0.33	-4.17	4.08E-5	Breast cancer	
OV	cis	1	rs200807	chr6:97903674	NDUFAF4	chr6:97338140-97345767:-	0.26	4.15	4.45E-5	Body mass index	
OV	cis	1	rs200810	chr6:97922184	NDUFAF4	chr6:97338140-97345767:-	0.25	3.95	9.78E-5	Body mass index	
OV	cis	1	rs200825	chr6:97888120	NDUFAF4	chr6:97338140-97345767:-	0.26	4.13	4.73E-5	Body mass index	
OV	cis	1	rs200827	chr6:97893014	NDUFAF4	chr6:97338140-97345767:-	-0.26	-4.09	5.6E-5	Body mass index	
OV	cis	1	rs200830	chr6:97895282	NDUFAF4	chr6:97338140-97345767:-	0.26	4.08	5.97E-5	Body mass index	
OV	cis	1	rs200832	chr6:97896930	NDUFAF4	chr6:97338140-97345767:-	0.26	4.17	4.12E-5	Body mass index	
OV	cis	1	rs2010648	chr14:35604892	KIAA0391	chr14:35591776-35786673:+	0.38	4.24	3.1E-5	Atopic dermatitis	
OV	cis	1	rs2010648	chr14:35604892	PPP2R3C	chr14:35554679-35591679:-	0.38	4.51	9.58E-6	Atopic dermatitis	
OV	cis	1	rs2014572	chr19:57760018	ZNF264	chr19:57702869-57734212:+	-0.22	-4.45	1.26E-5	Hyperactive-impulsive symptoms	
OV	cis	1	rs2027003	chr20:25350498	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2027003	chr20:25350498	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2027004	chr20:25350618	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2027004	chr20:25350618	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2045554	chr3:48494542	TREX1	chr3:48501186-48509043:+	0.25	4.74	3.37E-6	Longevity	
OV	cis	1	rs2048765	chr2:240208154	MGC16025	chr2:240115027-240117153:-	0.64	4.65	5.05E-6	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs2052197	chr7:36492212	KIAA0895	chr7:36363759-36429734:-	0.36	3.87	0.000136	Systolic blood pressure	
OV	cis	1	rs2056603	chr3:134312749	ANAPC13	chr3:134196547-134204865:-	0.4	5.53	7.41E-8	Height	
OV	cis	1	rs2056604	chr3:134312648	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs2058059	chr7:72311817	TYW1B	chr7:72023729-72298813:-	-0.58	-6.08	4.08E-9	Subcutaneous adipose tissue	
OV	cis	1	rs2058337	chr4:17678649	LAP3	chr4:17578927-17609590:+	-0.27	-4.65	5.15E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2058338	chr4:17678600	LAP3	chr4:17578927-17609590:+	0.29	5.06	7.72E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2058339	chr4:17678456	LAP3	chr4:17578927-17609590:+	-0.25	-4.31	2.31E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2069502	chr12:58144665	FAM119B	chr12:58166383-58176323:+	-0.34	-4.99	1.08E-6	Multiple sclerosis	
OV	cis	1	rs2069502	chr12:58144665	TSFM	chr12:58176536-58191367:+	0.35	5.99	6.67E-9	Multiple sclerosis	
OV	cis	1	rs2072052	chr12:58146719	FAM119B	chr12:58166383-58176323:+	0.35	5.07	7.39E-7	Multiple sclerosis	
OV	cis	1	rs2072052	chr12:58146719	TSFM	chr12:58176536-58191367:+	-0.36	-6.15	2.69E-9	Multiple sclerosis	
OV	cis	1	rs2072293	chr14:74537885	LIN52	chr14:74551656-74667117:+	0.26	4.02	7.42E-5	Common traits (Other)	
OV	cis	1	rs2074038	chr11:44087989	ACCS	chr11:44087475-44105569:+	0.66	6.66	1.46E-10	IgA nephropathy	
OV	cis	1	rs2074580	chr7:27833853	TAX1BP1	chr7:27778992-27869384:+	0.33	4.09	5.59E-5	Hypospadias	
OV	cis	1	rs2074771	chr2:242350944	SEPT2	chr2:242254723-242293439:+	0.67	5.77	2.16E-8	Chronic lymphocytic leukemia	
OV	cis	1	rs2077808	chr1:45988115	CCDC163P	chr1:45960581-45965646:-	-0.98	-16.51	4.3E-43	Homocysteine levels	
OV	cis	1	rs2077808	chr1:45988115	MMACHC	chr1:45965856-45976737:+	-0.3	-4.15	4.38E-5	Homocysteine levels	
OV	cis	1	rs2087343	chr12:48675783	TMEM106C	chr12:48357330-48362660:+	0.42	4.53	8.75E-6	Prostate cancer	
OV	cis	1	rs2109522	chr4:17658645	LAP3	chr4:17578927-17609590:+	-0.26	-4.5	9.95E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2113078	chr5:56087190	C5orf35	chr5:56205103-56213010:+	0.7	9.07	2.23E-17	Type 2 diabetes	
OV	cis	1	rs2113079	chr5:56157951	C5orf35	chr5:56205103-56213010:+	0.73	9.83	9.21E-20	Type 2 diabetes	
OV	cis	1	rs2126129	chr2:212548	SH3YL1	chr2:218138-264810:-	-0.5	-6.93	3.03E-11	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs2128834	chr3:41862645	ULK4	chr3:41288091-42003660:-	0.58	7.43	1.37E-12	Diastolic blood pressure	
OV	cis	1	rs2128835	chr3:41862873	ULK4	chr3:41288091-42003660:-	0.59	7.52	7.85E-13	Diastolic blood pressure	
OV	cis	1	rs2137920	chr10:50229638	PARG	chr10:51026327-51729967:-	-0.31	-3.85	0.000145	Migraine with aura	
OV	cis	1	rs2141924	chr7:66186246	CCT6P1	chr7:65216092-65228661:+	0.33	3.93	0.000106	Gout	
OV	cis	1	rs2143950	chr14:35572357	KIAA0391	chr14:35591776-35786673:+	0.42	4.52	9.3E-6	Atopic dermatitis	
OV	cis	1	rs2143950	chr14:35572357	PPP2R3C	chr14:35554679-35591679:-	0.37	4.26	2.84E-5	Atopic dermatitis	
OV	cis	1	rs2154536	chr21:38492147	PIGP	chr21:38437664-38445458:-	-0.32	-5.73	2.58E-8	Eye color traits	
OV	cis	1	rs2159583	chr4:17658838	LAP3	chr4:17578927-17609590:+	-0.27	-4.71	3.99E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2159584	chr4:17620568	LAP3	chr4:17578927-17609590:+	-0.23	-3.86	0.000139	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2160392	chr2:37527393	CEBPZ	chr2:37428778-37458740:-	-0.27	-4.12	4.93E-5	Chronic lymphocytic leukemia	
OV	cis	1	rs2160393	chr2:37516950	CEBPZ	chr2:37428778-37458740:-	-0.28	-4.44	1.29E-5	Chronic lymphocytic leukemia	
OV	cis	1	rs2163167	chr3:53131772	RFT1	chr3:53122503-53164470:-	-0.33	-4.71	3.98E-6	Height	
OV	cis	1	rs2163287	chr6:158041283	ARID1B	chr6:157099086-157530401:+	0.53	5.14	5.12E-7	Response to anti-depressant treatment in major depressive disorder	
OV	cis	1	rs2163287	chr6:158041283	GTF2H5	chr6:158589379-158620366:+	0.53	4.63	5.58E-6	Response to anti-depressant treatment in major depressive disorder	
OV	cis	1	rs2163287	chr6:158041283	SNX9	chr6:158244294-158366109:+	0.55	4.41	1.45E-5	Response to anti-depressant treatment in major depressive disorder	
OV	cis	1	rs2163846	chr19:22505844	ZNF98	chr19:22573899-22605148:-	0.26	3.91	0.000115	Telomere length	
OV	cis	1	rs2164879	chr2:86261579	LOC90784	chr2:86247339-86250991:-	-0.6	-4.53	8.74E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs2166663	chr6:86593896	SNHG5	chr6:86386726-86388451:-	-0.65	-11.25	1.98E-24	Response to antipsychotic treatment	
OV	cis	1	rs2177601	chr3:134245434	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs2177703	chr7:65391717	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs2184000	chr20:25395878	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.14E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2184000	chr20:25395878	FAM182B	chr20:25744102-25848786:-	-0.33	-5.07	7.46E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2210913	chr1:157668993	FCRL3	chr1:157646278-157670775:-	0.27	4.62	5.97E-6	Type 1 diabetes autoantibodies	
OV	cis	1	rs2215450	chr4:17675394	LAP3	chr4:17578927-17609590:+	-0.25	-4.18	3.85E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2229384	chr6:49425521	CENPQ	chr6:49431096-49460820:+	0.23	4.01	7.88E-5	Homocysteine levels	
OV	cis	1	rs2229687	chr1:10473196	PGD	chr1:10459085-10480200:+	0.35	4.96	1.21E-6	Hepatocellular carcinoma	
OV	cis	1	rs223116	chr14:23977010	C14orf93	chr14:23456111-23479360:-	0.31	4.15	4.41E-5	Resting heart rate	
OV	cis	1	rs2235542	chr1:209807815	C1orf107	chr1:210001333-210030908:+	0.43	4.1	5.51E-5	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours)	
OV	cis	1	rs2236246	chr14:104379206	TDRD9	chr14:104394817-104519002:+	-0.35	-4.77	2.94E-6	Bipolar disorder	
OV	cis	1	rs2236247	chr14:104378087	TDRD9	chr14:104394817-104519002:+	0.4	5.34	1.97E-7	Bipolar disorder	
OV	cis	1	rs2242050	chr10:102059329	SLC25A28	chr10:101370275-101418994:-	0.49	4.63	5.55E-6	Obesity-related traits	
OV	cis	1	rs2242150	chr3:48505964	TREX1	chr3:48501186-48509043:+	0.26	4.82	2.4E-6	Longevity	
OV	cis	1	rs2242471	chr4:76878716	NAAA	chr4:76831809-76862166:-	0.27	4.58	7.07E-6	Longevity	
OV	cis	1	rs2242473	chr4:76878956	NAAA	chr4:76831809-76862166:-	0.27	4.6	6.55E-6	Longevity	
OV	cis	1	rs2242474	chr4:76878982	NAAA	chr4:76831809-76862166:-	0.27	4.58	7.07E-6	Longevity	
OV	cis	1	rs224333	chr20:34023962	GDF5	chr20:33897002-34042568:-	0.34	4.55	8.17E-6	Height	
OV	cis	1	rs2243480	chr7:65599196	CCT6P1	chr7:65216092-65228661:+	0.31	3.95	9.94E-5	Diabetic kidney disease	
OV	cis	1	rs2244967	chr10:50224766	PARG	chr10:51026327-51729967:-	0.3	3.92	0.000114	Migraine with aura	
OV	cis	1	rs2246833	chr10:91005854	LIPA	chr10:90973328-91174382:-	0.26	5.33	2.03E-7	Fibrinogen levels	
OV	cis	1	rs2248393	chr20:33926103	GDF5	chr20:33897002-34042568:-	0.29	3.95	9.75E-5	Height	
OV	cis	1	rs2252502	chr7:158738634	WDR60	chr7:158649269-158738882:+	0.27	4.14	4.61E-5	Height	
OV	cis	1	rs2253209	chr3:53115160	RFT1	chr3:53122503-53164470:-	-0.33	-4.7	4.19E-6	Height	
OV	cis	1	rs2253656	chr3:53119099	RFT1	chr3:53122503-53164470:-	-0.34	-4.8	2.64E-6	Height	
OV	cis	1	rs2253685	chr3:53119703	RFT1	chr3:53122503-53164470:-	-0.34	-4.75	3.33E-6	Height	
OV	cis	1	rs2253796	chr3:53120098	RFT1	chr3:53122503-53164470:-	-0.34	-4.75	3.29E-6	Height	
OV	cis	1	rs2257420	chr20:25275890	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257420	chr20:25275890	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257432	chr20:25271086	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257432	chr20:25271086	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257496	chr20:25279315	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257496	chr20:25279315	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257790	chr7:65600450	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs2257808	chr20:25266450	ABHD12	chr20:25275380-25371477:-	0.41	5.97	7.2E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257808	chr20:25266450	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257809	chr20:25266476	ABHD12	chr20:25275380-25371477:-	0.41	5.97	7.2E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257809	chr20:25266476	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257982	chr20:25269630	ABHD12	chr20:25275380-25371477:-	0.41	5.97	7.28E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257982	chr20:25269630	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.9E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257985	chr20:25269743	ABHD12	chr20:25275380-25371477:-	0.41	5.97	7.28E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257985	chr20:25269743	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.9E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257988	chr20:25270003	ABHD12	chr20:25275380-25371477:-	0.41	5.97	7.28E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257988	chr20:25270003	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.9E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257991	chr20:25270339	ABHD12	chr20:25275380-25371477:-	-0.39	-5.63	4.31E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2257991	chr20:25270339	FAM182B	chr20:25744102-25848786:-	-0.32	-4.88	1.76E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258066	chr20:25271326	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258066	chr20:25271326	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258135	chr20:25272323	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258135	chr20:25272323	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258201	chr20:25272490	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258201	chr20:25272490	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258563	chr20:25273435	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258563	chr20:25273435	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258617	chr20:25274318	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258617	chr20:25274318	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258719	chr20:25275843	ABHD12	chr20:25275380-25371477:-	0.39	5.63	4.38E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258719	chr20:25275843	FAM182B	chr20:25744102-25848786:-	0.33	5.06	7.64E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258769	chr20:25276680	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258769	chr20:25276680	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258879	chr20:25279213	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258879	chr20:25279213	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258884	chr20:25279539	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2258884	chr20:25279539	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259837	chr20:25280205	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259837	chr20:25280205	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259873	chr20:25280781	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259873	chr20:25280781	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259926	chr20:25281733	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259926	chr20:25281733	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259928	chr20:25281834	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259928	chr20:25281834	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259956	chr20:25282433	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2259956	chr20:25282433	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2269186	chr14:104379912	TDRD9	chr14:104394817-104519002:+	0.41	5.49	9.23E-8	Bipolar disorder	
OV	cis	1	rs2272006	chr3:41997059	ULK4	chr3:41288091-42003660:-	-0.67	-9.11	1.66E-17	Diastolic blood pressure	
OV	cis	1	rs2272007	chr3:41996136	ULK4	chr3:41288091-42003660:-	-0.7	-9.33	3.6E-18	Diastolic blood pressure	
OV	cis	1	rs2272390	chr2:202195311	PPIL3	chr2:201735680-201753999:-	-0.51	-4.63	5.51E-6	Rheumatoid arthritis	
OV	cis	1	rs2273695	chr10:102259568	SEC31B	chr10:102246403-102289636:-	-0.27	-4.18	3.85E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2273	chr4:76889388	NAAA	chr4:76831809-76862166:-	0.29	4.98	1.11E-6	Longevity	
OV	cis	1	rs2274459	chr6:33762242	IP6K3	chr6:33689443-33714762:-	0.49	5.35	1.87E-7	Obesity (extreme)	
OV	cis	1	rs2275426	chr1:46487552	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.96	2.4E-11	Body mass index	
OV	cis	1	rs2276547	chr2:28975107	TRMT61B	chr2:29072690-29093175:-	-0.3	-3.88	0.000132	Body mass index	
OV	cis	1	rs2277862	chr20:34152782	CPNE1	chr20:34213968-34262539:-	-0.59	-6.28	1.34E-9	Cholesterol, total	
OV	cis	1	rs2278238	chr19:18576484	SSBP4	chr19:18530221-18545371:+	-0.31	-3.97	9.15E-5	Breast cancer	
OV	cis	1	rs2278842	chr10:102056745	SLC25A28	chr10:101370275-101418994:-	0.47	4.77	2.99E-6	Obesity-related traits	
OV	cis	1	rs2278843	chr10:102056508	DNMBP	chr10:101635334-101769676:-	0.25	4.45	1.22E-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)	
OV	cis	1	rs2279077	chr3:48474249	TREX1	chr3:48501186-48509043:+	-0.27	-5.15	4.87E-7	Longevity	
OV	cis	1	rs2281006	chr1:171110869	FMO3	chr1:171060018-171086957:+	-0.35	-4.19	3.8E-5	Blood metabolite levels	
OV	cis	1	rs2286771	chr4:17643848	LAP3	chr4:17578927-17609590:+	-0.26	-4.59	6.73E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2286809	chr11:22851455	SVIP	chr11:22843600-22851382:-	0.28	4.29	2.5E-5	Dialysis-related mortality	
OV	cis	1	rs2288073	chr2:24413298	LOC375190	chr2:24299728-24397519:+	0.35	4.73	3.54E-6	Venous thromboembolism (SNP x SNP interaction)	
OV	cis	1	rs2290822	chr3:48473204	NME6	chr3:48335591-48342886:-	-0.28	-3.92	0.00011	Longevity	
OV	cis	1	rs2290822	chr3:48473204	TREX1	chr3:48501186-48509043:+	-0.26	-4.93	1.39E-6	Longevity	
OV	cis	1	rs2290911	chr2:224919	SH3YL1	chr2:218138-264810:-	-0.55	-7.65	3.38E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs2292239	chr12:56482180	RPS26	chr12:56435686-56438005:+	0.4	7.13	8.54E-12	Cognitive function	
OV	cis	1	rs2294010	chr8:143762430	LY6K	chr8:143781529-143785582:+	0.29	4.03	7.33E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2294010	chr8:143762430	PSCA	chr8:143761875-143764142:+	0.28	4.42	1.42E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2295700	chr20:33591627	CPNE1	chr20:34213968-34262539:-	0.43	3.87	0.000138	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs2295772	chr10:102265183	SEC31B	chr10:102246403-102289636:-	-0.31	-4.68	4.49E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2295773	chr10:102265815	SEC31B	chr10:102246403-102289636:-	-0.31	-4.68	4.49E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2295774	chr10:102265847	SEC31B	chr10:102246403-102289636:-	-0.29	-4.21	3.41E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2295776	chr10:102295629	SEC31B	chr10:102246403-102289636:-	-0.27	-4.12	5.03E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2295779	chr10:102296061	SEC31B	chr10:102246403-102289636:-	-0.27	-4.12	4.94E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2296749	chr6:33763127	IP6K3	chr6:33689443-33714762:-	0.49	5.35	1.87E-7	Obesity (extreme)	
OV	cis	1	rs2297496	chr20:25295787	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2297496	chr20:25295787	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2297497	chr20:25297909	ABHD12	chr20:25275380-25371477:-	-0.42	-6.24	1.62E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2297497	chr20:25297909	FAM182B	chr20:25744102-25848786:-	-0.31	-4.73	3.62E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2298074	chr10:102247526	SEC31B	chr10:102246403-102289636:-	-0.27	-4.04	6.81E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2298914	chr1:171710405	VAMP4	chr1:171669298-171711214:-	0.37	4.59	6.59E-6	Hippocampal atrophy	
OV	cis	1	rs2303695	chr19:18562624	SSBP4	chr19:18530221-18545371:+	-0.33	-4.14	4.63E-5	Breast cancer	
OV	cis	1	rs2303697	chr19:18546678	SSBP4	chr19:18530221-18545371:+	-0.34	-4.32	2.14E-5	Breast cancer	
OV	cis	1	rs2303790	chr16:57017292	AMFR	chr16:56395365-56459444:-	-0.62	-4.27	2.66E-5	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	BBS2	chr16:56518259-56554008:-	-0.66	-4.8	2.58E-6	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	CIAPIN1	chr16:57462087-57481369:-	-0.63	-4.23	3.14E-5	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	FAM192A	chr16:57186382-57219976:-	-0.72	-4.83	2.23E-6	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	KATNB1	chr16:57769660-57791162:+	-0.59	-3.99	8.3E-5	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	NUDT21	chr16:56463049-56485261:-	-0.68	-4.71	3.86E-6	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	NUP93	chr16:56764017-56878676:+	-0.73	-4.64	5.49E-6	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	OGFOD1	chr16:56485424-56511406:+	-0.87	-5.77	2.07E-8	Exudative age-related macular degeneration	
OV	cis	1	rs2303790	chr16:57017292	POLR2C	chr16:57496551-57505921:+	-0.66	-4.82	2.39E-6	Exudative age-related macular degeneration	
OV	cis	1	rs2315556	chr4:17670861	LAP3	chr4:17578927-17609590:+	-0.25	-4.32	2.21E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2315560	chr4:17677305	LAP3	chr4:17578927-17609590:+	-0.24	-4.09	5.76E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2315561	chr4:17679695	LAP3	chr4:17578927-17609590:+	-0.25	-4.3	2.4E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2324843	chr6:86617501	SNHG5	chr6:86386726-86388451:-	-0.69	-11.48	3.32E-25	Response to antipsychotic treatment	
OV	cis	1	rs2336540	chr3:52974589	SFMBT1	chr3:52938628-53080070:-	-0.54	-5.05	7.9E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs2336541	chr3:52974630	SFMBT1	chr3:52938628-53080070:-	-0.54	-5.05	7.9E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs2336723	chr3:53106047	RFT1	chr3:53122503-53164470:-	-0.32	-4.64	5.49E-6	Height	
OV	cis	1	rs2353605	chr4:219538	ZNF718	chr4:53272-156488:+	0.39	4.14	4.53E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs2354550	chr6:107141943	C6orf203	chr6:107349407-107372544:+	0.33	4.55	7.87E-6	Daytime sleep phenotypes	
OV	cis	1	rs2356559	chr1:45981512	CCDC163P	chr1:45960581-45965646:-	-0.98	-16.44	7.21E-43	Homocysteine levels	
OV	cis	1	rs2356561	chr1:45980862	CCDC163P	chr1:45960581-45965646:-	-0.9	-14.76	8.76E-37	Homocysteine levels	
OV	cis	1	rs2356561	chr1:45980862	MMACHC	chr1:45965856-45976737:+	-0.3	-4.14	4.52E-5	Homocysteine levels	
OV	cis	1	rs2358628	chr14:74631757	LIN52	chr14:74551656-74667117:+	-0.26	-4	8.2E-5	Common traits (Other)	
OV	cis	1	rs2362450	chr3:48461313	TREX1	chr3:48501186-48509043:+	-0.25	-4.74	3.47E-6	Longevity	
OV	cis	1	rs2362452	chr3:48418214	TREX1	chr3:48501186-48509043:+	0.23	4.33	2.07E-5	Longevity	
OV	cis	1	rs2363731	chr2:88521793	THNSL2	chr2:88469835-88486145:+	-0.75	-7.8	1.31E-13	Plasma clusterin levels	
OV	cis	1	rs236373	chr6:36792057	PPIL1	chr6:36822606-36842800:-	0.26	4.18	3.86E-5	Heart rate	
OV	cis	1	rs2370578	chr3:134199612	ANAPC13	chr3:134196547-134204865:-	0.4	5.6	5.24E-8	Height	
OV	cis	1	rs2370641	chr3:134222161	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs2370642	chr3:134222136	ANAPC13	chr3:134196547-134204865:-	0.41	5.85	1.4E-8	Height	
OV	cis	1	rs2371244	chr7:143757611	ARHGEF35	chr7:143883677-143892736:-	-0.44	-5.58	5.62E-8	Obesity-related traits	
OV	cis	1	rs2371244	chr7:143757611	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.92	0.000114	Obesity-related traits	
OV	cis	1	rs2371244	chr7:143757611	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.26	2.77E-5	Obesity-related traits	
OV	cis	1	rs2371247	chr7:143764179	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.64	4.29E-8	Obesity-related traits	
OV	cis	1	rs2371247	chr7:143764179	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.97	9.04E-5	Obesity-related traits	
OV	cis	1	rs2371247	chr7:143764179	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.23	3.16E-5	Obesity-related traits	
OV	cis	1	rs2371248	chr7:143764189	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.64	4.29E-8	Obesity-related traits	
OV	cis	1	rs2371248	chr7:143764189	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.97	9.04E-5	Obesity-related traits	
OV	cis	1	rs2371248	chr7:143764189	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.23	3.16E-5	Obesity-related traits	
OV	cis	1	rs2371623	chr3:41761083	ULK4	chr3:41288091-42003660:-	0.6	7.93	5.47E-14	Diastolic blood pressure	
OV	cis	1	rs2371627	chr3:41839219	ULK4	chr3:41288091-42003660:-	0.61	8.08	2.05E-14	Diastolic blood pressure	
OV	cis	1	rs2373865	chr3:134291556	ANAPC13	chr3:134196547-134204865:-	-0.41	-5.59	5.49E-8	Height	
OV	cis	1	rs2387880	chr20:25377787	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.25E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2387880	chr20:25377787	FAM182B	chr20:25744102-25848786:-	-0.33	-5.06	7.73E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2387881	chr20:25378172	ABHD12	chr20:25275380-25371477:-	-0.41	-6	6.07E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2387881	chr20:25378172	FAM182B	chr20:25744102-25848786:-	-0.31	-4.79	2.67E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2387884	chr20:25379069	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.37E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2387884	chr20:25379069	FAM182B	chr20:25744102-25848786:-	-0.33	-5.1	6.45E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2403083	chr8:86108149	LRRCC1	chr8:86019377-86058312:+	0.3	4.12	4.97E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
OV	cis	1	rs2420170	chr7:65656053	CCT6P1	chr7:65216092-65228661:+	-0.33	-3.94	0.000104	Diabetic kidney disease	
OV	cis	1	rs2424700	chr20:25266513	ABHD12	chr20:25275380-25371477:-	0.38	5.61	4.95E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424700	chr20:25266513	FAM182B	chr20:25744102-25848786:-	0.33	5.08	6.97E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424704	chr20:25273929	ABHD12	chr20:25275380-25371477:-	0.41	6.08	3.99E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424704	chr20:25273929	FAM182B	chr20:25744102-25848786:-	0.33	5.05	8.19E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424710	chr20:25283886	ABHD12	chr20:25275380-25371477:-	0.41	6.02	5.5E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424710	chr20:25283886	FAM182B	chr20:25744102-25848786:-	0.31	4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424712	chr20:25416942	ABHD12	chr20:25275380-25371477:-	0.41	6.03	5.17E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424712	chr20:25416942	FAM182B	chr20:25744102-25848786:-	0.32	5.03	8.77E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424713	chr20:25418482	ABHD12	chr20:25275380-25371477:-	0.39	5.8	1.81E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424713	chr20:25418482	FAM182B	chr20:25744102-25848786:-	0.33	5.11	6.13E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424716	chr20:25423538	ABHD12	chr20:25275380-25371477:-	0.4	6	6.05E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2424716	chr20:25423538	FAM182B	chr20:25744102-25848786:-	0.31	4.77	3.01E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2432195	chr5:56120413	C5orf35	chr5:56205103-56213010:+	0.73	10.21	5.38E-21	Type 2 diabetes	
OV	cis	1	rs2448704	chr6:49453672	CENPQ	chr6:49431096-49460820:+	0.24	4.07	6.2E-5	Homocysteine levels	
OV	cis	1	rs2460422	chr7:65601505	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs2462569	chr7:65474846	CCT6P1	chr7:65216092-65228661:+	-0.38	-4.7	4.03E-6	Diabetic kidney disease	
OV	cis	1	rs2474777	chr20:25272633	ABHD12	chr20:25275380-25371477:-	0.42	6.31	1.1E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2474777	chr20:25272633	FAM182B	chr20:25744102-25848786:-	0.3	4.61	6.12E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482911	chr20:25395528	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.32E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482911	chr20:25395528	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	2.97E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482919	chr20:25299756	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482919	chr20:25299756	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482927	chr20:25327151	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482927	chr20:25327151	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482928	chr20:25331530	ABHD12	chr20:25275380-25371477:-	-0.41	-6.05	4.71E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482928	chr20:25331530	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482930	chr20:25334115	ABHD12	chr20:25275380-25371477:-	-0.41	-6.05	4.71E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482930	chr20:25334115	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482931	chr20:25334445	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482931	chr20:25334445	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482937	chr20:25340786	ABHD12	chr20:25275380-25371477:-	-0.41	-6.05	4.71E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482937	chr20:25340786	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482940	chr20:25349830	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482940	chr20:25349830	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482941	chr20:25361216	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482941	chr20:25361216	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482943	chr20:25380593	ABHD12	chr20:25275380-25371477:-	-0.39	-5.73	2.56E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2482943	chr20:25380593	FAM182B	chr20:25744102-25848786:-	-0.34	-5.31	2.27E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2486447	chr1:46545724	CCDC163P	chr1:45960581-45965646:-	-0.47	-7.07	1.28E-11	Body mass index	
OV	cis	1	rs2489034	chr10:102319192	SEC31B	chr10:102246403-102289636:-	-0.27	-4.1	5.52E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2489035	chr10:102319395	SEC31B	chr10:102246403-102289636:-	-0.28	-4.18	3.94E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2489036	chr10:102319581	SEC31B	chr10:102246403-102289636:-	-0.27	-4.1	5.52E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2489039	chr10:102328036	SEC31B	chr10:102246403-102289636:-	-0.27	-3.86	0.000142	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2489043	chr10:102334327	SEC31B	chr10:102246403-102289636:-	-0.28	-4.13	4.73E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2489045	chr10:102344754	SEC31B	chr10:102246403-102289636:-	-0.27	-3.85	0.000146	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2489048	chr10:102348497	SEC31B	chr10:102246403-102289636:-	-0.28	-4.01	7.8E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2495741	chr10:102331795	SEC31B	chr10:102246403-102289636:-	-0.28	-4.08	5.87E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2495747	chr10:102328247	SEC31B	chr10:102246403-102289636:-	-0.27	-3.99	8.31E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs2500404	chr20:25359758	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500404	chr20:25359758	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500405	chr20:25360826	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500405	chr20:25360826	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500418	chr20:25382268	ABHD12	chr20:25275380-25371477:-	-0.4	-5.87	1.25E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500418	chr20:25382268	FAM182B	chr20:25744102-25848786:-	-0.35	-5.37	1.7E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500424	chr20:25391969	ABHD12	chr20:25275380-25371477:-	-0.39	-5.77	2.07E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500424	chr20:25391969	FAM182B	chr20:25744102-25848786:-	-0.33	-5.06	7.8E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500432	chr20:25290512	ABHD12	chr20:25275380-25371477:-	0.36	5.36	1.75E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500432	chr20:25290512	FAM182B	chr20:25744102-25848786:-	0.29	4.5	9.87E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500436	chr20:25406366	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.25E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500436	chr20:25406366	FAM182B	chr20:25744102-25848786:-	-0.31	-4.71	3.97E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500443	chr20:25331442	ABHD12	chr20:25275380-25371477:-	-0.41	-6.05	4.71E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500443	chr20:25331442	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500446	chr20:25339664	ABHD12	chr20:25275380-25371477:-	-0.41	-6.05	4.71E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500446	chr20:25339664	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500448	chr20:25404027	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.79E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2500448	chr20:25404027	FAM182B	chr20:25744102-25848786:-	-0.33	-5.07	7.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2524005	chr6:29899677	HCG4	chr6:29758809-29760850:-	-0.41	-4.75	3.24E-6	Bipolar disorder and schizophrenia	
OV	cis	1	rs2524005	chr6:29899677	ZFP57	chr6:29640171-29648887:-	0.54	6.57	2.41E-10	Bipolar disorder and schizophrenia	
OV	cis	1	rs2527199	chr7:158737113	WDR60	chr7:158649269-158738882:+	0.28	4.38	1.68E-5	Height	
OV	cis	1	rs252887	chr5:56166188	C5orf35	chr5:56205103-56213010:+	0.71	9.07	2.23E-17	Type 2 diabetes	
OV	cis	1	rs252898	chr5:56188931	C5orf35	chr5:56205103-56213010:+	0.73	9.35	3.01E-18	Type 2 diabetes	
OV	cis	1	rs252902	chr5:56116085	C5orf35	chr5:56205103-56213010:+	0.69	9.67	3.11E-19	Type 2 diabetes	
OV	cis	1	rs252904	chr5:56118733	C5orf35	chr5:56205103-56213010:+	0.68	9.58	5.76E-19	Type 2 diabetes	
OV	cis	1	rs252909	chr5:56121131	C5orf35	chr5:56205103-56213010:+	0.73	10.19	6.41E-21	Type 2 diabetes	
OV	cis	1	rs252910	chr5:56192983	C5orf35	chr5:56205103-56213010:+	0.75	9.54	7.56E-19	Type 2 diabetes	
OV	cis	1	rs252915	chr5:56121754	C5orf35	chr5:56205103-56213010:+	-0.73	-10.49	6.65E-22	Type 2 diabetes	
OV	cis	1	rs252916	chr5:56121788	C5orf35	chr5:56205103-56213010:+	0.73	10.19	6.34E-21	Type 2 diabetes	
OV	cis	1	rs252919	chr5:56124111	C5orf35	chr5:56205103-56213010:+	0.74	10.28	3.18E-21	Type 2 diabetes	
OV	cis	1	rs252921	chr5:56137787	C5orf35	chr5:56205103-56213010:+	0.7	9.48	1.18E-18	Type 2 diabetes	
OV	cis	1	rs252922	chr5:56136343	C5orf35	chr5:56205103-56213010:+	0.69	9.3	4.43E-18	Type 2 diabetes	
OV	cis	1	rs2533288	chr7:66056711	CCT6P1	chr7:65216092-65228661:+	0.34	4.16	4.29E-5	Diabetic kidney disease	
OV	cis	1	rs2548664	chr5:56133555	C5orf35	chr5:56205103-56213010:+	0.72	9.85	8.0E-20	Type 2 diabetes	
OV	cis	1	rs2548665	chr5:56131805	C5orf35	chr5:56205103-56213010:+	0.72	9.85	8.0E-20	Type 2 diabetes	
OV	cis	1	rs2563999	chr2:5973886	SOX11	chr2:5832799-5841516:+	0.5	4.03	7.18E-5	Chronic kidney disease	
OV	cis	1	rs2564000	chr2:5973914	SOX11	chr2:5832799-5841516:+	0.5	4.03	7.18E-5	Chronic kidney disease	
OV	cis	1	rs2564002	chr2:5975588	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs2564921	chr3:53125585	RFT1	chr3:53122503-53164470:-	0.32	4.58	7.12E-6	Height	
OV	cis	1	rs2564926	chr3:53094730	SFMBT1	chr3:52938628-53080070:-	0.48	4.49	1.05E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs2564940	chr3:53107569	RFT1	chr3:53122503-53164470:-	-0.34	-4.81	2.47E-6	Height	
OV	cis	1	rs2564956	chr3:53070462	ITIH4	chr3:52847007-52866554:-	-0.19	-4.04	6.8E-5	Ulcerative colitis	
OV	cis	1	rs2572910	chr8:143770135	LY6K	chr8:143781529-143785582:+	0.3	4.11	5.14E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2572910	chr8:143770135	PSCA	chr8:143761875-143764142:+	0.27	4.21	3.5E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2577946	chr4:53404086	SCFD2	chr4:53739152-54232242:-	0.43	4.04	6.97E-5	Biochemical measures	
OV	cis	1	rs2581782	chr3:53122257	RFT1	chr3:53122503-53164470:-	-0.34	-4.77	3.0E-6	Height	
OV	cis	1	rs2581783	chr3:53122258	RFT1	chr3:53122503-53164470:-	-0.34	-4.77	3.0E-6	Height	
OV	cis	1	rs2581786	chr3:53126143	RFT1	chr3:53122503-53164470:-	-0.33	-4.7	4.13E-6	Height	
OV	cis	1	rs2581787	chr3:53127677	RFT1	chr3:53122503-53164470:-	-0.33	-4.63	5.55E-6	Height	
OV	cis	1	rs2581800	chr3:53109352	RFT1	chr3:53122503-53164470:-	-0.32	-4.52	9.27E-6	Height	
OV	cis	1	rs2581817	chr3:53071797	ITIH4	chr3:52847007-52866554:-	-0.19	-3.89	0.000128	Ulcerative colitis	
OV	cis	1	rs2585179	chr8:143774193	LY6K	chr8:143781529-143785582:+	0.3	4.05	6.66E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2585179	chr8:143774193	PSCA	chr8:143761875-143764142:+	0.27	4.27	2.73E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2602381	chr2:234584324	USP40	chr2:234384166-234475428:-	-0.25	-4.11	5.25E-5	Attention deficit hyperactivity disorder	
OV	cis	1	rs2611665	chr4:53400165	SCFD2	chr4:53739152-54232242:-	0.43	4.04	6.97E-5	Biochemical measures	
OV	cis	1	rs2617170	chr12:10560957	KLRC1	chr12:10594863-10606984:-	0.3	5.3	2.37E-7	Behcet's disease	
OV	cis	1	rs262147	chr7:158745142	WDR60	chr7:158649269-158738882:+	-0.45	-4.81	2.53E-6	Hippocampal volume	
OV	cis	1	rs2625667	chr3:41900951	ULK4	chr3:41288091-42003660:-	0.63	8.36	3.05E-15	Diastolic blood pressure	
OV	cis	1	rs2625668	chr3:41905930	ULK4	chr3:41288091-42003660:-	0.61	8.01	3.13E-14	Diastolic blood pressure	
OV	cis	1	rs2657345	chr7:158744169	WDR60	chr7:158649269-158738882:+	0.32	4.83	2.22E-6	Height	
OV	cis	1	rs2657365	chr7:158722753	WDR60	chr7:158649269-158738882:+	0.27	4.14	4.68E-5	Height	
OV	cis	1	rs2683695	chr3:41914928	ULK4	chr3:41288091-42003660:-	0.62	8.3	4.51E-15	Diastolic blood pressure	
OV	cis	1	rs2683696	chr3:41914898	ULK4	chr3:41288091-42003660:-	0.63	8.37	2.95E-15	Diastolic blood pressure	
OV	cis	1	rs26965	chr5:112739017	APC	chr5:112043218-112181935:+	0.31	4.38	1.66E-5	F-cell distribution	
OV	cis	1	rs26965	chr5:112739017	DCP2	chr5:112312433-112356666:+	0.33	4.5	1.01E-5	F-cell distribution	
OV	cis	1	rs26965	chr5:112739017	REEP5	chr5:112212081-112258031:-	0.33	4.84	2.15E-6	F-cell distribution	
OV	cis	1	rs26965	chr5:112739017	SRP19	chr5:112196993-112228774:+	0.46	6.21	1.9E-9	F-cell distribution	
OV	cis	1	rs26965	chr5:112739017	YTHDC2	chr5:112849410-112930979:+	0.43	5.73	2.64E-8	F-cell distribution	
OV	cis	1	rs2702040	chr2:24541561	SF3B14	chr2:24290455-24299314:-	0.64	5.18	4.23E-7	Response to antipsychotic treatment in schizophrenia (working memory)	
OV	cis	1	rs2707831	chr7:66062511	CCT6P1	chr7:65216092-65228661:+	0.38	4.55	7.94E-6	Diabetic kidney disease	
OV	cis	1	rs2707832	chr7:66136549	CCT6P1	chr7:65216092-65228661:+	0.36	4.32	2.22E-5	Gout	
OV	cis	1	rs2707844	chr7:66059509	CCT6P1	chr7:65216092-65228661:+	0.38	4.55	7.94E-6	Diabetic kidney disease	
OV	cis	1	rs2709450	chr2:5974386	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs2709451	chr2:5974464	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs2709452	chr2:5974468	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs2709453	chr2:5974622	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs2709454	chr2:5974901	SOX11	chr2:5832799-5841516:+	0.5	4.02	7.58E-5	Chronic kidney disease	
OV	cis	1	rs271621	chr19:18631332	SSBP4	chr19:18530221-18545371:+	-0.31	-3.98	8.85E-5	Breast cancer	
OV	cis	1	rs271623	chr19:18628947	SSBP4	chr19:18530221-18545371:+	-0.31	-4.03	7.32E-5	Breast cancer	
OV	cis	1	rs2717562	chr8:143776668	LY6K	chr8:143781529-143785582:+	0.29	3.99	8.53E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2717562	chr8:143776668	PSCA	chr8:143761875-143764142:+	0.27	4.22	3.26E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2730241	chr7:158723014	WDR60	chr7:158649269-158738882:+	0.28	4.33	2.1E-5	Height	
OV	cis	1	rs2730245	chr7:158724789	WDR60	chr7:158649269-158738882:+	0.29	4.49	1.04E-5	Height	
OV	cis	1	rs2758870	chr6:39244214	KCNK17	chr6:39266778-39282237:-	0.31	4.11	5.2E-5	Cholesterol, total	
OV	cis	1	rs2758873	chr6:39246856	KCNK17	chr6:39266778-39282237:-	0.31	3.94	0.000101	Cholesterol, total	
OV	cis	1	rs2758880	chr6:39249189	KCNK17	chr6:39266778-39282237:-	0.31	3.94	0.000101	Cholesterol, total	
OV	cis	1	rs2758886	chr6:39250837	KCNK17	chr6:39266778-39282237:-	0.31	3.95	0.0001	Cholesterol, total	
OV	cis	1	rs2799079	chr6:28235176	ZNF187	chr6:28234788-28245978:+	-0.29	-3.94	0.000105	Depression	
OV	cis	1	rs2799079	chr6:28235176	ZNF389	chr6:28129551-28137375:+	-0.36	-4.19	3.77E-5	Depression	
OV	cis	1	rs2812972	chr6:86669880	SNHG5	chr6:86386726-86388451:-	-0.67	-11.71	5.17E-26	Response to antipsychotic treatment	
OV	cis	1	rs2815047	chr6:39247406	KCNK17	chr6:39266778-39282237:-	0.31	3.94	0.000101	Cholesterol, total	
OV	cis	1	rs2816815	chr6:86691656	SNHG5	chr6:86386726-86388451:-	-0.67	-11.89	1.34E-26	Response to antipsychotic treatment	
OV	cis	1	rs2816821	chr6:86657084	SNHG5	chr6:86386726-86388451:-	-0.67	-11.71	5.27E-26	Response to antipsychotic treatment	
OV	cis	1	rs282175	chr1:26895802	TRIM63	chr1:26377798-26394121:-	0.28	4.08	6.01E-5	Glucose homeostasis traits	
OV	cis	1	rs2835607	chr21:38491973	PIGP	chr21:38437664-38445458:-	-0.32	-5.73	2.63E-8	Eye color traits	
OV	cis	1	rs2835608	chr21:38493455	PIGP	chr21:38437664-38445458:-	-0.32	-5.73	2.58E-8	Eye color traits	
OV	cis	1	rs28365850	chr14:35591316	KIAA0391	chr14:35591776-35786673:+	0.44	4.59	6.61E-6	Atopic dermatitis	
OV	cis	1	rs28365850	chr14:35591316	PPP2R3C	chr14:35554679-35591679:-	0.41	4.47	1.13E-5	Atopic dermatitis	
OV	cis	1	rs2838009	chr21:42694284	FAM3B	chr21:42676177-42729654:+	-0.43	-5.46	1.04E-7	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
OV	cis	1	rs2839181	chr21:47685939	C21orf57	chr21:47706267-47717664:+	-0.3	-4.45	1.24E-5	Testicular germ cell tumor	
OV	cis	1	rs2839186	chr21:47690068	C21orf57	chr21:47706267-47717664:+	-0.3	-4.53	8.74E-6	Testicular germ cell tumor	
OV	cis	1	rs28399702	chr14:35625217	KIAA0391	chr14:35591776-35786673:+	0.35	4.02	7.59E-5	Atopic dermatitis	
OV	cis	1	rs28399702	chr14:35625217	PPP2R3C	chr14:35554679-35591679:-	0.36	4.32	2.14E-5	Atopic dermatitis	
OV	cis	1	rs28409322	chr3:134252385	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs28501187	chr4:17643620	LAP3	chr4:17578927-17609590:+	-0.28	-4.8	2.65E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs28545485	chr4:17645376	LAP3	chr4:17578927-17609590:+	-0.26	-4.59	6.73E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2856	chr20:25433536	ABHD12	chr20:25275380-25371477:-	0.42	6.15	2.7E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs2856	chr20:25433536	FAM182B	chr20:25744102-25848786:-	0.34	5.22	3.59E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs28572537	chr19:18552208	SSBP4	chr19:18530221-18545371:+	-0.31	-3.94	0.000103	Breast cancer	
OV	cis	1	rs28599680	chr16:29860685	MVP	chr16:29831787-29859342:+	-0.27	-4.13	4.84E-5	Multiple sclerosis	
OV	cis	1	rs28627645	chr7:36405175	KIAA0895	chr7:36363759-36429734:-	0.41	4.55	8.15E-6	Systolic blood pressure	
OV	cis	1	rs2862961	chr11:43656535	HSD17B12	chr11:43702143-43878160:+	0.42	6.24	1.59E-9	Forced vital capacity	
OV	cis	1	rs2862963	chr11:43640115	HSD17B12	chr11:43702143-43878160:+	0.43	6.33	9.65E-10	Forced vital capacity	
OV	cis	1	rs2862985	chr10:102062809	SLC25A28	chr10:101370275-101418994:-	0.49	4.44	1.29E-5	Obesity-related traits	
OV	cis	1	rs2862996	chr11:43653833	HSD17B12	chr11:43702143-43878160:+	-0.41	-6.17	2.46E-9	Forced vital capacity	
OV	cis	1	rs28661978	chr3:156579739	LEKR1	chr3:156544076-156763918:+	-0.61	-7.57	5.63E-13	Bone mineral density	
OV	cis	1	rs28693609	chr4:17645233	LAP3	chr4:17578927-17609590:+	-0.26	-4.44	1.29E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs28702390	chr3:41889920	ULK4	chr3:41288091-42003660:-	0.61	7.51	8.37E-13	Diastolic blood pressure	
OV	cis	1	rs2872958	chr4:17665032	LAP3	chr4:17578927-17609590:+	-0.26	-4.53	8.76E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs2872959	chr4:17677163	LAP3	chr4:17578927-17609590:+	0.27	4.58	7.1E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs28733681	chr3:41863444	ULK4	chr3:41288091-42003660:-	0.59	7.58	5.34E-13	Diastolic blood pressure	
OV	cis	1	rs2874490	chr3:156635513	LEKR1	chr3:156544076-156763918:+	-0.58	-7.24	4.49E-12	Bone mineral density	
OV	cis	1	rs2874491	chr3:156649111	LEKR1	chr3:156544076-156763918:+	-0.6	-7.38	1.83E-12	Bone mineral density	
OV	cis	1	rs28755797	chr3:41774446	ULK4	chr3:41288091-42003660:-	0.56	7.05	1.45E-11	Diastolic blood pressure	
OV	cis	1	rs28824259	chr3:48425675	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs2885510	chr3:48418226	TREX1	chr3:48501186-48509043:+	0.26	4.86	1.96E-6	Longevity	
OV	cis	1	rs2887797	chr3:134202506	ANAPC13	chr3:134196547-134204865:-	0.43	6.12	3.24E-9	Height	
OV	cis	1	rs2905425	chr19:19475717	GMIP	chr19:19740286-19754455:-	-0.27	-4.1	5.54E-5	Schizophrenia	
OV	cis	1	rs2907948	chr7:150638484	ATG9B	chr7:150709306-150721586:-	0.31	4.22	3.36E-5	QT interval	
OV	cis	1	rs2920292	chr8:143765699	LY6K	chr8:143781529-143785582:+	0.28	3.92	0.00011	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920292	chr8:143765699	PSCA	chr8:143761875-143764142:+	0.28	4.39	1.62E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920293	chr8:143765414	LY6K	chr8:143781529-143785582:+	0.3	4.18	3.99E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920293	chr8:143765414	PSCA	chr8:143761875-143764142:+	0.28	4.45	1.25E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920294	chr8:143765326	LY6K	chr8:143781529-143785582:+	0.3	4.18	3.99E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920294	chr8:143765326	PSCA	chr8:143761875-143764142:+	0.28	4.45	1.25E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920295	chr8:143764937	LY6K	chr8:143781529-143785582:+	0.32	4.46	1.21E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920295	chr8:143764937	PSCA	chr8:143761875-143764142:+	0.29	4.55	7.97E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920296	chr8:143763109	LY6K	chr8:143781529-143785582:+	0.29	3.96	9.46E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920296	chr8:143763109	PSCA	chr8:143761875-143764142:+	0.28	4.33	2.09E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920297	chr8:143763083	LY6K	chr8:143781529-143785582:+	0.29	3.96	9.46E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920297	chr8:143763083	PSCA	chr8:143761875-143764142:+	0.28	4.33	2.09E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920298	chr8:143763043	LY6K	chr8:143781529-143785582:+	0.29	3.96	9.46E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2920298	chr8:143763043	PSCA	chr8:143761875-143764142:+	0.28	4.33	2.09E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2922809	chr8:6350464	AGPAT5	chr8:6565878-6619019:+	0.61	4.15	4.52E-5	Cytomegalovirus antibody response	
OV	cis	1	rs2922809	chr8:6350464	MCPH1	chr8:6264121-6506025:+	0.57	3.88	0.000133	Cytomegalovirus antibody response	
OV	cis	1	rs2924584	chr4:99988208	ADH5	chr4:99992132-100009931:-	0.24	4.25	2.96E-5	HDL cholesterol	
OV	cis	1	rs2932538	chr1:113216543	ST7L	chr1:113066142-113162405:-	-0.36	-4.45	1.24E-5	Systolic blood pressure;Hypertension;Diastolic blood pressure;Blood pressure	
OV	cis	1	rs2951308	chr7:143767149	ARHGEF35	chr7:143883677-143892736:-	0.44	5.67	3.51E-8	Obesity-related traits	
OV	cis	1	rs2951308	chr7:143767149	CTAGE6	chr7:143452184-143454843:-	0.33	4.14	4.69E-5	Obesity-related traits	
OV	cis	1	rs2951308	chr7:143767149	OR2A9P	chr7:143991573-143997832:+;chr7	0.32	3.94	0.000104	Obesity-related traits	
OV	cis	1	rs2951353	chr7:143761116	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.62	4.77E-8	Obesity-related traits	
OV	cis	1	rs2951353	chr7:143761116	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.98	8.85E-5	Obesity-related traits	
OV	cis	1	rs2951353	chr7:143761116	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.24	3.07E-5	Obesity-related traits	
OV	cis	1	rs2951354	chr7:143761001	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.62	4.77E-8	Obesity-related traits	
OV	cis	1	rs2951354	chr7:143761001	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.98	8.85E-5	Obesity-related traits	
OV	cis	1	rs2951354	chr7:143761001	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.24	3.07E-5	Obesity-related traits	
OV	cis	1	rs2951360	chr7:143757349	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.63	4.43E-8	Obesity-related traits	
OV	cis	1	rs2951360	chr7:143757349	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.01	7.71E-5	Obesity-related traits	
OV	cis	1	rs2951360	chr7:143757349	OR2A9P	chr7:143991573-143997832:+;chr7	-0.34	-4.11	5.27E-5	Obesity-related traits	
OV	cis	1	rs2951363	chr7:143754724	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.93	8.95E-9	Obesity-related traits	
OV	cis	1	rs2951363	chr7:143754724	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.18	3.95E-5	Obesity-related traits	
OV	cis	1	rs2951363	chr7:143754724	OR2A9P	chr7:143991573-143997832:+;chr7	-0.38	-4.61	6.04E-6	Obesity-related traits	
OV	cis	1	rs2951364	chr7:143754483	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.93	8.95E-9	Obesity-related traits	
OV	cis	1	rs2951364	chr7:143754483	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.18	3.95E-5	Obesity-related traits	
OV	cis	1	rs2951364	chr7:143754483	OR2A9P	chr7:143991573-143997832:+;chr7	-0.38	-4.61	6.04E-6	Obesity-related traits	
OV	cis	1	rs2951368	chr7:143752821	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.93	8.95E-9	Obesity-related traits	
OV	cis	1	rs2951368	chr7:143752821	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.18	3.95E-5	Obesity-related traits	
OV	cis	1	rs2951368	chr7:143752821	OR2A9P	chr7:143991573-143997832:+;chr7	-0.38	-4.61	6.04E-6	Obesity-related traits	
OV	cis	1	rs2951369	chr7:143752638	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.93	8.95E-9	Obesity-related traits	
OV	cis	1	rs2951369	chr7:143752638	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.18	3.95E-5	Obesity-related traits	
OV	cis	1	rs2951369	chr7:143752638	OR2A9P	chr7:143991573-143997832:+;chr7	-0.38	-4.61	6.04E-6	Obesity-related traits	
OV	cis	1	rs2951372	chr7:143749503	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.69	3.3E-8	Obesity-related traits	
OV	cis	1	rs2951372	chr7:143749503	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.94	0.000102	Obesity-related traits	
OV	cis	1	rs2951372	chr7:143749503	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.2	3.62E-5	Obesity-related traits	
OV	cis	1	rs2961102	chr7:65424658	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs2961115	chr7:143753371	ARHGEF35	chr7:143883677-143892736:-	-0.47	-5.93	8.95E-9	Obesity-related traits	
OV	cis	1	rs2961115	chr7:143753371	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.18	3.95E-5	Obesity-related traits	
OV	cis	1	rs2961115	chr7:143753371	OR2A9P	chr7:143991573-143997832:+;chr7	-0.38	-4.61	6.04E-6	Obesity-related traits	
OV	cis	1	rs2961117	chr7:143755253	ARHGEF35	chr7:143883677-143892736:-	-0.43	-5.62	4.62E-8	Obesity-related traits	
OV	cis	1	rs2961117	chr7:143755253	OR2A9P	chr7:143991573-143997832:+;chr7	-0.33	-4.17	4.05E-5	Obesity-related traits	
OV	cis	1	rs2961118	chr7:143755443	ARHGEF35	chr7:143883677-143892736:-	-0.46	-5.82	1.61E-8	Obesity-related traits	
OV	cis	1	rs2961118	chr7:143755443	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.02	7.51E-5	Obesity-related traits	
OV	cis	1	rs2961118	chr7:143755443	OR2A9P	chr7:143991573-143997832:+;chr7	-0.37	-4.54	8.53E-6	Obesity-related traits	
OV	cis	1	rs2961119	chr7:143755852	ARHGEF35	chr7:143883677-143892736:-	-0.46	-5.82	1.61E-8	Obesity-related traits	
OV	cis	1	rs2961119	chr7:143755852	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.02	7.51E-5	Obesity-related traits	
OV	cis	1	rs2961119	chr7:143755852	OR2A9P	chr7:143991573-143997832:+;chr7	-0.37	-4.54	8.53E-6	Obesity-related traits	
OV	cis	1	rs2961120	chr7:143756585	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.66	3.74E-8	Obesity-related traits	
OV	cis	1	rs2961120	chr7:143756585	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.01	7.81E-5	Obesity-related traits	
OV	cis	1	rs2961120	chr7:143756585	OR2A9P	chr7:143991573-143997832:+;chr7	-0.34	-4.14	4.62E-5	Obesity-related traits	
OV	cis	1	rs2961125	chr7:143761770	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.62	4.77E-8	Obesity-related traits	
OV	cis	1	rs2961125	chr7:143761770	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.98	8.85E-5	Obesity-related traits	
OV	cis	1	rs2961125	chr7:143761770	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.24	3.07E-5	Obesity-related traits	
OV	cis	1	rs2961126	chr7:143762736	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.62	4.77E-8	Obesity-related traits	
OV	cis	1	rs2961126	chr7:143762736	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.98	8.85E-5	Obesity-related traits	
OV	cis	1	rs2961126	chr7:143762736	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.24	3.07E-5	Obesity-related traits	
OV	cis	1	rs2961128	chr7:143763483	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.62	4.77E-8	Obesity-related traits	
OV	cis	1	rs2961128	chr7:143763483	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.98	8.85E-5	Obesity-related traits	
OV	cis	1	rs2961128	chr7:143763483	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.24	3.07E-5	Obesity-related traits	
OV	cis	1	rs2961132	chr7:143768128	ARHGEF35	chr7:143883677-143892736:-	-0.45	-5.71	2.98E-8	Obesity-related traits	
OV	cis	1	rs2961132	chr7:143768128	CTAGE6	chr7:143452184-143454843:-	-0.33	-4.07	6.07E-5	Obesity-related traits	
OV	cis	1	rs2961132	chr7:143768128	OR2A9P	chr7:143991573-143997832:+;chr7	-0.33	-4	8.22E-5	Obesity-related traits	
OV	cis	1	rs2961134	chr7:143771062	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.2	3.91E-7	Obesity-related traits	
OV	cis	1	rs2961144	chr7:143747870	ARHGEF35	chr7:143883677-143892736:-	0.47	5.96	7.67E-9	Obesity-related traits	
OV	cis	1	rs2961144	chr7:143747870	CTAGE6	chr7:143452184-143454843:-	0.34	4.21	3.41E-5	Obesity-related traits	
OV	cis	1	rs2961144	chr7:143747870	OR2A9P	chr7:143991573-143997832:+;chr7	0.38	4.6	6.38E-6	Obesity-related traits	
OV	cis	1	rs2967684	chr19:8786624	OR1M1	chr19:9203921-9204861:+	0.35	4.15	4.49E-5	Atopic dermatitis	
OV	cis	1	rs2968854	chr7:150637834	ATG9B	chr7:150709306-150721586:-	0.3	4.18	3.91E-5	QT interval	
OV	cis	1	rs2968864	chr7:150622162	ATG9B	chr7:150709306-150721586:-	0.31	3.91	0.000114	QT interval	
OV	cis	1	rs2975734	chr8:10090097	TNKS	chr8:9413445-9639855:+	0.3	4.02	7.4E-5	Chronotype;Morning vs. evening chronotype	
OV	cis	1	rs2976392	chr8:143762932	LY6K	chr8:143781529-143785582:+	0.29	4.02	7.58E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2976392	chr8:143762932	PSCA	chr8:143761875-143764142:+	0.28	4.41	1.47E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2976394	chr8:143763622	LY6K	chr8:143781529-143785582:+	0.29	3.96	9.46E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2976394	chr8:143763622	PSCA	chr8:143761875-143764142:+	0.28	4.33	2.09E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2976396	chr8:143764001	PSCA	chr8:143761875-143764142:+	-0.3	-4.85	2.09E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2976398	chr8:143764879	LY6K	chr8:143781529-143785582:+	0.31	4.24	3.05E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2976398	chr8:143764879	PSCA	chr8:143761875-143764142:+	0.28	4.37	1.74E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2978982	chr8:143763490	LY6K	chr8:143781529-143785582:+	0.29	4.03	7.33E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2978982	chr8:143763490	PSCA	chr8:143761875-143764142:+	0.28	4.42	1.42E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
OV	cis	1	rs2993259	chr1:46001550	CCDC163P	chr1:45960581-45965646:-	-0.96	-15.97	3.82E-41	Homocysteine levels	
OV	cis	1	rs2993259	chr1:46001550	MMACHC	chr1:45965856-45976737:+	-0.3	-4.11	5.26E-5	Homocysteine levels	
OV	cis	1	rs3002702	chr20:25268920	ABHD12	chr20:25275380-25371477:-	0.41	5.97	7.28E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs3002702	chr20:25268920	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.9E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs3020282	chr8:6328628	AGPAT5	chr8:6565878-6619019:+	-0.65	-4.25	2.95E-5	Cytomegalovirus antibody response	
OV	cis	1	rs3020282	chr8:6328628	MCPH1	chr8:6264121-6506025:+	-0.66	-4.25	2.94E-5	Cytomegalovirus antibody response	
OV	cis	1	rs3020282	chr8:6328628	XKR5	chr8:6666043-6693037:-	-0.54	-4.05	6.64E-5	Cytomegalovirus antibody response	
OV	cis	1	rs3091242	chr1:25674785	RHCE	chr1:25688741-25756683:-	0.35	5.64	4.22E-8	Erythrocyte sedimentation rate	
OV	cis	1	rs3091242	chr1:25674785	RHD	chr1:25598981-25656935:+	-0.55	-9.63	3.9E-19	Erythrocyte sedimentation rate	
OV	cis	1	rs3097417	chr3:53088601	SFMBT1	chr3:52938628-53080070:-	0.44	4.49	1.03E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs3099459	chr5:56137170	C5orf35	chr5:56205103-56213010:+	0.7	9.28	4.89E-18	Type 2 diabetes	
OV	cis	1	rs3135071	chr4:2406321	RNF4	chr4:2470807-2517581:+	-0.41	-4.03	7.23E-5	Influenza A (H1N1) severity	
OV	cis	1	rs313798	chr7:65493031	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs313799	chr7:65494330	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs313802	chr7:65516373	CCT6P1	chr7:65216092-65228661:+	0.36	4.29	2.5E-5	Diabetic kidney disease	
OV	cis	1	rs313803	chr7:65514731	CCT6P1	chr7:65216092-65228661:+	0.36	4.29	2.5E-5	Diabetic kidney disease	
OV	cis	1	rs313807	chr7:65499481	CCT6P1	chr7:65216092-65228661:+	0.35	4.23	3.23E-5	Diabetic kidney disease	
OV	cis	1	rs313809	chr7:65499983	CCT6P1	chr7:65216092-65228661:+	0.35	4.26	2.84E-5	Diabetic kidney disease	
OV	cis	1	rs313813	chr7:65503500	CCT6P1	chr7:65216092-65228661:+	0.35	4.22	3.33E-5	Diabetic kidney disease	
OV	cis	1	rs313814	chr7:65503293	CCT6P1	chr7:65216092-65228661:+	0.36	4.28	2.53E-5	Diabetic kidney disease	
OV	cis	1	rs313820	chr7:65574466	CCT6P1	chr7:65216092-65228661:+	0.34	4.23	3.24E-5	Diabetic kidney disease	
OV	cis	1	rs313824	chr7:65581207	CCT6P1	chr7:65216092-65228661:+	0.34	4.23	3.23E-5	Diabetic kidney disease	
OV	cis	1	rs313831	chr7:65551226	CCT6P1	chr7:65216092-65228661:+	0.35	4.28	2.56E-5	Diabetic kidney disease	
OV	cis	1	rs313832	chr7:65550891	CCT6P1	chr7:65216092-65228661:+	0.35	4.28	2.56E-5	Diabetic kidney disease	
OV	cis	1	rs316307	chr7:65570171	CCT6P1	chr7:65216092-65228661:+	0.34	4.21	3.49E-5	Diabetic kidney disease	
OV	cis	1	rs316312	chr7:65596491	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs316313	chr7:65593548	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs316325	chr7:65609518	CCT6P1	chr7:65216092-65228661:+	0.32	3.91	0.000118	Diabetic kidney disease	
OV	cis	1	rs316326	chr7:65609453	CCT6P1	chr7:65216092-65228661:+	0.32	3.91	0.000118	Diabetic kidney disease	
OV	cis	1	rs316327	chr7:65609201	CCT6P1	chr7:65216092-65228661:+	-0.34	-4.28	2.62E-5	Diabetic kidney disease	
OV	cis	1	rs316329	chr7:65608416	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	4.96E-5	Diabetic kidney disease	
OV	cis	1	rs316330	chr7:65605372	CCT6P1	chr7:65216092-65228661:+	0.33	4.03	7.12E-5	Diabetic kidney disease	
OV	cis	1	rs316331	chr7:65604622	CCT6P1	chr7:65216092-65228661:+	-0.31	-3.86	0.000142	Diabetic kidney disease	
OV	cis	1	rs316332	chr7:65604299	CCT6P1	chr7:65216092-65228661:+	0.33	4.03	7.12E-5	Diabetic kidney disease	
OV	cis	1	rs316334	chr7:65602126	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs3208509	chr1:150129335	CTSS	chr1:150702554-150738305:-	0.19	4.09	5.65E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
OV	cis	1	rs3214041	chr3:48454468	TREX1	chr3:48501186-48509043:+	-0.28	-5.38	1.61E-7	Longevity	
OV	cis	1	rs321622	chr4:48024380	CNGA1	chr4:47937996-48018610:-	0.29	3.88	0.00013	Renal underexcretion gout;Gout	
OV	cis	1	rs321622	chr4:48024380	NIPAL1	chr4:48018791-48039078:+	0.49	7.36	2.07E-12	Renal underexcretion gout;Gout	
OV	cis	1	rs33322	chr5:56175226	C5orf35	chr5:56205103-56213010:+	0.72	9.19	9.74E-18	Type 2 diabetes	
OV	cis	1	rs33325	chr5:56142547	C5orf35	chr5:56205103-56213010:+	0.71	9.64	3.71E-19	Type 2 diabetes	
OV	cis	1	rs33326	chr5:56142601	C5orf35	chr5:56205103-56213010:+	0.72	9.63	4.07E-19	Type 2 diabetes	
OV	cis	1	rs33999310	chr3:52883332	SFMBT1	chr3:52938628-53080070:-	-0.51	-4.68	4.47E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs33999310	chr3:52883332	TMEM110	chr3:52867139-52931547:-	0.46	4.01	7.95E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs34102169	chr1:46424864	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.82	5.55E-11	Body mass index	
OV	cis	1	rs34106666	chr6:86676258	SNHG5	chr6:86386726-86388451:-	-0.65	-10.89	3.29E-23	Response to antipsychotic treatment	
OV	cis	1	rs34121720	chr3:53072167	SFMBT1	chr3:52938628-53080070:-	-0.5	-4.62	5.97E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs34127220	chr16:29842891	MVP	chr16:29831787-29859342:+	-0.31	-4.83	2.31E-6	Multiple sclerosis	
OV	cis	1	rs34136756	chr7:65381256	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs34139049	chr6:33716784	IP6K3	chr6:33689443-33714762:-	0.48	5.11	6.05E-7	Obesity (extreme)	
OV	cis	1	rs34171762	chr19:18559410	SSBP4	chr19:18530221-18545371:+	-0.34	-4.34	1.98E-5	Breast cancer	
OV	cis	1	rs34193460	chr7:65393110	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.8E-6	Diabetic kidney disease	
OV	cis	1	rs34244302	chr3:53102236	SFMBT1	chr3:52938628-53080070:-	-0.56	-5.05	8.0E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs34256197	chr19:18606472	SSBP4	chr19:18530221-18545371:+	-0.32	-4.16	4.31E-5	Breast cancer	
OV	cis	1	rs34281561	chr6:86701872	SNHG5	chr6:86386726-86388451:-	-0.7	-11.86	1.66E-26	Response to antipsychotic treatment	
OV	cis	1	rs34286592	chr16:29820480	MVP	chr16:29831787-29859342:+	-0.32	-4.84	2.17E-6	Multiple sclerosis	
OV	cis	1	rs34313969	chr3:52995166	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.31	2.24E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs34339105	chr6:33723457	IP6K3	chr6:33689443-33714762:-	0.52	5.57	6.11E-8	Obesity (extreme)	
OV	cis	1	rs34340609	chr3:53077276	SFMBT1	chr3:52938628-53080070:-	-0.42	-4.25	2.95E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs344081	chr3:156555984	LEKR1	chr3:156544076-156763918:+	-0.59	-7.56	6.09E-13	Bone mineral density	
OV	cis	1	rs344088	chr3:156561361	LEKR1	chr3:156544076-156763918:+	-0.6	-7.63	3.75E-13	Bone mineral density	
OV	cis	1	rs344090	chr3:156563140	LEKR1	chr3:156544076-156763918:+	-0.6	-7.63	3.75E-13	Bone mineral density	
OV	cis	1	rs34460334	chr1:27215079	CD52	chr1:26644411-26647013:+	0.39	3.89	0.000125	HDL cholesterol;Triglycerides;LDL cholesterol	
OV	cis	1	rs34460651	chr6:33731312	IP6K3	chr6:33689443-33714762:-	0.5	5.49	9.07E-8	Obesity (extreme)	
OV	cis	1	rs34529418	chr7:65403209	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs34530577	chr3:53103796	RFT1	chr3:53122503-53164470:-	-0.33	-4.59	6.74E-6	Height	
OV	cis	1	rs34560516	chr7:65404092	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.8E-6	Diabetic kidney disease	
OV	cis	1	rs34577383	chr7:65385726	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs34581302	chr6:86705948	SNHG5	chr6:86386726-86388451:-	-0.7	-11.96	7.24E-27	Response to antipsychotic treatment	
OV	cis	1	rs34622557	chr6:86630852	SNHG5	chr6:86386726-86388451:-	-0.65	-11	1.32E-23	Response to antipsychotic treatment	
OV	cis	1	rs34637256	chr7:65360131	CCT6P1	chr7:65216092-65228661:+	0.36	4.52	9.28E-6	Diabetic kidney disease	
OV	cis	1	rs34645895	chr20:25368373	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.33E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs34645895	chr20:25368373	FAM182B	chr20:25744102-25848786:-	-0.33	-5.06	7.59E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs34702770	chr7:65344823	CCT6P1	chr7:65216092-65228661:+	0.36	4.52	9.28E-6	Diabetic kidney disease	
OV	cis	1	rs34703416	chr7:65300642	CCT6P1	chr7:65216092-65228661:+	0.36	4.5	9.96E-6	Diabetic kidney disease	
OV	cis	1	rs34746918	chr19:18539744	SSBP4	chr19:18530221-18545371:+	-0.31	-3.92	0.000114	Breast cancer	
OV	cis	1	rs34815098	chr7:65292254	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.11E-5	Diabetic kidney disease	
OV	cis	1	rs34869648	chr6:33724059	IP6K3	chr6:33689443-33714762:-	0.52	5.57	6.11E-8	Obesity (extreme)	
OV	cis	1	rs34884883	chr6:33768726	IP6K3	chr6:33689443-33714762:-	0.53	5.44	1.2E-7	Obesity (extreme)	
OV	cis	1	rs34933390	chr3:53006265	SFMBT1	chr3:52938628-53080070:-	-0.58	-5.41	1.33E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs34933526	chr7:65383199	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs34943350	chr3:53012888	SFMBT1	chr3:52938628-53080070:-	-0.58	-5.27	2.73E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs34964872	chr14:104448435	TDRD9	chr14:104394817-104519002:+	0.4	5.37	1.67E-7	Bipolar disorder	
OV	cis	1	rs34970380	chr7:65431493	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs34974928	chr7:65364006	CCT6P1	chr7:65216092-65228661:+	0.36	4.49	1.04E-5	Diabetic kidney disease	
OV	cis	1	rs34979715	chr3:53048960	SFMBT1	chr3:52938628-53080070:-	-0.6	-5.68	3.46E-8	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs35046236	chr7:65408613	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.17E-5	Diabetic kidney disease	
OV	cis	1	rs35058610	chr7:65390925	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs35060985	chr11:43693110	HSD17B12	chr11:43702143-43878160:+	-0.43	-6.34	9.35E-10	Forced vital capacity	
OV	cis	1	rs35099099	chr6:39284857	KCNK17	chr6:39266778-39282237:-	0.32	4.62	6.0E-6	Type 2 diabetes	
OV	cis	1	rs35106985	chr10:102307542	SEC31B	chr10:102246403-102289636:-	-0.28	-4.12	4.98E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs35141484	chr4:39088341	FAM114A1	chr4:38869437-38945424:+	-0.5	-5.02	9.41E-7	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	LIAS	chr4:39460665-39479269:+	-0.56	-5.16	4.79E-7	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	N4BP2	chr4:40058524-40157017:+	-0.63	-6.71	1.12E-10	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	PDS5A	chr4:39824484-39979576:-	-0.82	-7.62	4.11E-13	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	RFC1	chr4:39289076-39367995:-	-0.87	-8.47	1.45E-15	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	RPL9	chr4:39455747-39460568:-	-0.6	-4.75	3.28E-6	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	UBE2K	chr4:39699664-39784408:+	-0.8	-7.08	1.16E-11	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	UGDH	chr4:39500375-39529211:-	-0.74	-6.05	4.8E-9	Asthma (childhood onset)	
OV	cis	1	rs35141484	chr4:39088341	WDR19	chr4:39184024-39287429:+	-0.53	-6.23	1.71E-9	Asthma (childhood onset)	
OV	cis	1	rs35163227	chr3:53127876	SFMBT1	chr3:52938628-53080070:-	-0.53	-4.8	2.55E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs35174175	chr3:53041509	SFMBT1	chr3:52938628-53080070:-	-0.6	-5.82	1.6E-8	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs35274562	chr6:33716831	IP6K3	chr6:33689443-33714762:-	0.48	5.11	6.05E-7	Obesity (extreme)	
OV	cis	1	rs35283677	chr7:65359233	CCT6P1	chr7:65216092-65228661:+	0.37	4.57	7.35E-6	Diabetic kidney disease	
OV	cis	1	rs35343234	chr11:28034379	CCDC34	chr11:27360061-27384795:-	0.33	3.95	9.87E-5	Bipolar disorder	
OV	cis	1	rs35385043	chr6:86648546	SNHG5	chr6:86386726-86388451:-	-0.66	-11.67	7.28E-26	Response to antipsychotic treatment	
OV	cis	1	rs35391607	chr7:65360829	CCT6P1	chr7:65216092-65228661:+	0.36	4.49	1.03E-5	Diabetic kidney disease	
OV	cis	1	rs35396113	chr7:65495461	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs35419329	chr6:86702291	SNHG5	chr6:86386726-86388451:-	-0.7	-11.86	1.66E-26	Response to antipsychotic treatment	
OV	cis	1	rs35421653	chr7:65363429	CCT6P1	chr7:65216092-65228661:+	0.37	4.57	7.41E-6	Diabetic kidney disease	
OV	cis	1	rs35424364	chr6:109643605	AKD1	chr6:109814059-110012415:-	-0.42	-4.29	2.46E-5	Obstructive sleep apnea trait (average respiratory event duration)	
OV	cis	1	rs35432774	chr7:65393019	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs35468353	chr16:31056433	HSD3B7	chr16:30996519-31000473:+	0.3	4.83	2.23E-6	Response to metformin (IC50)	
OV	cis	1	rs35468353	chr16:31056433	STX1B	chr16:31000577-31021829:-	0.25	3.85	0.000146	Response to metformin (IC50)	
OV	cis	1	rs35507120	chr3:53053924	SFMBT1	chr3:52938628-53080070:-	-0.6	-5.7	3.06E-8	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs35542501	chr7:65431215	CCT6P1	chr7:65216092-65228661:+	0.37	4.59	6.62E-6	Diabetic kidney disease	
OV	cis	1	rs35576914	chr3:53092270	SFMBT1	chr3:52938628-53080070:-	-0.53	-4.84	2.19E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs35646598	chr6:33717416	IP6K3	chr6:33689443-33714762:-	0.48	5.1	6.39E-7	Obesity (extreme)	
OV	cis	1	rs35718987	chr3:134272783	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs35720014	chr3:52982110	SFMBT1	chr3:52938628-53080070:-	-0.58	-5.36	1.73E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs35735127	chr7:65300423	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.2E-5	Diabetic kidney disease	
OV	cis	1	rs35737577	chr3:53002557	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.31	2.24E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs35760725	chr6:86648985	SNHG5	chr6:86386726-86388451:-	-0.66	-11.67	7.28E-26	Response to antipsychotic treatment	
OV	cis	1	rs35820085	chr7:65442758	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs35825738	chr7:65318027	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.11E-5	Diabetic kidney disease	
OV	cis	1	rs35849389	chr3:53005235	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.34	1.93E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs36033484	chr7:65390558	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.8E-6	Diabetic kidney disease	
OV	cis	1	rs36068983	chr7:65408991	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.17E-5	Diabetic kidney disease	
OV	cis	1	rs36090694	chr3:53010742	SFMBT1	chr3:52938628-53080070:-	-0.55	-5.07	7.33E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs36096931	chr6:86693134	SNHG5	chr6:86386726-86388451:-	-0.66	-11.33	1.03E-24	Response to antipsychotic treatment	
OV	cis	1	rs36122085	chr6:33765255	IP6K3	chr6:33689443-33714762:-	0.49	5.35	1.87E-7	Obesity (extreme)	
OV	cis	1	rs36216559	chr2:262335	SH3YL1	chr2:218138-264810:-	-0.52	-7.29	3.27E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs371674	chr21:42695445	FAM3B	chr21:42676177-42729654:+	0.38	4.76	3.15E-6	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
OV	cis	1	rs3732276	chr2:242343404	SEPT2	chr2:242254723-242293439:+	0.67	5.77	2.15E-8	Chronic lymphocytic leukemia	
OV	cis	1	rs3734618	chr6:39284184	KCNK17	chr6:39266778-39282237:-	0.3	4.5	1.0E-5	Type 2 diabetes	
OV	cis	1	rs3735400	chr7:36438709	KIAA0895	chr7:36363759-36429734:-	0.38	4	8.07E-5	Systolic blood pressure	
OV	cis	1	rs3742500	chr14:24611978	FAM158A	chr14:24608175-24610797:-	-0.44	-7.52	7.86E-13	IgG glycosylation	
OV	cis	1	rs3745937	chr19:42071289	CEACAM21	chr19:42055886-42093196:+	0.44	6.59	2.26E-10	Schizophrenia	
OV	cis	1	rs3746231	chr19:57760057	ZNF264	chr19:57702869-57734212:+	-0.22	-4.45	1.26E-5	Hyperactive-impulsive symptoms	
OV	cis	1	rs3750626	chr10:102266316	SEC31B	chr10:102246403-102289636:-	-0.31	-4.68	4.49E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3750627	chr10:102275642	SEC31B	chr10:102246403-102289636:-	-0.28	-4.32	2.21E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3750629	chr10:102275727	SEC31B	chr10:102246403-102289636:-	-0.25	-3.94	0.000102	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3750630	chr10:102275780	SEC31B	chr10:102246403-102289636:-	-0.26	-4.02	7.39E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3750719	chr10:102248950	SEC31B	chr10:102246403-102289636:-	-0.28	-4.11	5.26E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3750720	chr10:102248884	SEC31B	chr10:102246403-102289636:-	-0.27	-4.21	3.42E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3756416	chr5:43383502	NNT	chr5:43602791-43705667:+	-0.29	-4.02	7.39E-5	Metabolite levels  (X-11787)	
OV	cis	1	rs3761117	chr20:25388070	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.14E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs3761117	chr20:25388070	FAM182B	chr20:25744102-25848786:-	-0.33	-5.07	7.46E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs3761959	chr1:157669278	FCRL3	chr1:157646278-157670775:-	0.27	4.72	3.82E-6	Type 1 diabetes autoantibodies	
OV	cis	1	rs3763695	chr10:102269206	SEC31B	chr10:102246403-102289636:-	-0.29	-4.51	9.65E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3770087	chr2:86267068	LOC90784	chr2:86247339-86250991:-	-0.58	-4.42	1.42E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs3770090	chr2:86263288	LOC90784	chr2:86247339-86250991:-	-0.6	-4.53	8.74E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
OV	cis	1	rs3770752	chr2:37576136	CEBPZ	chr2:37428778-37458740:-	0.3	4.9	1.65E-6	Schizophrenia	
OV	cis	1	rs3774372	chr3:41877414	ULK4	chr3:41288091-42003660:-	0.66	8.07	2.13E-14	Diastolic blood pressure	
OV	cis	1	rs3774808	chr3:48481647	TREX1	chr3:48501186-48509043:+	-0.27	-5.15	4.87E-7	Longevity	
OV	cis	1	rs3782130	chr12:58161898	FAM119B	chr12:58166383-58176323:+	0.36	5.23	3.42E-7	Multiple sclerosis	
OV	cis	1	rs3782130	chr12:58161898	TSFM	chr12:58176536-58191367:+	-0.35	-5.98	6.69E-9	Multiple sclerosis	
OV	cis	1	rs3791220	chr2:227066	SH3YL1	chr2:218138-264810:-	-0.51	-7.27	3.59E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs3791221	chr2:226933	SH3YL1	chr2:218138-264810:-	-0.52	-7.33	2.51E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs3791223	chr2:222336	SH3YL1	chr2:218138-264810:-	-0.53	-7.5	8.45E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs3791224	chr2:221981	SH3YL1	chr2:218138-264810:-	-0.51	-7.16	7.35E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs3793079	chr6:33767788	LEMD2	chr6:33738991-33756906:-	-0.24	-3.9	0.00012	Crohn's disease	
OV	cis	1	rs3793080	chr6:33767803	IP6K3	chr6:33689443-33714762:-	-0.48	-5.32	2.16E-7	Obesity (extreme)	
OV	cis	1	rs3793706	chr10:102269085	SEC31B	chr10:102246403-102289636:-	0.26	4.05	6.55E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs3796352	chr3:52913279	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.49	9.09E-8	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs3806107	chr6:33767413	IP6K3	chr6:33689443-33714762:-	0.46	5.21	3.75E-7	Obesity (extreme)	
OV	cis	1	rs3806692	chr3:53080987	SFMBT1	chr3:52938628-53080070:-	-0.43	-4.26	2.79E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs3806988	chr6:49431569	MUT	chr6:49398994-49431031:-	0.26	4.09	5.73E-5	Folate pathway vitamin levels	
OV	cis	1	rs3810429	chr19:18543270	SSBP4	chr19:18530221-18545371:+	-0.34	-4.32	2.14E-5	Breast cancer	
OV	cis	1	rs3813227	chr2:73651967	ALMS1P	chr2:73872046-73912692:+	-0.35	-5.64	4.23E-8	Metabolite levels	
OV	cis	1	rs3813948	chr1:207269858	C4BPA	chr1:207277511-207318308:+	0.5	5.1	6.42E-7	C4b binding protein levels	
OV	cis	1	rs3815413	chr4:17654648	LAP3	chr4:17578927-17609590:+	-0.3	-5.16	4.72E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs3815414	chr4:17606659	LAP3	chr4:17578927-17609590:+	0.22	3.87	0.000138	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs3815824	chr16:29852860	MVP	chr16:29831787-29859342:+	-0.27	-4.24	3.02E-5	Multiple sclerosis	
OV	cis	1	rs3823114	chr6:49431720	MUT	chr6:49398994-49431031:-	0.26	4.1	5.47E-5	Folate pathway vitamin levels	
OV	cis	1	rs3825079	chr12:58203354	FAM119B	chr12:58166383-58176323:+	0.37	5.34	1.9E-7	Multiple sclerosis	
OV	cis	1	rs3825079	chr12:58203354	TSFM	chr12:58176536-58191367:+	-0.37	-6.38	7.31E-10	Multiple sclerosis	
OV	cis	1	rs3827066	chr20:44586023	WFDC3	chr20:44402847-44420547:-	-0.42	-4.19	3.8E-5	Abdominal aortic aneurysm	
OV	cis	1	rs3828165	chr2:220889	SH3YL1	chr2:218138-264810:-	-0.54	-7.62	3.94E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs383402	chr7:65586653	CCT6P1	chr7:65216092-65228661:+	-0.37	-4.68	4.43E-6	Diabetic kidney disease	
OV	cis	1	rs3846055	chr3:134203973	ANAPC13	chr3:134196547-134204865:-	0.43	6.07	4.28E-9	Height	
OV	cis	1	rs3846056	chr3:134227292	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs3846357	chr4:17635887	LAP3	chr4:17578927-17609590:+	-0.27	-4.76	3.17E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs3862436	chr15:91082869	FES	chr15:91427665-91439004:+	0.44	3.87	0.000138	Response to exercise (triglyceride levels)	
OV	cis	1	rs387676	chr7:65598220	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs3885839	chr7:65290403	CCT6P1	chr7:65216092-65228661:+	0.37	4.55	7.94E-6	Diabetic kidney disease	
OV	cis	1	rs3890604	chr3:41760625	ULK4	chr3:41288091-42003660:-	0.61	8.21	8.56E-15	Diastolic blood pressure	
OV	cis	1	rs3932818	chr3:134206069	ANAPC13	chr3:134196547-134204865:-	0.4	5.6	5.21E-8	Height	
OV	cis	1	rs3933453	chr4:17636319	LAP3	chr4:17578927-17609590:+	-0.29	-5.11	6.01E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs3934103	chr3:41977214	ULK4	chr3:41288091-42003660:-	-0.64	-8.18	1.03E-14	Diastolic blood pressure	
OV	cis	1	rs397119	chr20:25440187	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs397119	chr20:25440187	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs398036	chr20:25439850	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs398036	chr20:25439850	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs401166	chr20:25446308	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs401166	chr20:25446308	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs402418	chr7:65509469	CCT6P1	chr7:65216092-65228661:+	0.37	4.43	1.38E-5	Diabetic kidney disease	
OV	cis	1	rs404394	chr20:25447896	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs404394	chr20:25447896	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4073846	chr1:46462881	CCDC163P	chr1:45960581-45965646:-	0.46	6.82	5.7E-11	Body mass index	
OV	cis	1	rs4076006	chr1:46438076	CCDC163P	chr1:45960581-45965646:-	-0.47	-7.07	1.24E-11	Body mass index	
OV	cis	1	rs4077341	chr8:22962348	BIN3	chr8:22477949-22526661:-	0.38	4.76	3.1E-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077341	chr8:22962348	BMP1	chr8:22022675-22069837:+	0.23	3.86	0.00014	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077341	chr8:22962348	CHMP7	chr8:23101150-23119512:+	0.32	3.94	0.000103	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077341	chr8:22962348	KIAA1967	chr8:22462257-22477981:+	0.34	4.59	6.85E-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077341	chr8:22962348	POLR3D	chr8:22102619-22108679:+	0.36	4.64	5.36E-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077341	chr8:22962348	R3HCC1	chr8:23145612-23153791:+	0.3	4.4	1.56E-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077341	chr8:22962348	REEP4	chr8:21995533-21999448:-	0.29	4.16	4.33E-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077341	chr8:22962348	TNFRSF10B	chr8:22877648-22926700:-	0.29	3.96	9.58E-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4077468	chr1:205914757	PM20D1	chr1:205797154-205819245:-	0.31	4.21	3.48E-5	Cystic fibrosis-related diabetes	
OV	cis	1	rs4077469	chr1:205914885	PM20D1	chr1:205797154-205819245:-	0.31	4.21	3.48E-5	Cystic fibrosis-related diabetes	
OV	cis	1	rs4078160	chr10:52565940	ASAH2B	chr10:52499696-52514567:+	-0.37	-3.9	0.000121	Urate levels in lean individuals	
OV	cis	1	rs410128	chr7:65603173	CCT6P1	chr7:65216092-65228661:+	0.38	4.48	1.08E-5	Diabetic kidney disease	
OV	cis	1	rs41266839	chr6:26409890	BTN3A2	chr6:26365398-26378546:+	-0.72	-5.25	3.09E-7	Schizophrenia	
OV	cis	1	rs4129956	chr4:302008	ZNF718	chr4:53272-156488:+	0.42	4.14	4.61E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs4134386	chr1:46395089	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs41433250	chr13:31495835	HMGB1	chr13:31032881-31191510:-	0.64	5.97	7.2E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	cis	1	rs41433250	chr13:31495835	HSPH1	chr13:31710765-31736502:-	0.62	5.41	1.34E-7	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	cis	1	rs41433250	chr13:31495835	USPL1	chr13:31191830-31233686:+	0.52	4.88	1.78E-6	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	cis	1	rs4150575	chr11:18356466	GTF2H1	chr11:18343816-18388590:+	0.27	3.89	0.000128	Pancreatic cancer	
OV	cis	1	rs4150612	chr11:18364358	GTF2H1	chr11:18343816-18388590:+	0.29	4.08	5.85E-5	Pancreatic cancer	
OV	cis	1	rs4150622	chr11:18365710	GTF2H1	chr11:18343816-18388590:+	0.28	4	7.99E-5	Pancreatic cancer	
OV	cis	1	rs4150650	chr11:18374279	GTF2H1	chr11:18343816-18388590:+	0.27	3.86	0.000143	Pancreatic cancer	
OV	cis	1	rs4150651	chr11:18374425	GTF2H1	chr11:18343816-18388590:+	0.27	3.86	0.000143	Pancreatic cancer	
OV	cis	1	rs4150661	chr11:18379629	GTF2H1	chr11:18343816-18388590:+	0.28	3.95	0.0001	Pancreatic cancer	
OV	cis	1	rs419603	chr7:65597341	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs422164	chr7:65586605	CCT6P1	chr7:65216092-65228661:+	0.33	4.15	4.5E-5	Diabetic kidney disease	
OV	cis	1	rs422424	chr20:25445446	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs422424	chr20:25445446	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs422844	chr20:25445591	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs422844	chr20:25445591	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4235388	chr4:17682030	LAP3	chr4:17578927-17609590:+	-0.23	-3.9	0.000118	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4237643	chr11:43648368	HSD17B12	chr11:43702143-43878160:+	0.42	6.05	4.6E-9	Forced vital capacity	
OV	cis	1	rs4243774	chr1:85356878	SPATA1	chr1:84971974-85031875:+	0.32	3.93	0.000109	Smoking cessation	
OV	cis	1	rs4244338	chr10:102272802	SEC31B	chr10:102246403-102289636:-	-0.28	-4.16	4.31E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs4256922	chr10:52568616	ASAH2B	chr10:52499696-52514567:+	-0.39	-4.06	6.28E-5	Urate levels in lean individuals	
OV	cis	1	rs4263408	chr4:39785276	RPL9	chr4:39455747-39460568:-	-0.32	-4.54	8.36E-6	Plasma amyloid beta peptide concentrations (ABx-40)	
OV	cis	1	rs4267943	chr6:49439805	CENPQ	chr6:49431096-49460820:+	0.26	4.26	2.81E-5	Folate pathway vitamin levels	
OV	cis	1	rs427044	chr7:65508545	CCT6P1	chr7:65216092-65228661:+	0.36	4.37	1.78E-5	Diabetic kidney disease	
OV	cis	1	rs4272382	chr8:8433488	CLDN23	chr8:8559666-8561616:+	-0.51	-5.02	9.09E-7	Response to cytidine analogues (gemcitabine)	
OV	cis	1	rs4272382	chr8:8433488	ERI1	chr8:8860314-8890849:+	-0.84	-8.98	4.3E-17	Response to cytidine analogues (gemcitabine)	
OV	cis	1	rs4272382	chr8:8433488	FLJ10661	chr8:8086092-8102386:+	-0.45	-5.02	9.05E-7	Response to cytidine analogues (gemcitabine)	
OV	cis	1	rs4272382	chr8:8433488	MFHAS1	chr8:8641999-8751131:-	-0.56	-5.84	1.49E-8	Response to cytidine analogues (gemcitabine)	
OV	cis	1	rs4272382	chr8:8433488	PPP1R3B	chr8:8993774-9009084:-	-0.54	-6.23	1.73E-9	Response to cytidine analogues (gemcitabine)	
OV	cis	1	rs4272382	chr8:8433488	TNKS	chr8:9413445-9639855:+	-0.68	-7.68	2.72E-13	Response to cytidine analogues (gemcitabine)	
OV	cis	1	rs4282209	chr4:76919536	NAAA	chr4:76831809-76862166:-	-0.29	-4.91	1.54E-6	Longevity	
OV	cis	1	rs4286230	chr2:127623712	POLR2D	chr2:128603841-128615729:-	0.34	4.11	5.2E-5	Pelvic organ prolapse (moderate/severe)	
OV	cis	1	rs4309773	chr3:134277301	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs431076	chr7:65600320	CCT6P1	chr7:65216092-65228661:+	0.33	4.12	5.04E-5	Diabetic kidney disease	
OV	cis	1	rs431318	chr7:65511597	CCT6P1	chr7:65216092-65228661:+	0.37	4.42	1.4E-5	Diabetic kidney disease	
OV	cis	1	rs4315635	chr22:49571530	BRD1	chr22:50166938-50221180:-	0.4	4.81	2.5E-6	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)	
OV	cis	1	rs43184	chr5:56141777	C5orf35	chr5:56205103-56213010:+	0.72	9.63	4.07E-19	Type 2 diabetes	
OV	cis	1	rs4323544	chr9:123647377	LOC253039	chr9:123605320-123616644:+	-0.27	-3.86	0.000139	Rheumatoid arthritis	
OV	cis	1	rs4334685	chr3:134304335	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs433852	chr19:49117104	SEC1	chr19:49141296-49185501:+	-0.38	-4.61	6.16E-6	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease	
OV	cis	1	rs4356975	chr4:69972463	UGT2B7	chr4:69962193-69978704:+	-0.39	-5.79	1.89E-8	Obesity-related traits	
OV	cis	1	rs4367113	chr3:134287975	ANAPC13	chr3:134196547-134204865:-	0.41	5.72	2.73E-8	Height	
OV	cis	1	rs4368544	chr3:134300014	ANAPC13	chr3:134196547-134204865:-	-0.41	-5.59	5.49E-8	Height	
OV	cis	1	rs4372836	chr2:28973883	TRMT61B	chr2:29072690-29093175:-	-0.3	-3.94	0.000104	Body mass index	
OV	cis	1	rs4376778	chr1:46288846	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.37E-11	Body mass index	
OV	cis	1	rs437889	chr7:65509234	CCT6P1	chr7:65216092-65228661:+	0.37	4.46	1.17E-5	Diabetic kidney disease	
OV	cis	1	rs439295	chr3:156572455	LEKR1	chr3:156544076-156763918:+	-0.6	-7.63	3.75E-13	Bone mineral density	
OV	cis	1	rs4408846	chr3:41753679	ULK4	chr3:41288091-42003660:-	0.54	6.98	2.16E-11	Diastolic blood pressure	
OV	cis	1	rs4417907	chr3:134291363	ANAPC13	chr3:134196547-134204865:-	0.43	5.93	9.01E-9	Height	
OV	cis	1	rs441810	chr21:42698907	FAM3B	chr21:42676177-42729654:+	0.37	4.71	3.88E-6	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
OV	cis	1	rs4423809	chr3:134300107	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.51	8.21E-8	Height	
OV	cis	1	rs447722	chr20:25443510	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs447722	chr20:25443510	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4478072	chr3:53106125	SFMBT1	chr3:52938628-53080070:-	-0.45	-4.59	6.8E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs448396	chr20:25440269	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs448396	chr20:25440269	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4490383	chr3:48484683	TREX1	chr3:48501186-48509043:+	-0.27	-5.16	4.76E-7	Longevity	
OV	cis	1	rs449043	chr21:42700410	FAM3B	chr21:42676177-42729654:+	-0.36	-4.62	5.85E-6	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
OV	cis	1	rs4497901	chr2:239969	SH3YL1	chr2:218138-264810:-	-0.52	-7.32	2.73E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs4498009	chr3:134198008	ANAPC13	chr3:134196547-134204865:-	0.4	5.57	5.87E-8	Height	
OV	cis	1	rs4502439	chr2:240214762	MGC16025	chr2:240115027-240117153:-	0.61	4.58	6.9E-6	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs451396	chr7:65484074	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs453329	chr20:25440593	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs453329	chr20:25440593	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4535272	chr3:134299916	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.43	1.24E-7	Height	
OV	cis	1	rs4545281	chr1:46360054	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.83	5.24E-11	Body mass index	
OV	cis	1	rs4548056	chr7:65298873	CCT6P1	chr7:65216092-65228661:+	0.35	4.35	1.89E-5	Diabetic kidney disease	
OV	cis	1	rs4549034	chr2:28972579	TRMT61B	chr2:29072690-29093175:-	-0.3	-3.94	0.000104	Body mass index	
OV	cis	1	rs4549329	chr4:239785	ZNF718	chr4:53272-156488:+	0.38	4.06	6.3E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs4572812	chr3:134291177	ANAPC13	chr3:134196547-134204865:-	-0.41	-5.59	5.49E-8	Height	
OV	cis	1	rs4579776	chr1:85357025	SPATA1	chr1:84971974-85031875:+	-0.32	-3.91	0.000118	Smoking cessation	
OV	cis	1	rs4582105	chr4:246342	ZNF718	chr4:53272-156488:+	0.41	4.15	4.4E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs458291	chr7:65520479	CCT6P1	chr7:65216092-65228661:+	0.36	4.29	2.5E-5	Diabetic kidney disease	
OV	cis	1	rs4594164	chr14:35509571	KIAA0391	chr14:35591776-35786673:+	0.39	4.35	1.92E-5	Atopic dermatitis	
OV	cis	1	rs4595905	chr19:18547305	SSBP4	chr19:18530221-18545371:+	-0.34	-4.32	2.14E-5	Breast cancer	
OV	cis	1	rs4604805	chr10:102261409	SEC31B	chr10:102246403-102289636:-	-0.36	-5.61	4.94E-8	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs462853	chr7:65558167	CCT6P1	chr7:65216092-65228661:+	0.35	4.24	3.03E-5	Diabetic kidney disease	
OV	cis	1	rs4642241	chr4:17617111	LAP3	chr4:17578927-17609590:+	-0.23	-3.99	8.38E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4646536	chr12:58157988	FAM119B	chr12:58166383-58176323:+	0.3	4.11	5.23E-5	Multiple sclerosis	
OV	cis	1	rs4646536	chr12:58157988	TSFM	chr12:58176536-58191367:+	-0.33	-5.43	1.25E-7	Multiple sclerosis	
OV	cis	1	rs464895	chr7:65527106	CCT6P1	chr7:65216092-65228661:+	0.33	3.94	0.000103	Diabetic kidney disease	
OV	cis	1	rs465359	chr7:65558164	CCT6P1	chr7:65216092-65228661:+	0.35	4.24	3.03E-5	Diabetic kidney disease	
OV	cis	1	rs4660306	chr1:45978675	CCDC163P	chr1:45960581-45965646:-	0.96	16.15	8.18E-42	Homocysteine levels	
OV	cis	1	rs4660306	chr1:45978675	MMACHC	chr1:45965856-45976737:+	0.29	4.02	7.59E-5	Homocysteine levels	
OV	cis	1	rs4660317	chr1:46326226	CCDC163P	chr1:45960581-45965646:-	-0.45	-6.76	8.35E-11	Body mass index	
OV	cis	1	rs4660319	chr1:46341623	CCDC163P	chr1:45960581-45965646:-	-0.45	-6.76	8.35E-11	Body mass index	
OV	cis	1	rs4660321	chr1:46366760	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs4660870	chr1:45995231	CCDC163P	chr1:45960581-45965646:-	-0.89	-14.03	3.82E-34	Homocysteine levels	
OV	cis	1	rs4660898	chr1:46402171	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs4660910	chr1:46548402	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.16	7.23E-12	Body mass index	
OV	cis	1	rs4666118	chr2:28951698	TRMT61B	chr2:29072690-29093175:-	-0.29	-3.9	0.000119	Body mass index	
OV	cis	1	rs4666119	chr2:28975690	TRMT61B	chr2:29072690-29093175:-	-0.32	-4.31	2.31E-5	Body mass index	
OV	cis	1	rs466983	chr7:65520496	CCT6P1	chr7:65216092-65228661:+	0.36	4.3	2.38E-5	Diabetic kidney disease	
OV	cis	1	rs4687697	chr3:53090490	ITIH4	chr3:52847007-52866554:-	0.2	4.06	6.52E-5	Ulcerative colitis	
OV	cis	1	rs4687701	chr3:53121276	RFT1	chr3:53122503-53164470:-	0.35	4.96	1.24E-6	Height	
OV	cis	1	rs4698198	chr4:17656536	LAP3	chr4:17578927-17609590:+	-0.26	-4.6	6.54E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4698199	chr4:17656738	LAP3	chr4:17578927-17609590:+	-0.26	-4.6	6.54E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4698200	chr4:17657051	LAP3	chr4:17578927-17609590:+	-0.26	-4.45	1.26E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4698634	chr4:17630192	LAP3	chr4:17578927-17609590:+	0.25	4.23	3.12E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4698635	chr4:17630242	LAP3	chr4:17578927-17609590:+	-0.25	-4.24	3.03E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4698641	chr4:17642630	LAP3	chr4:17578927-17609590:+	-0.28	-4.93	1.39E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs4704780	chr5:158246785	RNF145	chr5:158584419-158637061:-	0.41	4.09	5.73E-5	Hip circumference (psychosocial stress interaction)	
OV	cis	1	rs4706254	chr6:86602813	SNHG5	chr6:86386726-86388451:-	-0.65	-11.2	2.85E-24	Response to antipsychotic treatment	
OV	cis	1	rs4707239	chr6:86610717	SNHG5	chr6:86386726-86388451:-	-0.66	-11.67	7.28E-26	Response to antipsychotic treatment	
OV	cis	1	rs4713684	chr6:33766488	LEMD2	chr6:33738991-33756906:-	-0.24	-3.87	0.000136	Crohn's disease	
OV	cis	1	rs4715129	chr6:49415043	MUT	chr6:49398994-49431031:-	0.27	4.14	4.66E-5	Folate pathway vitamin levels	
OV	cis	1	rs4718269	chr7:65200778	CCT6P1	chr7:65216092-65228661:+	-0.4	-4.62	5.76E-6	Diabetic kidney disease	
OV	cis	1	rs4718270	chr7:65202407	CCT6P1	chr7:65216092-65228661:+	0.4	4.56	7.53E-6	Diabetic kidney disease	
OV	cis	1	rs4718317	chr7:65648901	CCT6P1	chr7:65216092-65228661:+	-0.33	-4.12	5.0E-5	Diabetic kidney disease	
OV	cis	1	rs4726669	chr7:143758191	ARHGEF35	chr7:143883677-143892736:-	-0.44	-5.58	5.62E-8	Obesity-related traits	
OV	cis	1	rs4726669	chr7:143758191	CTAGE6	chr7:143452184-143454843:-	-0.32	-3.92	0.000114	Obesity-related traits	
OV	cis	1	rs4726669	chr7:143758191	OR2A9P	chr7:143991573-143997832:+;chr7	-0.35	-4.26	2.77E-5	Obesity-related traits	
OV	cis	1	rs4728142	chr7:128573967	IRF5	chr7:128577769-128590086:+	0.35	5.9	1.06E-8	Systemic lupus erythematosus;Ulcerative colitis;Inflammatory bowel disease	
OV	cis	1	rs4733384	chr8:29985381	MBOAT4	chr8:29989188-30002200:-	0.43	4.1	5.46E-5	Migraine	
OV	cis	1	rs4737918	chr8:69736234	C8orf34	chr8:69243457-69731256:+	-0.39	-4.2	3.56E-5	Obesity-related traits	
OV	cis	1	rs4755726	chr11:43642130	HSD17B12	chr11:43702143-43878160:+	-0.42	-6.11	3.37E-9	Forced vital capacity	
OV	cis	1	rs4759229	chr12:56474480	RPS26	chr12:56435686-56438005:+	-0.41	-7.39	1.7E-12	Cognitive function	
OV	cis	1	rs477692	chr10:131426022	MGMT	chr10:131265454-131565783:+	0.24	3.88	0.00013	Response to temozolomide	
OV	cis	1	rs4787480	chr16:29857316	MVP	chr16:29831787-29859342:+	-0.27	-4.13	4.87E-5	Multiple sclerosis	
OV	cis	1	rs4788187	chr16:29845685	MVP	chr16:29831787-29859342:+	0.24	4.06	6.52E-5	Multiple sclerosis	
OV	cis	1	rs4788188	chr16:29860863	MVP	chr16:29831787-29859342:+	-0.25	-4.13	4.76E-5	Multiple sclerosis	
OV	cis	1	rs4801652	chr19:56462970	ZNF835	chr19:57174955-57184246:-	0.54	3.89	0.000124	Immune reponse to smallpox (secreted IFN-alpha);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
OV	cis	1	rs4803480	chr19:42066279	CEACAM21	chr19:42055886-42093196:+	0.46	6.94	2.74E-11	Schizophrenia	
OV	cis	1	rs480643	chr10:131400308	MGMT	chr10:131265454-131565783:+	0.24	4.01	7.83E-5	Response to temozolomide	
OV	cis	1	rs4808133	chr19:18608518	SSBP4	chr19:18530221-18545371:+	-0.32	-4.14	4.68E-5	Breast cancer	
OV	cis	1	rs4808134	chr19:18608579	SSBP4	chr19:18530221-18545371:+	-0.32	-4.14	4.68E-5	Breast cancer	
OV	cis	1	rs4808804	chr19:18585325	SSBP4	chr19:18530221-18545371:+	-0.31	-3.88	0.000129	Breast cancer	
OV	cis	1	rs4813562	chr20:25352588	ABHD12	chr20:25275380-25371477:-	-0.41	-5.99	6.61E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4813562	chr20:25352588	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.39E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4813563	chr20:25365340	ABHD12	chr20:25275380-25371477:-	-0.4	-6	6.18E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4813563	chr20:25365340	FAM182B	chr20:25744102-25848786:-	-0.31	-4.8	2.62E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4813566	chr20:25386465	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.3E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4813566	chr20:25386465	FAM182B	chr20:25744102-25848786:-	-0.33	-5.09	6.48E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815191	chr20:23268637	CST1	chr20:23728191-23731574:-	0.32	4.15	4.51E-5	Obesity-related traits	
OV	cis	1	rs4815404	chr20:25301845	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815404	chr20:25301845	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815405	chr20:25317492	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815405	chr20:25317492	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815406	chr20:25341316	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815406	chr20:25341316	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815407	chr20:25341478	ABHD12	chr20:25275380-25371477:-	-0.4	-6	6.29E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815407	chr20:25341478	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.91E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815408	chr20:25346678	ABHD12	chr20:25275380-25371477:-	-0.4	-6	6.29E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815408	chr20:25346678	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.91E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815409	chr20:25346697	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815409	chr20:25346697	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815411	chr20:25350223	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.19E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815411	chr20:25350223	FAM182B	chr20:25744102-25848786:-	-0.32	-4.99	1.06E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815412	chr20:25350325	ABHD12	chr20:25275380-25371477:-	0.41	5.99	6.45E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815412	chr20:25350325	FAM182B	chr20:25744102-25848786:-	0.33	5.13	5.49E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815417	chr20:25379526	ABHD12	chr20:25275380-25371477:-	-0.41	-6.23	1.73E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815417	chr20:25379526	FAM182B	chr20:25744102-25848786:-	-0.3	-4.73	3.54E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815418	chr20:25382211	ABHD12	chr20:25275380-25371477:-	-0.41	-6.1	3.63E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815418	chr20:25382211	FAM182B	chr20:25744102-25848786:-	-0.34	-5.29	2.53E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815420	chr20:25383979	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.3E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815420	chr20:25383979	FAM182B	chr20:25744102-25848786:-	-0.33	-5.09	6.48E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815421	chr20:25386509	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.3E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815421	chr20:25386509	FAM182B	chr20:25744102-25848786:-	-0.33	-5.09	6.48E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815424	chr20:25390284	ABHD12	chr20:25275380-25371477:-	-0.4	-5.94	8.37E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815424	chr20:25390284	FAM182B	chr20:25744102-25848786:-	-0.31	-4.8	2.58E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815426	chr20:25405186	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.13E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4815426	chr20:25405186	FAM182B	chr20:25744102-25848786:-	-0.32	-5.01	9.79E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs4845934	chr1:10468946	PGD	chr1:10459085-10480200:+	0.3	4.23	3.24E-5	Hepatocellular carcinoma	
OV	cis	1	rs4851969	chr2:240223767	MGC16025	chr2:240115027-240117153:-	-0.59	-5.15	4.84E-7	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs4852715	chr2:71088070	ATP6V1B1	chr2:71162998-71192560:+	0.4	3.87	0.000133	IgG glycosylation	
OV	cis	1	rs485576	chr10:131425496	MGMT	chr10:131265454-131565783:+	0.24	3.88	0.00013	Response to temozolomide	
OV	cis	1	rs4858817	chr3:48416756	TREX1	chr3:48501186-48509043:+	0.24	4.44	1.3E-5	Longevity	
OV	cis	1	rs4859413	chr4:76898250	NAAA	chr4:76831809-76862166:-	0.28	4.69	4.24E-6	Longevity	
OV	cis	1	rs4859581	chr4:76906974	NAAA	chr4:76831809-76862166:-	-0.28	-4.81	2.5E-6	Longevity	
OV	cis	1	rs4859582	chr4:76907213	NAAA	chr4:76831809-76862166:-	-0.28	-4.85	2.03E-6	Longevity	
OV	cis	1	rs4889609	chr16:31026427	HSD3B7	chr16:30996519-31000473:+	0.32	5.02	9.06E-7	Response to metformin (IC50)	
OV	cis	1	rs490049	chr13:33564863	N4BP2L2	chr13:33006930-33112936:-	0.55	4.03	7.11E-5	Diabetic kidney disease	
OV	cis	1	rs490049	chr13:33564863	RFC3	chr13:34392206-34540694:+	0.51	4.07	6.22E-5	Diabetic kidney disease	
OV	cis	1	rs4903604	chr14:78028378	SPTLC2	chr14:77973272-78083110:-	-0.26	-3.97	9.03E-5	Gut microbiome composition (winter)	
OV	cis	1	rs4919468	chr10:102288343	SEC31B	chr10:102246403-102289636:-	-0.28	-4.07	6.06E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs4919469	chr10:102298855	SEC31B	chr10:102246403-102289636:-	-0.26	-3.96	9.48E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs4919471	chr10:102299239	SEC31B	chr10:102246403-102289636:-	-0.26	-3.93	0.000109	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs4919472	chr10:102315864	SEC31B	chr10:102246403-102289636:-	-0.26	-3.93	0.000108	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs4919690	chr10:104616500	C10orf32	chr10:104613967-104624718:+	0.39	5.07	7.3E-7	Arsenic metabolism	
OV	cis	1	rs4925540	chr1:247214878	ZNF670	chr1:247200087-247242069:-	-0.3	-4.16	4.21E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs4942487	chr13:46709389	TPT1	chr13:45911304-45915297:-	-0.25	-3.95	9.98E-5	Non-alcoholic fatty liver disease histology (other)	
OV	cis	1	rs4951261	chr1:205717823	PM20D1	chr1:205797154-205819245:-	0.33	4.3	2.38E-5	Menarche (age at onset)	
OV	cis	1	rs4955485	chr3:134295843	ANAPC13	chr3:134196547-134204865:-	0.39	5.34	1.93E-7	Height	
OV	cis	1	rs4955555	chr3:134286427	ANAPC13	chr3:134196547-134204865:-	0.41	5.72	2.73E-8	Height	
OV	cis	1	rs4970712	chr1:92993547	EVI5	chr1:92974255-93257961:-	0.29	3.97	9.0E-5	Cholesterol, total	
OV	cis	1	rs4971316	chr1:247210903	ZNF670	chr1:247200087-247242069:-	-0.31	-4.33	2.04E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs4971319	chr1:247211565	ZNF670	chr1:247200087-247242069:-	-0.31	-4.33	2.04E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs4973991	chr3:41927273	ULK4	chr3:41288091-42003660:-	-0.61	-8.09	1.89E-14	Diastolic blood pressure	
OV	cis	1	rs4974483	chr3:134219001	ANAPC13	chr3:134196547-134204865:-	0.39	5.5	8.64E-8	Height	
OV	cis	1	rs4974484	chr3:134219019	ANAPC13	chr3:134196547-134204865:-	0.4	5.5	8.48E-8	Height	
OV	cis	1	rs4974493	chr3:134219993	ANAPC13	chr3:134196547-134204865:-	0.41	5.85	1.4E-8	Height	
OV	cis	1	rs4974559	chr4:1380848	CRIPAK	chr4:1385340-1389782:+	-0.27	-4.39	1.59E-5	Systolic blood pressure	
OV	cis	1	rs506274	chr10:131409392	MGMT	chr10:131265454-131565783:+	0.23	3.88	0.000132	Response to temozolomide	
OV	cis	1	rs508303	chr10:131424996	MGMT	chr10:131265454-131565783:+	-0.26	-4.45	1.25E-5	Response to temozolomide	
OV	cis	1	rs513736	chr10:131406489	MGMT	chr10:131265454-131565783:+	0.24	4.04	7.05E-5	Response to temozolomide	
OV	cis	1	rs531572	chr10:131427569	MGMT	chr10:131265454-131565783:+	-0.25	-4.17	4.1E-5	Response to temozolomide	
OV	cis	1	rs548390	chr10:131417427	MGMT	chr10:131265454-131565783:+	0.24	3.97	9.25E-5	Response to temozolomide	
OV	cis	1	rs554792	chr10:131423181	MGMT	chr10:131265454-131565783:+	0.23	3.89	0.000128	Response to temozolomide	
OV	cis	1	rs555	chr4:17625658	LAP3	chr4:17578927-17609590:+	-0.24	-4.05	6.72E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs55670848	chr1:171697497	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.52E-6	Hippocampal atrophy	
OV	cis	1	rs55734215	chr20:33585437	CPNE1	chr20:34213968-34262539:-	0.43	3.87	0.000138	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs55753056	chr2:243929	SH3YL1	chr2:218138-264810:-	-0.52	-7.23	4.58E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs55835850	chr2:28949296	TRMT61B	chr2:29072690-29093175:-	0.3	3.92	0.000111	Body mass index	
OV	cis	1	rs558764	chr10:131426957	MGMT	chr10:131265454-131565783:+	-0.24	-3.99	8.56E-5	Response to temozolomide	
OV	cis	1	rs55895244	chr7:65387678	CCT6P1	chr7:65216092-65228661:+	0.36	4.44	1.29E-5	Diabetic kidney disease	
OV	cis	1	rs55913793	chr3:134285968	ANAPC13	chr3:134196547-134204865:-	0.41	5.72	2.73E-8	Height	
OV	cis	1	rs55936726	chr2:258210	SH3YL1	chr2:218138-264810:-	-0.53	-7.46	1.11E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs55939327	chr4:17642937	LAP3	chr4:17578927-17609590:+	-0.26	-4.59	6.73E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs55946380	chr2:268293	SH3YL1	chr2:218138-264810:-	-0.53	-7.6	4.57E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs56016656	chr7:65383481	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.8E-6	Diabetic kidney disease	
OV	cis	1	rs56040780	chr16:28861881	EIF3C	chr16:28722782-28747052:+;chr16	0.3	3.93	0.000108	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
OV	cis	1	rs56040780	chr16:28861881	EIF3CL	chr16:28699879-28747052:+;chr16	0.32	4.75	3.31E-6	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
OV	cis	1	rs56091821	chr1:171651434	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.37E-6	Hippocampal atrophy	
OV	cis	1	rs56121764	chr3:41883975	ULK4	chr3:41288091-42003660:-	0.61	7.51	8.37E-13	Diastolic blood pressure	
OV	cis	1	rs56145559	chr2:73623439	ALMS1P	chr2:73872046-73912692:+	0.38	5.4	1.47E-7	Schizophrenia	
OV	cis	1	rs56154726	chr2:73721767	ALMS1P	chr2:73872046-73912692:+	0.36	5.54	6.95E-8	Metabolite levels	
OV	cis	1	rs56158380	chr3:41885588	ULK4	chr3:41288091-42003660:-	0.61	7.51	8.37E-13	Diastolic blood pressure	
OV	cis	1	rs56167434	chr2:282137	SH3YL1	chr2:218138-264810:-	-0.54	-7.63	3.69E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs56207540	chr3:41976627	ULK4	chr3:41288091-42003660:-	0.64	7.01	1.86E-11	Diastolic blood pressure	
OV	cis	1	rs56227395	chr2:54487496	C2orf73	chr2:54558071-54588714:+	0.29	4.06	6.48E-5	Telomere length	
OV	cis	1	rs56291018	chr7:65390339	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.8E-6	Diabetic kidney disease	
OV	cis	1	rs56308330	chr4:17643050	LAP3	chr4:17578927-17609590:+	-0.26	-4.44	1.29E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs56321614	chr2:268191	SH3YL1	chr2:218138-264810:-	-0.52	-7.36	2.12E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs56345529	chr1:171651372	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.37E-6	Hippocampal atrophy	
OV	cis	1	rs56357623	chr14:77697393	C14orf148	chr14:77860424-77889379:-	0.31	3.9	0.00012	Obsessive-compulsive symptoms	
OV	cis	1	rs565974	chr10:131423274	MGMT	chr10:131265454-131565783:+	0.23	3.89	0.000128	Response to temozolomide	
OV	cis	1	rs56672945	chr2:73622663	ALMS1P	chr2:73872046-73912692:+	0.38	5.84	1.43E-8	Metabolite levels	
OV	cis	1	rs567700	chr10:131423126	MGMT	chr10:131265454-131565783:+	0.23	3.89	0.000128	Response to temozolomide	
OV	cis	1	rs56776628	chr3:41866856	ULK4	chr3:41288091-42003660:-	0.6	7.65	3.37E-13	Diastolic blood pressure	
OV	cis	1	rs56844352	chr8:69738447	C8orf34	chr8:69243457-69731256:+	-0.4	-4.2	3.54E-5	Obesity-related traits	
OV	cis	1	rs568617	chr11:65653242	CTSW	chr11:65647284-65651212:+	-0.43	-8.52	1.07E-15	Crohn's disease	
OV	cis	1	rs568617	chr11:65653242	SNX32	chr11:65601410-65621170:+	0.33	4.15	4.38E-5	Crohn's disease	
OV	cis	1	rs56884994	chr1:247211057	ZNF670	chr1:247200087-247242069:-	-0.33	-4.58	7.04E-6	Response to taxane treatment (docetaxel)	
OV	cis	1	rs569235	chr10:131411620	MGMT	chr10:131265454-131565783:+	0.23	3.92	0.000114	Response to temozolomide	
OV	cis	1	rs56974987	chr4:17627856	LAP3	chr4:17578927-17609590:+	-0.24	-4.15	4.34E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs56985706	chr7:65394562	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs57057549	chr7:65405738	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs57060498	chr2:54479230	C2orf73	chr2:54558071-54588714:+	0.29	3.85	0.000144	Telomere length	
OV	cis	1	rs57075379	chr14:35577801	KIAA0391	chr14:35591776-35786673:+	0.42	4.54	8.56E-6	Atopic dermatitis	
OV	cis	1	rs57075379	chr14:35577801	PPP2R3C	chr14:35554679-35591679:-	0.38	4.32	2.21E-5	Atopic dermatitis	
OV	cis	1	rs57479675	chr3:41798038	ULK4	chr3:41288091-42003660:-	0.66	8.69	3.22E-16	Diastolic blood pressure	
OV	cis	1	rs57542652	chr2:228088	SH3YL1	chr2:218138-264810:-	-0.53	-7.38	1.82E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs57576577	chr16:31036367	HSD3B7	chr16:30996519-31000473:+	0.32	5.04	8.59E-7	Response to metformin (IC50)	
OV	cis	1	rs57804141	chr3:129962512	COL6A4P2	chr3:129931663-129992648:+	0.35	4.67	4.74E-6	Response to amphetamines	
OV	cis	1	rs57925408	chr8:96062930	C8orf38	chr8:95908040-96088396:+	-0.31	-3.93	0.000107	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
OV	cis	1	rs58062456	chr7:65394852	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs583583	chr1:147083114	ACP6	chr1:147119168-147142634:-	0.33	4.51	9.73E-6	Schizophrenia (negative symptoms)	
OV	cis	1	rs58455759	chr1:171674987	VAMP4	chr1:171669298-171711214:-	0.39	4.7	4.07E-6	Hippocampal atrophy	
OV	cis	1	rs58461606	chr2:267367	SH3YL1	chr2:218138-264810:-	-0.52	-7.35	2.18E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs58660500	chr3:53086573	SFMBT1	chr3:52938628-53080070:-	-0.53	-4.84	2.19E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs58669269	chr7:65951953	CCT6P1	chr7:65216092-65228661:+	0.38	4.49	1.07E-5	Diabetic kidney disease	
OV	cis	1	rs58749629	chr20:44571317	WFDC3	chr20:44402847-44420547:-	-0.39	-3.97	9.3E-5	Abdominal aortic aneurysm	
OV	cis	1	rs59015729	chr8:69738816	C8orf34	chr8:69243457-69731256:+	-0.4	-4.2	3.54E-5	Obesity-related traits	
OV	cis	1	rs59244547	chr3:156582997	LEKR1	chr3:156544076-156763918:+	-0.6	-7.35	2.29E-12	Bone mineral density	
OV	cis	1	rs59583591	chr3:53119581	SFMBT1	chr3:52938628-53080070:-	-0.43	-4.3	2.4E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs59794892	chr7:65415873	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.17E-5	Diabetic kidney disease	
OV	cis	1	rs59937473	chr2:271797	SH3YL1	chr2:218138-264810:-	-0.52	-7.39	1.78E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs6004862	chr22:26378073	HPS4	chr22:26847447-26879820:-	-0.31	-4.1	5.46E-5	Urate levels in lean individuals	
OV	cis	1	rs6004862	chr22:26378073	SRRD	chr22:26879846-26887903:+	-0.39	-4.68	4.54E-6	Urate levels in lean individuals	
OV	cis	1	rs6004862	chr22:26378073	TFIP11	chr22:26887894-26908437:-	-0.4	-4.85	2.07E-6	Urate levels in lean individuals	
OV	cis	1	rs6004862	chr22:26378073	TPST2	chr22:26921716-26986089:-	-0.26	-3.93	0.000107	Urate levels in lean individuals	
OV	cis	1	rs60149603	chr2:285421	SH3YL1	chr2:218138-264810:-	-0.57	-7.93	5.46E-14	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs6036630	chr20:24046233	C20orf3	chr20:24943581-24973425:-	0.52	4.48	1.09E-5	Erectile dysfunction and prostate cancer treatment	
OV	cis	1	rs6037086	chr20:25306338	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037086	chr20:25306338	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037095	chr20:25335687	ABHD12	chr20:25275380-25371477:-	-0.4	-6	6.29E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037095	chr20:25335687	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.91E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037099	chr20:25356876	ABHD12	chr20:25275380-25371477:-	-0.41	-5.99	6.61E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037099	chr20:25356876	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.39E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037105	chr20:25374199	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.33E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037105	chr20:25374199	FAM182B	chr20:25744102-25848786:-	-0.33	-5.06	7.59E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037121	chr20:25428311	ABHD12	chr20:25275380-25371477:-	0.41	6.03	5.17E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6037121	chr20:25428311	FAM182B	chr20:25744102-25848786:-	0.32	5.03	8.77E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs60484953	chr2:221560	SH3YL1	chr2:218138-264810:-	-0.54	-7.57	5.72E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs6050542	chr20:25318879	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050542	chr20:25318879	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050544	chr20:25320228	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050544	chr20:25320228	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050547	chr20:25326012	ABHD12	chr20:25275380-25371477:-	-0.41	-6.06	4.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050547	chr20:25326012	FAM182B	chr20:25744102-25848786:-	-0.32	-4.9	1.61E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050555	chr20:25328543	ABHD12	chr20:25275380-25371477:-	-0.4	-5.75	2.35E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050555	chr20:25328543	FAM182B	chr20:25744102-25848786:-	-0.29	-4.44	1.29E-5	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050559	chr20:25329915	ABHD12	chr20:25275380-25371477:-	0.4	6.03	5.26E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050559	chr20:25329915	FAM182B	chr20:25744102-25848786:-	0.31	4.8	2.59E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050561	chr20:25334855	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050561	chr20:25334855	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050562	chr20:25336186	ABHD12	chr20:25275380-25371477:-	-0.4	-6	6.29E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050562	chr20:25336186	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.91E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050564	chr20:25344231	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050564	chr20:25344231	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050565	chr20:25347563	ABHD12	chr20:25275380-25371477:-	-0.36	-5.26	2.85E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050565	chr20:25347563	FAM182B	chr20:25744102-25848786:-	-0.33	-5.07	7.42E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050566	chr20:25351071	ABHD12	chr20:25275380-25371477:-	-0.41	-5.97	7.28E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050566	chr20:25351071	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.9E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050573	chr20:25366065	ABHD12	chr20:25275380-25371477:-	0.42	6.17	2.37E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050573	chr20:25366065	FAM182B	chr20:25744102-25848786:-	0.33	5.13	5.55E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050590	chr20:25384994	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.3E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050590	chr20:25384994	FAM182B	chr20:25744102-25848786:-	-0.33	-5.09	6.48E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050598	chr20:25397257	ABHD12	chr20:25275380-25371477:-	0.39	5.93	9.22E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050598	chr20:25397257	FAM182B	chr20:25744102-25848786:-	0.32	5.05	7.9E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050599	chr20:25400240	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.2E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050599	chr20:25400240	FAM182B	chr20:25744102-25848786:-	-0.32	-5.05	8.13E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050602	chr20:25401203	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.2E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050602	chr20:25401203	FAM182B	chr20:25744102-25848786:-	-0.32	-5.05	8.13E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050609	chr20:25411751	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.21E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050609	chr20:25411751	FAM182B	chr20:25744102-25848786:-	-0.32	-5.01	9.6E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050617	chr20:25421648	ABHD12	chr20:25275380-25371477:-	0.41	6.03	5.17E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050617	chr20:25421648	FAM182B	chr20:25744102-25848786:-	0.32	5.03	8.77E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050626	chr20:25428261	ABHD12	chr20:25275380-25371477:-	0.41	6.03	5.17E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050626	chr20:25428261	FAM182B	chr20:25744102-25848786:-	0.32	5.03	8.77E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050629	chr20:25430680	ABHD12	chr20:25275380-25371477:-	0.41	6.03	5.17E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050629	chr20:25430680	FAM182B	chr20:25744102-25848786:-	0.32	5.03	8.77E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050630	chr20:25430745	ABHD12	chr20:25275380-25371477:-	0.41	6.03	5.17E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050630	chr20:25430745	FAM182B	chr20:25744102-25848786:-	0.32	5.03	8.77E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050631	chr20:25431749	ABHD12	chr20:25275380-25371477:-	0.4	6	6.04E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050631	chr20:25431749	FAM182B	chr20:25744102-25848786:-	0.31	4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050632	chr20:25432601	ABHD12	chr20:25275380-25371477:-	0.41	6.03	5.17E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6050632	chr20:25432601	FAM182B	chr20:25744102-25848786:-	0.32	5.03	8.77E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6051080	chr20:25975674	FAM182A	chr20:26035250-26067552:+	0.35	5.61	4.83E-8	Colorectal or endometrial cancer	
OV	cis	1	rs6051080	chr20:25975674	FAM182B	chr20:25744102-25848786:-	0.49	8.57	7.57E-16	Colorectal or endometrial cancer	
OV	cis	1	rs6051080	chr20:25975674	LOC100134868	chr20:25990435-26002424:+	-0.37	-5.3	2.42E-7	Colorectal or endometrial cancer	
OV	cis	1	rs60512868	chr3:48483445	TREX1	chr3:48501186-48509043:+	-0.27	-5.16	4.76E-7	Longevity	
OV	cis	1	rs6060230	chr20:33689308	CPNE1	chr20:34213968-34262539:-	-0.37	-3.92	0.000112	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs60652129	chr2:207649313	MDH1B	chr2:207598943-207630050:-	0.41	3.87	0.000136	Episodic memory	
OV	cis	1	rs60683927	chr7:65394768	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs60693825	chr14:35514456	KIAA0391	chr14:35591776-35786673:+	0.39	4.24	3.08E-5	Atopic dermatitis	
OV	cis	1	rs60693825	chr14:35514456	PPP2R3C	chr14:35554679-35591679:-	0.34	3.87	0.000135	Atopic dermatitis	
OV	cis	1	rs6076336	chr20:25319212	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6076336	chr20:25319212	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6076339	chr20:25348712	ABHD12	chr20:25275380-25371477:-	-0.39	-5.75	2.39E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6076339	chr20:25348712	FAM182B	chr20:25744102-25848786:-	-0.35	-5.49	8.9E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6076345	chr20:25381895	ABHD12	chr20:25275380-25371477:-	-0.4	-5.97	7.3E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6076345	chr20:25381895	FAM182B	chr20:25744102-25848786:-	-0.33	-5.09	6.48E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083804	chr20:25317060	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083804	chr20:25317060	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083805	chr20:25317356	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083805	chr20:25317356	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083809	chr20:25329309	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083809	chr20:25329309	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083813	chr20:25337671	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083813	chr20:25337671	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083825	chr20:25366424	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.33E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083825	chr20:25366424	FAM182B	chr20:25744102-25848786:-	-0.33	-5.06	7.59E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083828	chr20:25369918	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.33E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083828	chr20:25369918	FAM182B	chr20:25744102-25848786:-	-0.33	-5.06	7.59E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083844	chr20:25386832	ABHD12	chr20:25275380-25371477:-	-0.4	-5.95	7.96E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083844	chr20:25386832	FAM182B	chr20:25744102-25848786:-	-0.33	-5.09	6.72E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083856	chr20:25407585	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.25E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083856	chr20:25407585	FAM182B	chr20:25744102-25848786:-	-0.31	-4.71	3.97E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083862	chr20:25411086	ABHD12	chr20:25275380-25371477:-	-0.45	-6.89	3.85E-11	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6083862	chr20:25411086	FAM182B	chr20:25744102-25848786:-	-0.32	-5.07	7.2E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs60843830	chr2:286756	SH3YL1	chr2:218138-264810:-	-0.52	-7.09	1.15E-11	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs60844734	chr2:73623205	ALMS1P	chr2:73872046-73912692:+	0.38	5.84	1.43E-8	Metabolite levels	
OV	cis	1	rs6087704	chr20:34001058	GDF5	chr20:33897002-34042568:-	-0.29	-3.88	0.000131	Height	
OV	cis	1	rs60911031	chr8:69739049	C8orf34	chr8:69243457-69731256:+	-0.4	-4.2	3.54E-5	Obesity-related traits	
OV	cis	1	rs60942590	chr3:53016421	SFMBT1	chr3:52938628-53080070:-	-0.56	-5.22	3.56E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs60982898	chr6:49385806	MUT	chr6:49398994-49431031:-	0.27	4.17	4.11E-5	Folate pathway vitamin levels	
OV	cis	1	rs61037750	chr11:43681372	HSD17B12	chr11:43702143-43878160:+	-0.42	-6.2	2.08E-9	Forced vital capacity	
OV	cis	1	rs6107033	chr20:25363591	ABHD12	chr20:25275380-25371477:-	-0.39	-5.74	2.45E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6107033	chr20:25363591	FAM182B	chr20:25744102-25848786:-	-0.35	-5.5	8.65E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6107045	chr20:25441936	ABHD12	chr20:25275380-25371477:-	0.4	5.89	1.1E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6107045	chr20:25441936	FAM182B	chr20:25744102-25848786:-	0.31	4.74	3.39E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6107046	chr20:25442049	ABHD12	chr20:25275380-25371477:-	0.4	5.89	1.1E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6107046	chr20:25442049	FAM182B	chr20:25744102-25848786:-	0.31	4.74	3.39E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6107047	chr20:25442097	ABHD12	chr20:25275380-25371477:-	0.4	5.89	1.1E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6107047	chr20:25442097	FAM182B	chr20:25744102-25848786:-	0.31	4.74	3.39E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs61102033	chr1:46382441	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs6115140	chr20:25285507	ABHD12	chr20:25275380-25371477:-	0.41	6.02	5.5E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115140	chr20:25285507	FAM182B	chr20:25744102-25848786:-	0.31	4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115146	chr20:25304507	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115146	chr20:25304507	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115153	chr20:25325567	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115153	chr20:25325567	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115159	chr20:25350944	ABHD12	chr20:25275380-25371477:-	-0.41	-5.99	6.45E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115159	chr20:25350944	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.49E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115168	chr20:25372891	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.33E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115168	chr20:25372891	FAM182B	chr20:25744102-25848786:-	-0.33	-5.06	7.59E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115182	chr20:25410259	ABHD12	chr20:25275380-25371477:-	-0.41	-6.03	5.21E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115182	chr20:25410259	FAM182B	chr20:25744102-25848786:-	-0.32	-5.01	9.6E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115191	chr20:25440478	ABHD12	chr20:25275380-25371477:-	0.4	5.89	1.1E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6115191	chr20:25440478	FAM182B	chr20:25744102-25848786:-	0.31	4.74	3.39E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs61172708	chr3:52996052	SFMBT1	chr3:52938628-53080070:-	-0.57	-5.31	2.24E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs6120974	chr20:34126827	CPNE1	chr20:34213968-34262539:-	-0.62	-6.7	1.14E-10	Triglycerides	
OV	cis	1	rs6132835	chr20:25434667	ABHD12	chr20:25275380-25371477:-	0.4	5.87	1.26E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6132835	chr20:25434667	FAM182B	chr20:25744102-25848786:-	0.31	4.77	2.95E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6138572	chr20:25435934	ABHD12	chr20:25275380-25371477:-	0.39	5.67	3.68E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6138572	chr20:25435934	FAM182B	chr20:25744102-25848786:-	0.33	5.11	6.03E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6138575	chr20:25438952	ABHD12	chr20:25275380-25371477:-	0.39	5.67	3.68E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6138575	chr20:25438952	FAM182B	chr20:25744102-25848786:-	0.33	5.11	6.03E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6142360	chr20:33960486	GDF5	chr20:33897002-34042568:-	-0.32	-4.21	3.5E-5	Height	
OV	cis	1	rs6142379	chr20:33999267	GDF5	chr20:33897002-34042568:-	-0.29	-3.88	0.000131	Height	
OV	cis	1	rs61744385	chr3:41756986	ULK4	chr3:41288091-42003660:-	0.54	6.99	2.08E-11	Diastolic blood pressure	
OV	cis	1	rs61744388	chr3:41756965	ULK4	chr3:41288091-42003660:-	0.54	6.99	2.08E-11	Diastolic blood pressure	
OV	cis	1	rs61783200	chr1:46297403	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.84	4.96E-11	Body mass index	
OV	cis	1	rs61783220	chr1:46335312	CCDC163P	chr1:45960581-45965646:-	-0.45	-6.76	8.35E-11	Body mass index	
OV	cis	1	rs61792116	chr4:301077	ZNF718	chr4:53272-156488:+	0.41	4.05	6.53E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs61794996	chr4:209328	ZNF718	chr4:53272-156488:+	0.42	3.99	8.31E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs61794997	chr4:222103	ZNF718	chr4:53272-156488:+	0.42	4.08	5.85E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs61795001	chr4:242057	ZNF718	chr4:53272-156488:+	0.41	4.06	6.28E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs61795002	chr4:242797	ZNF718	chr4:53272-156488:+	0.41	4.06	6.28E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs61795006	chr4:253601	ZNF718	chr4:53272-156488:+	0.39	4.33	2.08E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs61795007	chr4:255264	ZNF718	chr4:53272-156488:+	0.39	4.33	2.08E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs61852630	chr1:247210193	ZNF670	chr1:247200087-247242069:-	-0.31	-4.33	2.04E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs61852637	chr1:247219636	ZNF670	chr1:247200087-247242069:-	-0.3	-4.18	3.85E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs62056375	chr16:29857901	MVP	chr16:29831787-29859342:+	-0.29	-4.38	1.68E-5	Multiple sclerosis	
OV	cis	1	rs62114497	chr2:214837	SH3YL1	chr2:218138-264810:-	-0.54	-7.39	1.74E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs62114501	chr2:231741	SH3YL1	chr2:218138-264810:-	-0.55	-7.69	2.56E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs62114505	chr2:242426	SH3YL1	chr2:218138-264810:-	-0.55	-7.66	3.19E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs62114544	chr2:269679	SH3YL1	chr2:218138-264810:-	-0.53	-7.6	4.57E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs62114548	chr2:274672	SH3YL1	chr2:218138-264810:-	-0.53	-7.54	6.77E-13	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs62139200	chr2:54475507	C2orf73	chr2:54558071-54588714:+	0.3	4.1	5.45E-5	Telomere length	
OV	cis	1	rs62139251	chr2:54478605	C2orf73	chr2:54558071-54588714:+	0.29	3.94	0.000103	Telomere length	
OV	cis	1	rs62151652	chr2:73700131	ALMS1P	chr2:73872046-73912692:+	0.38	5.75	2.38E-8	Metabolite levels	
OV	cis	1	rs62211529	chr20:33959315	GDF5	chr20:33897002-34042568:-	-0.29	-3.93	0.000106	Height	
OV	cis	1	rs62269547	chr3:134214042	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs62271513	chr3:134298412	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.51	8.21E-8	Height	
OV	cis	1	rs62271514	chr3:134298554	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.51	8.21E-8	Height	
OV	cis	1	rs62271515	chr3:134300507	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs62445266	chr7:36413367	KIAA0895	chr7:36363759-36429734:-	0.36	3.86	0.000141	Systolic blood pressure	
OV	cis	1	rs629301	chr1:109818306	PSRC1	chr1:109822179-109825808:-	-0.35	-4.81	2.47E-6	Cholesterol, total;Myocardial infarction;Coronary artery disease;Lipoprotein-associated phospholipase A2 activity and mass	
OV	cis	1	rs641018	chr11:65655393	CTSW	chr11:65647284-65651212:+	-0.43	-8.52	1.07E-15	Crohn's disease	
OV	cis	1	rs641018	chr11:65655393	SNX32	chr11:65601410-65621170:+	0.33	4.15	4.38E-5	Crohn's disease	
OV	cis	1	rs641862	chr13:110790232	CARKD	chr13:111267881-111292340:+	0.69	4.54	8.55E-6	Obesity-related traits	
OV	cis	1	rs641862	chr13:110790232	ING1	chr13:111365083-111373420:+	0.65	3.98	8.84E-5	Obesity-related traits	
OV	cis	1	rs6429567	chr1:45956700	CCDC163P	chr1:45960581-45965646:-	-1.01	-17.37	3.28E-46	Homocysteine levels	
OV	cis	1	rs6429567	chr1:45956700	MMACHC	chr1:45965856-45976737:+	-0.32	-4.29	2.47E-5	Homocysteine levels	
OV	cis	1	rs6429569	chr1:46001330	CCDC163P	chr1:45960581-45965646:-	-0.88	-14.43	1.35E-35	Homocysteine levels	
OV	cis	1	rs6429582	chr1:46321843	CCDC163P	chr1:45960581-45965646:-	0.4	5.93	8.97E-9	Body mass index	
OV	cis	1	rs6439484	chr3:134249899	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs6439487	chr3:134260860	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs6441104	chr3:156681441	LEKR1	chr3:156544076-156763918:+	-0.59	-7.3	3.03E-12	Bone mineral density	
OV	cis	1	rs6442117	chr3:48419897	TREX1	chr3:48501186-48509043:+	0.26	4.86	1.98E-6	Longevity	
OV	cis	1	rs6442118	chr3:48440047	TREX1	chr3:48501186-48509043:+	-0.28	-5.32	2.18E-7	Longevity	
OV	cis	1	rs6442119	chr3:48440178	TREX1	chr3:48501186-48509043:+	-0.3	-5.75	2.32E-8	Longevity	
OV	cis	1	rs6442120	chr3:48464503	TREX1	chr3:48501186-48509043:+	-0.28	-5.26	2.85E-7	Longevity	
OV	cis	1	rs6442123	chr3:48500286	TREX1	chr3:48501186-48509043:+	-0.27	-5.16	4.68E-7	Longevity	
OV	cis	1	rs6445557	chr3:53083969	SFMBT1	chr3:52938628-53080070:-	0.44	4.47	1.13E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs6449319	chr4:17640283	LAP3	chr4:17578927-17609590:+	-0.3	-5.32	2.14E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs6449323	chr4:17683916	LAP3	chr4:17578927-17609590:+	-0.25	-4.3	2.32E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs6450408	chr5:56098146	C5orf35	chr5:56205103-56213010:+	0.7	9.46	1.37E-18	Type 2 diabetes	
OV	cis	1	rs6450409	chr5:56101399	C5orf35	chr5:56205103-56213010:+	0.69	9.57	6.35E-19	Type 2 diabetes	
OV	cis	1	rs6454513	chr6:86720049	SNHG5	chr6:86386726-86388451:-	0.68	11.94	8.77E-27	Response to antipsychotic treatment	
OV	cis	1	rs6458690	chr6:49411619	MUT	chr6:49398994-49431031:-	0.27	4.13	4.78E-5	Folate pathway vitamin levels	
OV	cis	1	rs6460260	chr7:65215455	CCT6P1	chr7:65216092-65228661:+	-0.39	-4.42	1.43E-5	Diabetic kidney disease	
OV	cis	1	rs6460261	chr7:65215580	CCT6P1	chr7:65216092-65228661:+	-0.39	-4.42	1.43E-5	Diabetic kidney disease	
OV	cis	1	rs6462050	chr7:27844503	TAX1BP1	chr7:27778992-27869384:+	0.37	4.61	6.18E-6	Hypospadias	
OV	cis	1	rs6462051	chr7:27844661	TAX1BP1	chr7:27778992-27869384:+	0.37	4.61	6.18E-6	Hypospadias	
OV	cis	1	rs6464573	chr7:143748098	ARHGEF35	chr7:143883677-143892736:-	0.39	5.07	7.28E-7	Obesity-related traits	
OV	cis	1	rs6464574	chr7:143748257	ARHGEF35	chr7:143883677-143892736:-	-0.5	-6.3	1.17E-9	Obesity-related traits	
OV	cis	1	rs6464574	chr7:143748257	CTAGE6	chr7:143452184-143454843:-	-0.38	-4.66	4.87E-6	Obesity-related traits	
OV	cis	1	rs6464574	chr7:143748257	OR2A9P	chr7:143991573-143997832:+;chr7	-0.38	-4.56	7.85E-6	Obesity-related traits	
OV	cis	1	rs646776	chr1:109818530	PSRC1	chr1:109822179-109825808:-	-0.35	-4.88	1.79E-6	Cholesterol, total;Myocardial infarction;Coronary artery disease;Lipoprotein-associated phospholipase A2 activity and mass	
OV	cis	1	rs6478486	chr9:123655329	LOC253039	chr9:123605320-123616644:+	-0.31	-4.41	1.48E-5	Rheumatoid arthritis	
OV	cis	1	rs6483880	chr11:22852740	SVIP	chr11:22843600-22851382:-	0.28	4.18	3.93E-5	Dialysis-related mortality	
OV	cis	1	rs6485438	chr11:43686618	HSD17B12	chr11:43702143-43878160:+	-0.43	-6.24	1.59E-9	Forced vital capacity	
OV	cis	1	rs6485443	chr11:43696316	HSD17B12	chr11:43702143-43878160:+	0.44	6.46	4.64E-10	Forced vital capacity	
OV	cis	1	rs6515651	chr20:25414539	ABHD12	chr20:25275380-25371477:-	-0.4	-6	6.05E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6515651	chr20:25414539	FAM182B	chr20:25744102-25848786:-	-0.31	-4.77	3.01E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs6532078	chr4:76920809	NAAA	chr4:76831809-76862166:-	-0.29	-4.89	1.69E-6	Longevity	
OV	cis	1	rs6545883	chr2:61772257	C2orf74	chr2:61372243-61391964:+	0.5	7.04	1.51E-11	Tuberculosis	
OV	cis	1	rs6547872	chr2:28978074	TRMT61B	chr2:29072690-29093175:-	-0.35	-4.67	4.74E-6	Body mass index	
OV	cis	1	rs656980	chr11:65656282	CTSW	chr11:65647284-65651212:+	-0.43	-8.52	1.07E-15	Crohn's disease	
OV	cis	1	rs656980	chr11:65656282	SNX32	chr11:65601410-65621170:+	0.33	4.15	4.38E-5	Crohn's disease	
OV	cis	1	rs6573333	chr14:61308337	MNAT1	chr14:61201470-61435396:+	0.67	4.97	1.18E-6	Immune reponse to smallpox (secreted IFN-alpha)	
OV	cis	1	rs6573333	chr14:61308337	PPM1A	chr14:60712470-60765803:+	0.62	4.61	6.26E-6	Immune reponse to smallpox (secreted IFN-alpha)	
OV	cis	1	rs6573333	chr14:61308337	SNAPC1	chr14:62229075-62263145:+	0.59	4.39	1.59E-5	Immune reponse to smallpox (secreted IFN-alpha)	
OV	cis	1	rs6579245	chr20:34125271	CPNE1	chr20:34213968-34262539:-	-0.6	-6.34	9.42E-10	Cholesterol, total	
OV	cis	1	rs6581155	chr12:58178162	FAM119B	chr12:58166383-58176323:+	0.34	5.03	8.88E-7	Multiple sclerosis	
OV	cis	1	rs6581155	chr12:58178162	TSFM	chr12:58176536-58191367:+	-0.34	-5.89	1.12E-8	Multiple sclerosis	
OV	cis	1	rs6584383	chr10:102303065	SEC31B	chr10:102246403-102289636:-	-0.27	-3.9	0.000123	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs6599175	chr3:41786009	ULK4	chr3:41288091-42003660:-	-0.59	-8.07	2.2E-14	Diastolic blood pressure	
OV	cis	1	rs6599176	chr3:41788492	ULK4	chr3:41288091-42003660:-	-0.63	-8.52	1.04E-15	Diastolic blood pressure	
OV	cis	1	rs6599178	chr3:41842129	ULK4	chr3:41288091-42003660:-	0.61	8.11	1.67E-14	Diastolic blood pressure	
OV	cis	1	rs6599179	chr3:41855284	ULK4	chr3:41288091-42003660:-	0.61	8.11	1.67E-14	Diastolic blood pressure	
OV	cis	1	rs6599318	chr4:243968	ZNF718	chr4:53272-156488:+	0.4	3.94	0.000104	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs6603033	chr15:83335875	AP3B2	chr15:83328034-83378635:-	0.25	4.07	6.1E-5	Schizophrenia	
OV	cis	1	rs6656992	chr1:46333068	CCDC163P	chr1:45960581-45965646:-	-0.45	-6.76	8.35E-11	Body mass index	
OV	cis	1	rs6659874	chr1:171654180	VAMP4	chr1:171669298-171711214:-	0.34	4.14	4.57E-5	Hippocampal atrophy	
OV	cis	1	rs6661910	chr1:46290632	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.78	7.35E-11	Body mass index	
OV	cis	1	rs6662641	chr1:46571509	CCDC163P	chr1:45960581-45965646:-	-0.47	-7.07	1.28E-11	Body mass index	
OV	cis	1	rs6662720	chr1:171654616	VAMP4	chr1:171669298-171711214:-	0.34	4.14	4.57E-5	Hippocampal atrophy	
OV	cis	1	rs6662833	chr1:171654720	VAMP4	chr1:171669298-171711214:-	0.34	4.14	4.57E-5	Hippocampal atrophy	
OV	cis	1	rs66670017	chr6:33763563	IP6K3	chr6:33689443-33714762:-	0.49	5.35	1.87E-7	Obesity (extreme)	
OV	cis	1	rs6667191	chr1:45982844	CCDC163P	chr1:45960581-45965646:-	-1.02	-17.53	8.55E-47	Homocysteine levels	
OV	cis	1	rs6667191	chr1:45982844	MMACHC	chr1:45965856-45976737:+	-0.32	-4.35	1.9E-5	Homocysteine levels	
OV	cis	1	rs6667559	chr1:171653957	VAMP4	chr1:171669298-171711214:-	0.35	4.33	2.05E-5	Hippocampal atrophy	
OV	cis	1	rs6668284	chr1:46354510	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.93	2.94E-11	Body mass index	
OV	cis	1	rs6669263	chr1:171692311	VAMP4	chr1:171669298-171711214:-	0.38	4.64	5.44E-6	Hippocampal atrophy	
OV	cis	1	rs6669522	chr1:46397941	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs6670427	chr1:171654522	VAMP4	chr1:171669298-171711214:-	0.34	4.14	4.57E-5	Hippocampal atrophy	
OV	cis	1	rs6672898	chr1:46290588	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.37E-11	Body mass index	
OV	cis	1	rs6675726	chr1:46560643	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.16	7.23E-12	Body mass index	
OV	cis	1	rs6675946	chr1:46371774	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs6677007	chr1:46400590	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs6678890	chr1:171694566	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.52E-6	Hippocampal atrophy	
OV	cis	1	rs6679354	chr1:171668002	VAMP4	chr1:171669298-171711214:-	0.37	4.47	1.17E-5	Hippocampal atrophy	
OV	cis	1	rs6680380	chr1:46300189	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.37E-11	Body mass index	
OV	cis	1	rs6686643	chr1:165616588	MGST3	chr1:165600450-165624853:+	0.28	4.9	1.62E-6	Total ventricular volume	
OV	cis	1	rs6695809	chr1:46285461	CCDC163P	chr1:45960581-45965646:-	-0.47	-6.98	2.23E-11	Body mass index	
OV	cis	1	rs6700597	chr1:46284246	CCDC163P	chr1:45960581-45965646:-	-0.47	-7	1.97E-11	Body mass index	
OV	cis	1	rs6700866	chr1:10306038	PGD	chr1:10459085-10480200:+	0.26	3.92	0.00011	Hepatocellular carcinoma	
OV	cis	1	rs6701553	chr1:171654456	VAMP4	chr1:171669298-171711214:-	0.34	4.14	4.57E-5	Hippocampal atrophy	
OV	cis	1	rs6701614	chr1:46309420	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.37E-11	Body mass index	
OV	cis	1	rs6703976	chr1:21836934	USP48	chr1:22004794-22109688:-	-0.3	-4.01	7.69E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)	
OV	cis	1	rs6705489	chr2:73648811	ALMS1P	chr2:73872046-73912692:+	0.38	5.66	3.79E-8	Metabolite levels	
OV	cis	1	rs6707722	chr2:73654363	ALMS1P	chr2:73872046-73912692:+	0.39	6.16	2.56E-9	Metabolite levels	
OV	cis	1	rs6707848	chr2:28988083	TRMT61B	chr2:29072690-29093175:-	-0.36	-4.82	2.38E-6	Body mass index	
OV	cis	1	rs6708328	chr2:24412413	LOC375190	chr2:24299728-24397519:+	-0.36	-4.88	1.8E-6	Venous thromboembolism (SNP x SNP interaction)	
OV	cis	1	rs6709534	chr2:217334	SH3YL1	chr2:218138-264810:-	-0.53	-7.3	2.99E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs6710438	chr2:73820108	ALMS1P	chr2:73872046-73912692:+	-0.35	-5.45	1.14E-7	Metabolite levels	
OV	cis	1	rs6711033	chr2:73746643	ALMS1P	chr2:73872046-73912692:+	0.37	5.66	3.76E-8	Metabolite levels	
OV	cis	1	rs6711127	chr2:202213515	PPIL3	chr2:201735680-201753999:-	-0.49	-4.6	6.45E-6	Rheumatoid arthritis	
OV	cis	1	rs6711941	chr2:202178130	CFLAR	chr2:201980816-202029001:+	-0.38	-4.17	4.08E-5	Rheumatoid arthritis	
OV	cis	1	rs6711941	chr2:202178130	PPIL3	chr2:201735680-201753999:-	-0.57	-6.44	5.15E-10	Rheumatoid arthritis	
OV	cis	1	rs6715380	chr2:202214505	PPIL3	chr2:201735680-201753999:-	-0.49	-4.57	7.21E-6	Rheumatoid arthritis	
OV	cis	1	rs6720809	chr2:88528943	THNSL2	chr2:88469835-88486145:+	-0.76	-7.74	1.91E-13	Plasma clusterin levels	
OV	cis	1	rs6722069	chr2:88533151	THNSL2	chr2:88469835-88486145:+	-0.77	-7.88	7.55E-14	Plasma clusterin levels	
OV	cis	1	rs67239267	chr7:143745116	ARHGEF35	chr7:143883677-143892736:-	-0.44	-5.67	3.59E-8	Obesity-related traits	
OV	cis	1	rs67239267	chr7:143745116	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.05	6.61E-5	Obesity-related traits	
OV	cis	1	rs67239267	chr7:143745116	OR2A9P	chr7:143991573-143997832:+;chr7	-0.37	-4.52	9.07E-6	Obesity-related traits	
OV	cis	1	rs6730503	chr2:37528478	CEBPZ	chr2:37428778-37458740:-	0.26	4.02	7.49E-5	Chronic lymphocytic leukemia	
OV	cis	1	rs6736866	chr2:73661986	ALMS1P	chr2:73872046-73912692:+	0.39	5.67	3.58E-8	Metabolite levels	
OV	cis	1	rs6740223	chr2:73653332	ALMS1P	chr2:73872046-73912692:+	0.39	6.16	2.56E-9	Metabolite levels	
OV	cis	1	rs6742276	chr2:61768745	C2orf74	chr2:61372243-61391964:+	0.48	6.71	1.07E-10	Tuberculosis	
OV	cis	1	rs6745368	chr2:73809974	ALMS1P	chr2:73872046-73912692:+	0.37	5.81	1.71E-8	Metabolite levels	
OV	cis	1	rs6753344	chr2:73653138	ALMS1P	chr2:73872046-73912692:+	-0.39	-5.85	1.4E-8	Metabolite levels	
OV	cis	1	rs67536397	chr7:65947917	CCT6P1	chr7:65216092-65228661:+	0.38	4.49	1.07E-5	Diabetic kidney disease	
OV	cis	1	rs6755217	chr2:73641285	ALMS1P	chr2:73872046-73912692:+	0.38	5.59	5.56E-8	Metabolite levels	
OV	cis	1	rs6755241	chr2:73641364	ALMS1P	chr2:73872046-73912692:+	0.38	5.81	1.7E-8	Metabolite levels	
OV	cis	1	rs6759004	chr2:202004676	CFLAR	chr2:201980816-202029001:+	-0.41	-4.93	1.42E-6	Triptolide cytotoxicity	
OV	cis	1	rs6759004	chr2:202004676	PPIL3	chr2:201735680-201753999:-	-0.6	-7.63	3.83E-13	Triptolide cytotoxicity	
OV	cis	1	rs6761276	chr2:113832312	IL1F5	chr2:113816215-113822316:+	0.29	4.37	1.77E-5	Protein quantitative trait loci	
OV	cis	1	rs6763088	chr3:134254989	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs6763093	chr3:134254995	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs6763829	chr3:41897046	ULK4	chr3:41288091-42003660:-	0.63	8.36	3.05E-15	Diastolic blood pressure	
OV	cis	1	rs6765505	chr3:134208132	ANAPC13	chr3:134196547-134204865:-	0.41	5.77	2.09E-8	Height	
OV	cis	1	rs6766818	chr3:134226159	ANAPC13	chr3:134196547-134204865:-	0.41	5.85	1.4E-8	Height	
OV	cis	1	rs6766897	chr3:134191303	ANAPC13	chr3:134196547-134204865:-	0.38	5.34	1.98E-7	Height	
OV	cis	1	rs6768128	chr3:41865080	ULK4	chr3:41288091-42003660:-	0.6	7.59	4.81E-13	Diastolic blood pressure	
OV	cis	1	rs6768542	chr3:41865474	ULK4	chr3:41288091-42003660:-	0.59	7.43	1.32E-12	Diastolic blood pressure	
OV	cis	1	rs6768563	chr3:41865541	ULK4	chr3:41288091-42003660:-	0.58	7.3	3.1E-12	Diastolic blood pressure	
OV	cis	1	rs6769885	chr3:134286913	ANAPC13	chr3:134196547-134204865:-	0.41	5.72	2.73E-8	Height	
OV	cis	1	rs6770470	chr3:48435123	TREX1	chr3:48501186-48509043:+	-0.25	-4.69	4.26E-6	Longevity	
OV	cis	1	rs67728539	chr7:65378124	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.09E-5	Diabetic kidney disease	
OV	cis	1	rs6772896	chr3:134203347	ANAPC13	chr3:134196547-134204865:-	0.41	5.71	2.92E-8	Height	
OV	cis	1	rs6776700	chr3:48496758	TREX1	chr3:48501186-48509043:+	-0.28	-5.24	3.14E-7	Longevity	
OV	cis	1	rs677977	chr1:147083744	ACP6	chr1:147119168-147142634:-	-0.31	-4.18	3.94E-5	Schizophrenia (negative symptoms)	
OV	cis	1	rs6782563	chr3:134295959	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.2	3.86E-7	Height	
OV	cis	1	rs6783001	chr3:41862232	ULK4	chr3:41288091-42003660:-	0.62	8.3	4.48E-15	Diastolic blood pressure	
OV	cis	1	rs6784322	chr3:48422235	TREX1	chr3:48501186-48509043:+	-0.25	-4.51	9.61E-6	Longevity	
OV	cis	1	rs6784421	chr3:156655494	LEKR1	chr3:156544076-156763918:+	0.37	6.05	4.67E-9	Multiple sclerosis (severity)	
OV	cis	1	rs6785027	chr3:134211649	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.63	4.37E-8	Height	
OV	cis	1	rs6787371	chr3:134254991	ANAPC13	chr3:134196547-134204865:-	0.39	5.52	7.99E-8	Height	
OV	cis	1	rs6787952	chr3:156609375	LEKR1	chr3:156544076-156763918:+	-0.6	-7.38	1.87E-12	Bone mineral density	
OV	cis	1	rs6789260	chr3:41776350	ULK4	chr3:41288091-42003660:-	0.56	7.05	1.45E-11	Diastolic blood pressure	
OV	cis	1	rs6790466	chr3:134197740	ANAPC13	chr3:134196547-134204865:-	0.4	5.57	5.87E-8	Height	
OV	cis	1	rs6790732	chr3:41864872	ULK4	chr3:41288091-42003660:-	0.63	8.44	1.84E-15	Diastolic blood pressure	
OV	cis	1	rs6791806	chr3:41889995	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs67927699	chr2:61187415	C2orf74	chr2:61372243-61391964:+	0.37	4.77	3.02E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
OV	cis	1	rs6793487	chr3:134299426	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.2	3.86E-7	Height	
OV	cis	1	rs6794875	chr3:48455626	TREX1	chr3:48501186-48509043:+	-0.27	-5.1	6.34E-7	Longevity	
OV	cis	1	rs6796210	chr3:41851718	ULK4	chr3:41288091-42003660:-	0.61	8.11	1.67E-14	Diastolic blood pressure	
OV	cis	1	rs6796491	chr3:48430465	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs6797165	chr3:41887777	ULK4	chr3:41288091-42003660:-	0.63	8.49	1.28E-15	Diastolic blood pressure	
OV	cis	1	rs6800862	chr3:134228628	ANAPC13	chr3:134196547-134204865:-	0.39	5.5	8.64E-8	Height	
OV	cis	1	rs6801343	chr3:41767234	ULK4	chr3:41288091-42003660:-	0.61	8.22	8.04E-15	Diastolic blood pressure	
OV	cis	1	rs6801596	chr3:134252114	ANAPC13	chr3:134196547-134204865:-	0.38	5.38	1.56E-7	Height	
OV	cis	1	rs6802340	chr3:41894034	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs6802654	chr3:134217072	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs6803560	chr3:41824480	ULK4	chr3:41288091-42003660:-	0.65	8.67	3.79E-16	Diastolic blood pressure	
OV	cis	1	rs6803652	chr3:41824556	ULK4	chr3:41288091-42003660:-	0.65	8.67	3.79E-16	Diastolic blood pressure	
OV	cis	1	rs6804770	chr3:134230234	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs6804774	chr3:48430617	TREX1	chr3:48501186-48509043:+	-0.26	-4.94	1.39E-6	Longevity	
OV	cis	1	rs6805723	chr3:114788668	ZNF80	chr3:113953478-113956425:-	-0.41	-4.59	6.81E-6	Type 2 diabetes	
OV	cis	1	rs6805880	chr3:41865397	ULK4	chr3:41288091-42003660:-	0.59	7.43	1.32E-12	Diastolic blood pressure	
OV	cis	1	rs6806417	chr3:134211446	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.52	7.74E-8	Height	
OV	cis	1	rs6807015	chr3:41754514	ULK4	chr3:41288091-42003660:-	0.54	6.99	2.09E-11	Diastolic blood pressure	
OV	cis	1	rs6810060	chr3:48434748	TREX1	chr3:48501186-48509043:+	-0.25	-4.69	4.26E-6	Longevity	
OV	cis	1	rs6811887	chr4:17640858	LAP3	chr4:17578927-17609590:+	-0.28	-4.8	2.65E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs68141011	chr6:28217797	ZNF389	chr6:28129551-28137375:+	-0.41	-4.54	8.22E-6	Depression	
OV	cis	1	rs6818639	chr4:17633049	LAP3	chr4:17578927-17609590:+	-0.27	-4.74	3.44E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs68189316	chr7:65409169	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.17E-5	Diabetic kidney disease	
OV	cis	1	rs6827617	chr4:76916146	NAAA	chr4:76831809-76862166:-	-0.29	-4.91	1.54E-6	Longevity	
OV	cis	1	rs6829450	chr4:39116341	UGDH	chr4:39500375-39529211:-	0.32	4.36	1.83E-5	Uric acid levels	
OV	cis	1	rs6832503	chr4:48028442	NIPAL1	chr4:48018791-48039078:+	-0.47	-7.1	1.05E-11	Renal underexcretion gout;Gout	
OV	cis	1	rs6841948	chr4:7987802	AFAP1	chr4:7760440-7941653:-	-0.31	-4.53	8.76E-6	Post bronchodilator FEV1 in COPD	
OV	cis	1	rs6841948	chr4:7987802	C4orf23	chr4:8440604-8495258:+	-0.35	-4.13	4.76E-5	Post bronchodilator FEV1 in COPD	
OV	cis	1	rs6841948	chr4:7987802	GRPEL1	chr4:7061780-7069800:-	-0.32	-4.35	1.88E-5	Post bronchodilator FEV1 in COPD	
OV	cis	1	rs6841948	chr4:7987802	TADA2B	chr4:7045156-7059675:+	-0.33	-4.17	4.02E-5	Post bronchodilator FEV1 in COPD	
OV	cis	1	rs6846238	chr4:17629939	LAP3	chr4:17578927-17609590:+	-0.25	-4.24	3.03E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs6848360	chr4:17634442	LAP3	chr4:17578927-17609590:+	-0.3	-5.33	2.04E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs6849704	chr4:17652031	LAP3	chr4:17578927-17609590:+	-0.26	-4.6	6.54E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs6854733	chr4:17640526	LAP3	chr4:17578927-17609590:+	-0.26	-4.59	6.73E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs687672	chr11:65649984	CTSW	chr11:65647284-65651212:+	0.42	8.4	2.33E-15	Crohn's disease	
OV	cis	1	rs687672	chr11:65649984	SNX32	chr11:65601410-65621170:+	-0.34	-4.17	4.11E-5	Crohn's disease	
OV	cis	1	rs6885541	chr5:56110857	C5orf35	chr5:56205103-56213010:+	0.71	8.97	4.52E-17	Type 2 diabetes	
OV	cis	1	rs6901317	chr6:106036151	ATG5	chr6:106632354-106773695:-	-0.27	-3.88	0.000132	Beard thickness	
OV	cis	1	rs6901317	chr6:106036151	PREP	chr6:105725507-105850969:-	-0.26	-3.93	0.000107	Beard thickness	
OV	cis	1	rs6917749	chr6:97944222	NDUFAF4	chr6:97338140-97345767:-	-0.25	-3.92	0.00011	Body mass index	
OV	cis	1	rs6923124	chr6:49419864	MUT	chr6:49398994-49431031:-	0.31	4.67	4.78E-6	Folate pathway vitamin levels	
OV	cis	1	rs6923148	chr6:86767786	SNHG5	chr6:86386726-86388451:-	0.68	11.75	3.97E-26	Response to antipsychotic treatment	
OV	cis	1	rs6927188	chr6:42912589	GNMT	chr6:42928500-42931617:+	0.42	5.77	2.1E-8	Diabetic kidney disease	
OV	cis	1	rs6927188	chr6:42912589	PEX6	chr6:42931613-42946981:-	-0.5	-6.9	3.57E-11	Diabetic kidney disease	
OV	cis	1	rs6928546	chr6:46632006	TDRD6	chr6:46655866-46670149:+	0.28	3.88	0.000128	Lipoprotein-associated phospholipase A2 activity and mass	
OV	cis	1	rs6929299	chr6:161032089	MRPL18	chr6:160211022-160219460:+	-0.23	-4.1	5.47E-5	Lipoprotein (a) levels	
OV	cis	1	rs693824	chr11:65654783	CTSW	chr11:65647284-65651212:+	-0.43	-8.52	1.07E-15	Crohn's disease	
OV	cis	1	rs693824	chr11:65654783	SNX32	chr11:65601410-65621170:+	0.33	4.15	4.38E-5	Crohn's disease	
OV	cis	1	rs6940458	chr6:86644992	SNHG5	chr6:86386726-86388451:-	-0.65	-11	1.32E-23	Response to antipsychotic treatment	
OV	cis	1	rs6949812	chr7:65387101	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs694994	chr11:65653309	CTSW	chr11:65647284-65651212:+	-0.43	-8.56	7.84E-16	Crohn's disease	
OV	cis	1	rs694994	chr11:65653309	SNX32	chr11:65601410-65621170:+	0.35	4.34	2.0E-5	Crohn's disease	
OV	cis	1	rs6958289	chr7:65657111	CCT6P1	chr7:65216092-65228661:+	-0.32	-3.9	0.000121	Diabetic kidney disease	
OV	cis	1	rs6965685	chr7:158726462	WDR60	chr7:158649269-158738882:+	-0.3	-4.69	4.31E-6	Height	
OV	cis	1	rs6970243	chr7:65388490	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs6970578	chr7:27844038	TAX1BP1	chr7:27778992-27869384:+	0.37	4.47	1.14E-5	Hypospadias	
OV	cis	1	rs698500	chr15:83237769	AP3B2	chr15:83328034-83378635:-	-0.24	-4	8.21E-5	Schizophrenia	
OV	cis	1	rs7007450	chr8:71640269	XKR9	chr8:71581600-71648176:+	0.87	18.83	1.7E-51	Bone mineral density	
OV	cis	1	rs7017914	chr8:71591203	XKR9	chr8:71581600-71648176:+	0.89	19.02	3.51E-52	Bone mineral density	
OV	cis	1	rs7018	chr20:25278261	ABHD12	chr20:25275380-25371477:-	0.41	5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7018	chr20:25278261	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7019	chr20:25278278	ABHD12	chr20:25275380-25371477:-	0.41	6.02	5.5E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7019	chr20:25278278	FAM182B	chr20:25744102-25848786:-	0.31	4.77	3.03E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7020	chr20:25278600	ABHD12	chr20:25275380-25371477:-	0.39	5.63	4.51E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7020	chr20:25278600	FAM182B	chr20:25744102-25848786:-	0.29	4.46	1.19E-5	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7028436	chr9:21682141	CDKN2B	chr9:22002906-22009312:-	-0.29	-4.02	7.38E-5	Pediatric bone mineral content (radius)	
OV	cis	1	rs7028950	chr9:21682260	CDKN2A	chr9:21967752-21994490:-	-0.31	-4.31	2.32E-5	Pediatric bone mineral content (radius)	
OV	cis	1	rs7028950	chr9:21682260	CDKN2B	chr9:22002906-22009312:-	-0.32	-4.34	1.96E-5	Pediatric bone mineral content (radius)	
OV	cis	1	rs7037140	chr9:123656327	LOC253039	chr9:123605320-123616644:+	-0.31	-4.4	1.56E-5	Rheumatoid arthritis	
OV	cis	1	rs7037561	chr9:832711	KANK1	chr9:470294-746104:+	-0.51	-3.98	8.96E-5	Obesity-related traits	
OV	cis	1	rs703842	chr12:58162739	FAM119B	chr12:58166383-58176323:+	-0.3	-4.41	1.46E-5	Multiple sclerosis	
OV	cis	1	rs703842	chr12:58162739	TSFM	chr12:58176536-58191367:+	0.33	5.82	1.65E-8	Multiple sclerosis	
OV	cis	1	rs7045881	chr9:26935996	LRRC19	chr9:26993143-27005691:-	-0.45	-4.26	2.84E-5	Schizophrenia	
OV	cis	1	rs7046814	chr9:35142258	ATP8B5P	chr9:35406752-35483026:+	0.27	4.02	7.37E-5	Weight	
OV	cis	1	rs705696	chr12:56480648	RPS26	chr12:56435686-56438005:+	0.41	7.13	8.98E-12	Cognitive function	
OV	cis	1	rs7061710	chr1:171080615	FMO3	chr1:171060018-171086957:+	-0.38	-4.73	3.58E-6	Blood metabolite levels	
OV	cis	1	rs7070776	chr10:102264672	SEC31B	chr10:102246403-102289636:-	-0.28	-4.27	2.72E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7071271	chr10:102264824	SEC31B	chr10:102246403-102289636:-	-0.3	-4.62	5.9E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7072216	chr10:100156853	PYROXD2	chr10:100143323-100174978:-	0.67	10.86	3.94E-23	Metabolite levels	
OV	cis	1	rs7072776	chr10:22032942	C10orf114	chr10:21783422-21786213:-	-0.26	-3.89	0.000125	Breast cancer	
OV	cis	1	rs7073586	chr10:102307671	SEC31B	chr10:102246403-102289636:-	-0.27	-3.93	0.000107	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7078003	chr10:99359412	C10orf62	chr10:99349484-99350690:+	-0.5	-5.85	1.37E-8	Metabolite levels (small molecules and protein measures)	
OV	cis	1	rs7079136	chr10:102292709	SEC31B	chr10:102246403-102289636:-	-0.27	-4.11	5.17E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7079756	chr10:102302105	SEC31B	chr10:102246403-102289636:-	-0.28	-4.14	4.65E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7080356	chr10:102266735	SEC31B	chr10:102246403-102289636:-	-0.29	-4.32	2.14E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7084810	chr10:102297546	SEC31B	chr10:102246403-102289636:-	-0.26	-3.96	9.48E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7088512	chr10:102303498	SEC31B	chr10:102246403-102289636:-	-0.28	-4.14	4.6E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7088827	chr10:102303865	SEC31B	chr10:102246403-102289636:-	-0.29	-4.28	2.6E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7090431	chr10:102261753	SEC31B	chr10:102246403-102289636:-	-0.28	-4.27	2.66E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs709607	chr7:65449541	CCT6P1	chr7:65216092-65228661:+	-0.38	-4.58	7.15E-6	Diabetic kidney disease	
OV	cis	1	rs7099913	chr10:102314777	SEC31B	chr10:102246403-102289636:-	-0.3	-4.47	1.14E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7115737	chr11:43681249	HSD17B12	chr11:43702143-43878160:+	-0.42	-6.2	2.08E-9	Forced vital capacity	
OV	cis	1	rs712022	chr11:22843155	SVIP	chr11:22843600-22851382:-	-0.3	-4.69	4.2E-6	Dialysis-related mortality	
OV	cis	1	rs71299622	chr3:52917038	SFMBT1	chr3:52938628-53080070:-	-0.56	-5.24	3.2E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs71301804	chr3:53073314	SFMBT1	chr3:52938628-53080070:-	-0.51	-4.71	3.95E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs71301808	chr3:53085577	SFMBT1	chr3:52938628-53080070:-	-0.53	-4.84	2.19E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs71301809	chr3:53090312	SFMBT1	chr3:52938628-53080070:-	-0.53	-4.84	2.19E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs71301814	chr3:53117663	SFMBT1	chr3:52938628-53080070:-	-0.55	-5.11	6.14E-7	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs71327718	chr3:125592857	LOC100125556	chr3:125635444-125648865:+	0.75	6.41	6.42E-10	Metabolite levels (HVA/5-HIAA ratio)	
OV	cis	1	rs7144423	chr14:35572547	KIAA0391	chr14:35591776-35786673:+	0.43	4.44	1.27E-5	Atopic dermatitis	
OV	cis	1	rs7144423	chr14:35572547	PPP2R3C	chr14:35554679-35591679:-	0.39	4.31	2.29E-5	Atopic dermatitis	
OV	cis	1	rs7153160	chr14:74509377	LIN52	chr14:74551656-74667117:+	0.26	3.95	0.000101	Common traits (Other)	
OV	cis	1	rs7153587	chr14:74509660	LIN52	chr14:74551656-74667117:+	0.27	4.09	5.57E-5	Common traits (Other)	
OV	cis	1	rs7154306	chr14:35540499	KIAA0391	chr14:35591776-35786673:+	0.41	4.39	1.59E-5	Atopic dermatitis	
OV	cis	1	rs7154306	chr14:35540499	PPP2R3C	chr14:35554679-35591679:-	0.37	4.17	4.02E-5	Atopic dermatitis	
OV	cis	1	rs7156322	chr14:35544330	KIAA0391	chr14:35591776-35786673:+	0.41	4.33	2.12E-5	Atopic dermatitis	
OV	cis	1	rs7156322	chr14:35544330	PPP2R3C	chr14:35554679-35591679:-	0.37	4.11	5.18E-5	Atopic dermatitis	
OV	cis	1	rs7157940	chr14:94563193	IFI27L1	chr14:94547639-94569059:+	0.23	3.9	0.000121	Anthropometric traits	
OV	cis	1	rs71617204	chr3:53042951	SFMBT1	chr3:52938628-53080070:-	-0.6	-5.7	3.06E-8	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs7173833	chr15:75369618	SCAMP5	chr15:75287901-75313836:+	0.3	4.03	7.33E-5	Blood trace element (Zn levels)	
OV	cis	1	rs7182610	chr15:91064910	FES	chr15:91427665-91439004:+	-0.54	-4.35	1.96E-5	Response to exercise (triglyceride levels)	
OV	cis	1	rs718834	chr9:114844799	C9orf80	chr9:115448793-115480387:-	-0.34	-4.52	9.03E-6	Amyotrophic lateral sclerosis	
OV	cis	1	rs718834	chr9:114844799	KIAA0368	chr9:114122973-114247025:-	-0.31	-4.5	1.01E-5	Amyotrophic lateral sclerosis	
OV	cis	1	rs7189550	chr16:29911260	LOC440356	chr16:29875004-29879374:+	0.29	4.25	2.98E-5	Response to taxane treatment (placlitaxel)	
OV	cis	1	rs7189750	chr16:29911416	LOC440356	chr16:29875004-29879374:+	-0.29	-4.27	2.69E-5	Response to taxane treatment (placlitaxel)	
OV	cis	1	rs7201519	chr16:29859977	MVP	chr16:29831787-29859342:+	-0.26	-3.94	0.000102	Multiple sclerosis	
OV	cis	1	rs720475	chr7:144074929	OR2A7	chr7:143955790-143974852:-	-0.48	-5.32	2.18E-7	Breast cancer	
OV	cis	1	rs7205409	chr16:642610	WFIKKN1	chr16:679239-684116:+	0.35	5.21	3.63E-7	Height	
OV	cis	1	rs722782	chr8:516479	ERICH1	chr8:564749-681226:-	0.5	5.07	7.24E-7	Age-related macular degeneration (GA)	
OV	cis	1	rs722782	chr8:516479	FBXO25	chr8:356808-419873:+	0.58	5.51	8.02E-8	Age-related macular degeneration (GA)	
OV	cis	1	rs722782	chr8:516479	RPL23AP53	chr8:158347-182318:-	0.42	4.41	1.48E-5	Age-related macular degeneration (GA)	
OV	cis	1	rs722782	chr8:516479	ZNF596	chr8:182200-197332:+	0.46	4.53	8.85E-6	Age-related macular degeneration (GA)	
OV	cis	1	rs7251653	chr19:18608283	SSBP4	chr19:18530221-18545371:+	-0.32	-4.14	4.68E-5	Breast cancer	
OV	cis	1	rs7252848	chr19:18612351	SSBP4	chr19:18530221-18545371:+	-0.32	-4.28	2.63E-5	Breast cancer	
OV	cis	1	rs725309	chr3:48418708	TREX1	chr3:48501186-48509043:+	0.26	4.86	1.99E-6	Longevity	
OV	cis	1	rs725310	chr3:48418571	TREX1	chr3:48501186-48509043:+	0.26	5.05	8.07E-7	Longevity	
OV	cis	1	rs7255679	chr19:42063981	CEACAM21	chr19:42055886-42093196:+	0.44	6.69	1.26E-10	Schizophrenia	
OV	cis	1	rs7258465	chr19:18533642	SSBP4	chr19:18530221-18545371:+	-0.37	-4.74	3.37E-6	Breast cancer	
OV	cis	1	rs725908	chr20:33968067	GDF5	chr20:33897002-34042568:-	-0.33	-4.41	1.5E-5	Height	
OV	cis	1	rs7259376	chr19:22507705	ZNF98	chr19:22573899-22605148:-	-0.26	-3.86	0.000144	Telomere length	
OV	cis	1	rs7267979	chr20:25298087	ABHD12	chr20:25275380-25371477:-	0.38	5.63	4.41E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7267979	chr20:25298087	FAM182B	chr20:25744102-25848786:-	0.32	4.9	1.64E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7268053	chr20:25328286	ABHD12	chr20:25275380-25371477:-	-0.41	-6.02	5.48E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7268053	chr20:25328286	FAM182B	chr20:25744102-25848786:-	-0.33	-5.13	5.47E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7269138	chr20:33570007	GSS	chr20:33516237-33543601:-	0.4	3.99	8.62E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs7270354	chr20:44607661	WFDC3	chr20:44402847-44420547:-	-0.43	-4.75	3.26E-6	Abdominal aortic aneurysm	
OV	cis	1	rs7273734	chr20:33599403	CPNE1	chr20:34213968-34262539:-	0.42	4.32	2.14E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs7273734	chr20:33599403	GSS	chr20:33516237-33543601:-	0.36	3.89	0.000127	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs72768397	chr1:247219411	ZNF670	chr1:247200087-247242069:-	-0.32	-4.41	1.49E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs72800847	chr16:31022639	HSD3B7	chr16:30996519-31000473:+	0.27	4.04	6.96E-5	Response to metformin (IC50)	
OV	cis	1	rs72843784	chr6:26498758	BTN3A2	chr6:26365398-26378546:+	-0.7	-5.83	1.55E-8	Schizophrenia	
OV	cis	1	rs72929710	chr18:48372427	MRO	chr18:48321491-48351754:-	0.29	3.98	8.83E-5	Entorhinal cortical thickness	
OV	cis	1	rs72934960	chr2:202204749	PPIL3	chr2:201735680-201753999:-	-0.52	-4.82	2.41E-6	Rheumatoid arthritis	
OV	cis	1	rs72934973	chr2:202213934	PPIL3	chr2:201735680-201753999:-	-0.49	-4.6	6.45E-6	Rheumatoid arthritis	
OV	cis	1	rs72934999	chr2:202223524	PPIL3	chr2:201735680-201753999:-	-0.47	-4.3	2.35E-5	Rheumatoid arthritis	
OV	cis	1	rs72937106	chr2:202225520	PPIL3	chr2:201735680-201753999:-	-0.47	-4.3	2.35E-5	Rheumatoid arthritis	
OV	cis	1	rs72937118	chr2:202229527	PPIL3	chr2:201735680-201753999:-	-0.47	-4.3	2.35E-5	Rheumatoid arthritis	
OV	cis	1	rs72937120	chr2:202232611	PPIL3	chr2:201735680-201753999:-	-0.47	-4.29	2.45E-5	Rheumatoid arthritis	
OV	cis	1	rs729376	chr6:33704823	IP6K3	chr6:33689443-33714762:-	0.45	4.99	1.07E-6	Obesity (extreme)	
OV	cis	1	rs72939200	chr11:65441282	NRXN2	chr11:64373648-64490660:-	0.45	3.91	0.000115	Inflammatory bowel disease	
OV	cis	1	rs72992617	chr2:240220413	MGC16025	chr2:240115027-240117153:-	0.55	4.19	3.7E-5	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs73041998	chr1:171655119	VAMP4	chr1:171669298-171711214:-	0.35	4.27	2.65E-5	Hippocampal atrophy	
OV	cis	1	rs73042000	chr1:171655212	VAMP4	chr1:171669298-171711214:-	0.35	4.27	2.65E-5	Hippocampal atrophy	
OV	cis	1	rs73042001	chr1:171655251	VAMP4	chr1:171669298-171711214:-	0.35	4.27	2.65E-5	Hippocampal atrophy	
OV	cis	1	rs7304684	chr12:55895538	ITGA7	chr12:56078356-56106089:-	-0.3	-4.1	5.47E-5	Contrast sensitivity	
OV	cis	1	rs7304684	chr12:55895538	RDH5	chr12:56114151-56118525:+	-0.29	-3.88	0.00013	Contrast sensitivity	
OV	cis	1	rs73069392	chr3:41787009	ULK4	chr3:41288091-42003660:-	0.61	7.74	1.92E-13	Diastolic blood pressure	
OV	cis	1	rs73069394	chr3:41787233	ULK4	chr3:41288091-42003660:-	0.66	8.68	3.37E-16	Diastolic blood pressure	
OV	cis	1	rs73069396	chr3:41787236	ULK4	chr3:41288091-42003660:-	0.66	8.68	3.37E-16	Diastolic blood pressure	
OV	cis	1	rs73070048	chr2:207641394	MDH1B	chr2:207598943-207630050:-	0.36	4.3	2.37E-5	Episodic memory	
OV	cis	1	rs73071329	chr3:41810539	ULK4	chr3:41288091-42003660:-	0.66	8.8	1.45E-16	Diastolic blood pressure	
OV	cis	1	rs73074358	chr3:48427247	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs73077367	chr3:41851959	ULK4	chr3:41288091-42003660:-	0.6	7.74	1.87E-13	Diastolic blood pressure	
OV	cis	1	rs73079316	chr3:41863859	ULK4	chr3:41288091-42003660:-	0.6	7.33	2.56E-12	Diastolic blood pressure	
OV	cis	1	rs73079321	chr3:41863910	ULK4	chr3:41288091-42003660:-	0.6	7.65	3.37E-13	Diastolic blood pressure	
OV	cis	1	rs73081353	chr3:41906448	ULK4	chr3:41288091-42003660:-	0.58	7.15	7.53E-12	Diastolic blood pressure	
OV	cis	1	rs73081364	chr3:41913616	ULK4	chr3:41288091-42003660:-	0.58	7.15	7.53E-12	Diastolic blood pressure	
OV	cis	1	rs73116394	chr2:242367915	SEPT2	chr2:242254723-242293439:+	0.65	5.66	3.78E-8	Chronic lymphocytic leukemia	
OV	cis	1	rs73116396	chr2:242368693	SEPT2	chr2:242254723-242293439:+	0.65	5.66	3.78E-8	Chronic lymphocytic leukemia	
OV	cis	1	rs7314056	chr12:122342964	WDR66	chr12:122356480-122441830:+	-0.42	-3.86	0.00014	Urinary metabolites	
OV	cis	1	rs73142121	chr7:65311206	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.08E-5	Diabetic kidney disease	
OV	cis	1	rs73142122	chr7:65311298	CCT6P1	chr7:65216092-65228661:+	0.37	4.54	8.56E-6	Diabetic kidney disease	
OV	cis	1	rs73142162	chr7:65374296	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.82E-6	Diabetic kidney disease	
OV	cis	1	rs73142166	chr7:65375832	CCT6P1	chr7:65216092-65228661:+	0.37	4.53	8.75E-6	Diabetic kidney disease	
OV	cis	1	rs73150014	chr7:65450919	CCT6P1	chr7:65216092-65228661:+	0.36	4.49	1.05E-5	Diabetic kidney disease	
OV	cis	1	rs73198787	chr3:126787210	SEC61A1	chr3:127771212-127790525:+	0.3	4.02	7.45E-5	Amyotrophic lateral sclerosis (sporadic)	
OV	cis	1	rs7319942	chr13:42590292	DGKH	chr13:42614172-42830714:+	-0.27	-4.1	5.44E-5	Metabolite levels  (X-11787)	
OV	cis	1	rs73287482	chr8:69744129	C8orf34	chr8:69243457-69731256:+	-0.36	-3.96	9.5E-5	Obesity-related traits	
OV	cis	1	rs7336933	chr13:42559076	KBTBD6	chr13:41701709-41706936:-	0.38	5.15	4.88E-7	Calcium levels	
OV	cis	1	rs7336933	chr13:42559076	KBTBD7	chr13:41765711-41768702:-	0.33	4.25	2.93E-5	Calcium levels	
OV	cis	1	rs7336933	chr13:42559076	MTRF1	chr13:41790517-41837742:-	0.41	5.38	1.61E-7	Calcium levels	
OV	cis	1	rs7336933	chr13:42559076	NAA16	chr13:41885341-41951166:+	0.3	4.26	2.84E-5	Calcium levels	
OV	cis	1	rs7336933	chr13:42559076	WBP4	chr13:41635697-41658137:+	0.34	4.39	1.61E-5	Calcium levels	
OV	cis	1	rs7343481	chr20:25300113	ABHD12	chr20:25275380-25371477:-	-0.41	-5.96	7.46E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7343481	chr20:25300113	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7350721	chr14:56333513	C14orf34	chr14:56247854-56263392:-	0.3	4.32	2.13E-5	Body mass index (interaction)	
OV	cis	1	rs7356093	chr3:134238753	ANAPC13	chr3:134196547-134204865:-	0.41	5.87	1.26E-8	Height	
OV	cis	1	rs7371896	chr3:134249769	ANAPC13	chr3:134196547-134204865:-	0.39	5.44	1.17E-7	Height	
OV	cis	1	rs7372217	chr3:41990122	ULK4	chr3:41288091-42003660:-	-0.67	-9.11	1.66E-17	Diastolic blood pressure	
OV	cis	1	rs7374158	chr3:134270156	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs7374325	chr3:134275601	ANAPC13	chr3:134196547-134204865:-	0.42	5.82	1.62E-8	Height	
OV	cis	1	rs73905019	chr20:33560314	GSS	chr20:33516237-33543601:-	0.42	4.19	3.81E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs73905041	chr20:33592148	CPNE1	chr20:34213968-34262539:-	0.44	4.13	4.8E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs73985728	chr2:207668245	MDH1B	chr2:207598943-207630050:-	0.45	4.44	1.33E-5	Episodic memory	
OV	cis	1	rs74210981	chr10:102287520	SEC31B	chr10:102246403-102289636:-	-0.28	-4.04	6.84E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs74244824	chr14:56334877	C14orf34	chr14:56247854-56263392:-	-0.26	-4.03	7.34E-5	Body mass index (interaction)	
OV	cis	1	rs7425670	chr2:88522028	THNSL2	chr2:88469835-88486145:+	-0.76	-7.85	9.14E-14	Plasma clusterin levels	
OV	cis	1	rs7426847	chr3:134267519	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.48	9.59E-8	Height	
OV	cis	1	rs7427492	chr3:134261654	ANAPC13	chr3:134196547-134204865:-	0.42	5.82	1.62E-8	Height	
OV	cis	1	rs7428326	chr3:134251184	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs7429866	chr3:134236306	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.53	7.44E-8	Height	
OV	cis	1	rs7432268	chr3:134242051	ANAPC13	chr3:134196547-134204865:-	0.41	5.87	1.26E-8	Height	
OV	cis	1	rs7433663	chr3:134235790	ANAPC13	chr3:134196547-134204865:-	0.4	5.68	3.37E-8	Height	
OV	cis	1	rs7433991	chr3:134312292	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs7436021	chr4:76905472	NAAA	chr4:76831809-76862166:-	-0.28	-4.8	2.61E-6	Longevity	
OV	cis	1	rs7436403	chr4:17692685	LAP3	chr4:17578927-17609590:+	0.23	3.88	0.000133	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs7448069	chr5:175244034	FAF2	chr5:175875356-175937074:+	-0.42	-3.86	0.000139	Attention deficit hyperactivity disorder (inattention symptoms)	
OV	cis	1	rs7448069	chr5:175244034	RNF44	chr5:175953700-175965026:-	-0.41	-4.05	6.53E-5	Attention deficit hyperactivity disorder (inattention symptoms)	
OV	cis	1	rs7448069	chr5:175244034	TSPAN17	chr5:176074388-176086058:+	-0.41	-3.86	0.000139	Attention deficit hyperactivity disorder (inattention symptoms)	
OV	cis	1	rs7456042	chr7:65299778	CCT6P1	chr7:65216092-65228661:+	0.36	4.5	9.96E-6	Diabetic kidney disease	
OV	cis	1	rs74599371	chr20:33561495	GSS	chr20:33516237-33543601:-	0.43	4.12	5.01E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs74650218	chr10:102293830	SEC31B	chr10:102246403-102289636:-	-0.27	-4.12	5.03E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7477246	chr10:102261538	SEC31B	chr10:102246403-102289636:-	-0.31	-4.68	4.42E-6	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs7496954	chr15:83345536	AP3B2	chr15:83328034-83378635:-	0.25	4.18	3.91E-5	Schizophrenia	
OV	cis	1	rs74984113	chr4:250522	ZNF718	chr4:53272-156488:+	0.41	4.21	3.44E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs750474	chr3:53085280	SFMBT1	chr3:52938628-53080070:-	-0.44	-4.44	1.3E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs7511962	chr1:247212122	ZNF670	chr1:247200087-247242069:-	-0.31	-4.33	2.04E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs7512150	chr1:247212326	ZNF670	chr1:247200087-247242069:-	-0.33	-4.58	7.04E-6	Response to taxane treatment (docetaxel)	
OV	cis	1	rs7515491	chr1:46355079	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.15	7.85E-12	Body mass index	
OV	cis	1	rs7515577	chr1:93009438	EVI5	chr1:92974255-93257961:-	-0.29	-4.01	7.95E-5	Cholesterol, total	
OV	cis	1	rs75181745	chr2:88520408	THNSL2	chr2:88469835-88486145:+	-0.77	-7.84	1.01E-13	Plasma clusterin levels	
OV	cis	1	rs7519795	chr1:247212126	ZNF670	chr1:247200087-247242069:-	-0.31	-4.33	2.04E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs75217232	chr3:53132373	SFMBT1	chr3:52938628-53080070:-	-0.42	-4.23	3.18E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs7522601	chr1:46419021	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs7522705	chr1:45992300	CCDC163P	chr1:45960581-45965646:-	0.89	14.51	7.32E-36	Homocysteine levels	
OV	cis	1	rs7522705	chr1:45992300	MMACHC	chr1:45965856-45976737:+	0.28	3.97	9.2E-5	Homocysteine levels	
OV	cis	1	rs7524495	chr1:46266932	CCDC163P	chr1:45960581-45965646:-	-0.47	-7	1.97E-11	Body mass index	
OV	cis	1	rs75287019	chr20:33721261	CPNE1	chr20:34213968-34262539:-	0.44	4.13	4.73E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs75309929	chr2:88524377	THNSL2	chr2:88469835-88486145:+	-0.77	-7.82	1.12E-13	Plasma clusterin levels	
OV	cis	1	rs7534467	chr1:45988691	CCDC163P	chr1:45960581-45965646:-	-0.98	-16.51	4.3E-43	Homocysteine levels	
OV	cis	1	rs7534467	chr1:45988691	MMACHC	chr1:45965856-45976737:+	-0.3	-4.15	4.38E-5	Homocysteine levels	
OV	cis	1	rs7536436	chr1:171665914	VAMP4	chr1:171669298-171711214:-	0.35	4.33	2.1E-5	Hippocampal atrophy	
OV	cis	1	rs7536543	chr1:171666040	VAMP4	chr1:171669298-171711214:-	0.35	4.33	2.1E-5	Hippocampal atrophy	
OV	cis	1	rs7536557	chr1:45992114	CCDC163P	chr1:45960581-45965646:-	-0.89	-14.58	4.03E-36	Homocysteine levels	
OV	cis	1	rs7536557	chr1:45992114	MMACHC	chr1:45965856-45976737:+	-0.3	-4.2	3.59E-5	Homocysteine levels	
OV	cis	1	rs7539932	chr1:46292354	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.8	6.37E-11	Body mass index	
OV	cis	1	rs7540325	chr1:46338217	CCDC163P	chr1:45960581-45965646:-	-0.45	-6.76	8.35E-11	Body mass index	
OV	cis	1	rs7546342	chr1:247213292	ZNF670	chr1:247200087-247242069:-	-0.33	-4.58	7.04E-6	Response to taxane treatment (docetaxel)	
OV	cis	1	rs7549410	chr1:247214167	ZNF670	chr1:247200087-247242069:-	-0.3	-4.16	4.21E-5	Response to taxane treatment (docetaxel)	
OV	cis	1	rs7550746	chr1:46351719	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.85	4.7E-11	Body mass index	
OV	cis	1	rs755495	chr6:33734128	LEMD2	chr6:33738991-33756906:-	-0.33	-4.1	5.46E-5	Body mass index	
OV	cis	1	rs7556436	chr1:46363880	CCDC163P	chr1:45960581-45965646:-	0.44	6.67	1.38E-10	Body mass index	
OV	cis	1	rs7556457	chr1:85357289	SPATA1	chr1:84971974-85031875:+	0.32	3.92	0.00011	Smoking cessation	
OV	cis	1	rs7556480	chr1:85357347	SPATA1	chr1:84971974-85031875:+	0.32	3.92	0.00011	Smoking cessation	
OV	cis	1	rs7556615	chr1:46461369	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.95	2.68E-11	Body mass index	
OV	cis	1	rs7558944	chr2:73810909	ALMS1P	chr2:73872046-73912692:+	0.37	5.74	2.45E-8	Metabolite levels	
OV	cis	1	rs75607323	chr2:207635770	MDH1B	chr2:207598943-207630050:-	0.44	4.12	4.92E-5	Episodic memory	
OV	cis	1	rs7562170	chr2:28943516	TRMT61B	chr2:29072690-29093175:-	0.3	3.95	9.86E-5	Body mass index	
OV	cis	1	rs75635914	chr20:33555815	GSS	chr20:33516237-33543601:-	0.42	3.92	0.00011	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs7564890	chr2:73641853	ALMS1P	chr2:73872046-73912692:+	0.37	5.68	3.41E-8	Metabolite levels	
OV	cis	1	rs7566279	chr2:281178	SH3YL1	chr2:218138-264810:-	-0.52	-7.24	4.36E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs7572722	chr2:73724675	ALMS1P	chr2:73872046-73912692:+	0.35	5.48	9.38E-8	Metabolite levels	
OV	cis	1	rs7576245	chr2:73829678	ALMS1P	chr2:73872046-73912692:+	0.37	5.71	2.88E-8	Metabolite levels	
OV	cis	1	rs7579277	chr2:28996295	TRMT61B	chr2:29072690-29093175:-	-0.35	-4.63	5.57E-6	Body mass index	
OV	cis	1	rs757978	chr2:242371101	SEPT2	chr2:242254723-242293439:+	0.57	5.17	4.4E-7	Chronic lymphocytic leukemia	
OV	cis	1	rs7580825	chr2:73635148	ALMS1P	chr2:73872046-73912692:+	0.38	5.65	3.9E-8	Metabolite levels	
OV	cis	1	rs75824542	chr14:74523047	LIN52	chr14:74551656-74667117:+	0.27	4.09	5.77E-5	Common traits (Other)	
OV	cis	1	rs7582606	chr2:73813945	ALMS1P	chr2:73872046-73912692:+	0.36	5.65	4.06E-8	Metabolite levels	
OV	cis	1	rs7583236	chr2:70182805	SNRNP27	chr2:70121090-70132348:+	0.37	3.89	0.000127	Obesity-related traits	
OV	cis	1	rs7583255	chr2:73797996	ALMS1P	chr2:73872046-73912692:+	0.37	5.85	1.41E-8	Metabolite levels	
OV	cis	1	rs7584330	chr2:238387228	MLPH	chr2:238395053-238463960:+	-0.3	-4.35	1.93E-5	Prostate cancer	
OV	cis	1	rs7584575	chr2:73666402	ALMS1P	chr2:73872046-73912692:+	0.38	5.83	1.56E-8	Metabolite levels	
OV	cis	1	rs7586463	chr2:73798476	ALMS1P	chr2:73872046-73912692:+	0.37	5.85	1.41E-8	Metabolite levels	
OV	cis	1	rs75866240	chr20:33558839	GSS	chr20:33516237-33543601:-	0.42	3.92	0.00011	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs75889859	chr14:35539054	KIAA0391	chr14:35591776-35786673:+	0.41	4.48	1.11E-5	Atopic dermatitis	
OV	cis	1	rs75889859	chr14:35539054	PPP2R3C	chr14:35554679-35591679:-	0.37	4.28	2.56E-5	Atopic dermatitis	
OV	cis	1	rs7589728	chr2:88518440	THNSL2	chr2:88469835-88486145:+	-0.8	-7.85	9.29E-14	Plasma clusterin levels	
OV	cis	1	rs7591472	chr2:201889751	CFLAR	chr2:201980816-202029001:+	-0.29	-3.9	0.000123	Triptolide cytotoxicity	
OV	cis	1	rs7591472	chr2:201889751	PPIL3	chr2:201735680-201753999:-	-0.66	-10.33	2.24E-21	Triptolide cytotoxicity	
OV	cis	1	rs7594511	chr2:73681639	ALMS1P	chr2:73872046-73912692:+	0.39	5.91	1.02E-8	Metabolite levels	
OV	cis	1	rs7594645	chr2:207646674	MDH1B	chr2:207598943-207630050:-	0.44	4.4	1.58E-5	Episodic memory	
OV	cis	1	rs7595075	chr2:264019	SH3YL1	chr2:218138-264810:-	-0.52	-7.35	2.18E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs7596362	chr2:61204688	C2orf74	chr2:61372243-61391964:+	0.35	4.54	8.31E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
OV	cis	1	rs7598396	chr2:73652628	ALMS1P	chr2:73872046-73912692:+	0.37	5.82	1.58E-8	Metabolite levels	
OV	cis	1	rs7598419	chr2:73798223	ALMS1P	chr2:73872046-73912692:+	0.37	5.56	6.29E-8	Metabolite levels	
OV	cis	1	rs7598876	chr2:28974466	TRMT61B	chr2:29072690-29093175:-	-0.3	-3.94	0.000104	Body mass index	
OV	cis	1	rs7601738	chr2:242375813	SEPT2	chr2:242254723-242293439:+	-0.58	-5.32	2.14E-7	Chronic lymphocytic leukemia	
OV	cis	1	rs7605824	chr2:280819	SH3YL1	chr2:218138-264810:-	0.51	7.21	5.22E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs7608697	chr2:61204641	C2orf74	chr2:61372243-61391964:+	0.35	4.44	1.32E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
OV	cis	1	rs7608910	chr2:61204856	C2orf74	chr2:61372243-61391964:+	-0.33	-4.26	2.8E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
OV	cis	1	rs7609851	chr3:156638503	LEKR1	chr3:156544076-156763918:+	-0.55	-7.05	1.45E-11	Bone mineral density	
OV	cis	1	rs761025	chr20:25426968	ABHD12	chr20:25275380-25371477:-	0.4	6	6.05E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs761025	chr20:25426968	FAM182B	chr20:25744102-25848786:-	0.31	4.77	3.01E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs7611611	chr3:134307877	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs7611828	chr3:134250325	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs7614311	chr3:63813654	PSMD6	chr3:63996231-64009658:-	-0.32	-3.86	0.00014	Lung function (FEV1);Lung function (FVC)	
OV	cis	1	rs7615952	chr3:125649403	LOC100125556	chr3:125635444-125648865:+	-0.56	-6.65	1.6E-10	Blood pressure (smoking interaction)	
OV	cis	1	rs7616044	chr3:125649354	LOC100125556	chr3:125635444-125648865:+	0.56	6.18	2.29E-9	Blood pressure (smoking interaction)	
OV	cis	1	rs7616844	chr3:41874343	ULK4	chr3:41288091-42003660:-	0.63	8.36	3.05E-15	Diastolic blood pressure	
OV	cis	1	rs7617397	chr3:41959037	ULK4	chr3:41288091-42003660:-	-0.69	-9.21	8.33E-18	Diastolic blood pressure	
OV	cis	1	rs7617912	chr3:156576412	LEKR1	chr3:156544076-156763918:+	-0.62	-7.62	4.01E-13	Bone mineral density	
OV	cis	1	rs76191812	chr20:33563911	GSS	chr20:33516237-33543601:-	0.42	3.94	0.000104	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs7619451	chr3:134233238	ANAPC13	chr3:134196547-134204865:-	0.35	5.3	2.38E-7	Height	
OV	cis	1	rs76194	chr19:18630580	SSBP4	chr19:18530221-18545371:+	-0.31	-3.98	8.85E-5	Breast cancer	
OV	cis	1	rs7620458	chr3:156576850	LEKR1	chr3:156544076-156763918:+	-0.62	-7.62	4.15E-13	Bone mineral density	
OV	cis	1	rs7622259	chr3:41881351	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs7622420	chr3:53111069	SFMBT1	chr3:52938628-53080070:-	-0.45	-4.51	9.41E-6	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs7624372	chr3:41881107	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs7625448	chr3:53120766	SFMBT1	chr3:52938628-53080070:-	-0.43	-4.3	2.4E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs7630741	chr3:48419723	TREX1	chr3:48501186-48509043:+	-0.26	-4.86	2.01E-6	Longevity	
OV	cis	1	rs7630874	chr3:134293291	ANAPC13	chr3:134196547-134204865:-	-0.41	-5.59	5.49E-8	Height	
OV	cis	1	rs7631057	chr3:41817951	ULK4	chr3:41288091-42003660:-	0.61	7.8	1.26E-13	Diastolic blood pressure	
OV	cis	1	rs7632387	chr3:41853161	ULK4	chr3:41288091-42003660:-	0.59	7.72	2.1E-13	Diastolic blood pressure	
OV	cis	1	rs7634377	chr3:48421258	TREX1	chr3:48501186-48509043:+	-0.26	-4.86	2.01E-6	Longevity	
OV	cis	1	rs7635522	chr3:48423656	TREX1	chr3:48501186-48509043:+	-0.24	-4.41	1.49E-5	Longevity	
OV	cis	1	rs7636044	chr3:48484560	TREX1	chr3:48501186-48509043:+	-0.27	-5.16	4.76E-7	Longevity	
OV	cis	1	rs7636782	chr3:48421387	TREX1	chr3:48501186-48509043:+	-0.23	-4.32	2.15E-5	Longevity	
OV	cis	1	rs7637227	chr3:134244155	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs7639514	chr3:156576067	LEKR1	chr3:156544076-156763918:+	-0.59	-7.57	5.69E-13	Bone mineral density	
OV	cis	1	rs7640320	chr3:187430530	RPL39L	chr3:186838741-186857263:-	-0.43	-4.06	6.4E-5	Response to citalopram treatment	
OV	cis	1	rs7643617	chr3:114753078	ZNF80	chr3:113953478-113956425:-	0.4	4.35	1.89E-5	Type 2 diabetes	
OV	cis	1	rs7645295	chr3:134307734	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs7645611	chr3:53125297	SFMBT1	chr3:52938628-53080070:-	-0.43	-4.23	3.24E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs7646144	chr3:41853125	ULK4	chr3:41288091-42003660:-	0.58	7.46	1.1E-12	Diastolic blood pressure	
OV	cis	1	rs76471037	chr3:41799414	ULK4	chr3:41288091-42003660:-	0.66	8.69	3.22E-16	Diastolic blood pressure	
OV	cis	1	rs7648357	chr3:41849670	ULK4	chr3:41288091-42003660:-	0.61	8.07	2.13E-14	Diastolic blood pressure	
OV	cis	1	rs7648578	chr3:41858731	ULK4	chr3:41288091-42003660:-	0.61	8.19	9.81E-15	Diastolic blood pressure	
OV	cis	1	rs7648990	chr3:134244390	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs7650227	chr3:41794937	ULK4	chr3:41288091-42003660:-	0.66	8.87	9.29E-17	Diastolic blood pressure	
OV	cis	1	rs7651407	chr3:48443816	TREX1	chr3:48501186-48509043:+	-0.28	-5.32	2.18E-7	Longevity	
OV	cis	1	rs7653691	chr3:48419689	TREX1	chr3:48501186-48509043:+	0.26	4.85	2.04E-6	Longevity	
OV	cis	1	rs7659718	chr4:17638020	LAP3	chr4:17578927-17609590:+	-0.3	-5.33	2.04E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs7661631	chr4:17679751	LAP3	chr4:17578927-17609590:+	0.27	4.57	7.43E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs76644767	chr14:56334823	C14orf34	chr14:56247854-56263392:-	-0.26	-4.03	7.34E-5	Body mass index (interaction)	
OV	cis	1	rs7665727	chr4:277057	ZNF718	chr4:53272-156488:+	0.41	4.28	2.53E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs76708870	chr8:69739337	C8orf34	chr8:69243457-69731256:+	-0.4	-4.2	3.54E-5	Obesity-related traits	
OV	cis	1	rs7671752	chr4:17661398	LAP3	chr4:17578927-17609590:+	-0.27	-4.66	4.84E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs7673500	chr4:17621383	LAP3	chr4:17578927-17609590:+	-0.26	-4.37	1.77E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs7674560	chr4:263319	ZNF718	chr4:53272-156488:+	0.39	4.33	2.1E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs7686546	chr4:240614	ZNF718	chr4:53272-156488:+	0.41	4.06	6.28E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs7687557	chr4:39769260	RPL9	chr4:39455747-39460568:-	-0.29	-4.13	4.88E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
OV	cis	1	rs7694020	chr4:17682597	LAP3	chr4:17578927-17609590:+	-0.3	-5.04	8.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs7697889	chr4:17617961	LAP3	chr4:17578927-17609590:+	-0.24	-4.04	6.93E-5	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs77078697	chr4:252048	ZNF718	chr4:53272-156488:+	0.39	4.35	1.89E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs772021	chr10:104036449	C10orf26	chr10:104503727-104591851:+	0.25	3.98	8.85E-5	QT interval	
OV	cis	1	rs77234191	chr4:258294	ZNF718	chr4:53272-156488:+	0.42	4.17	4.15E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs7740487	chr6:28216486	ZNF389	chr6:28129551-28137375:+	-0.41	-4.59	6.86E-6	Depression	
OV	cis	1	rs77437249	chr20:33564738	GSS	chr20:33516237-33543601:-	0.42	3.94	0.000104	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs77477310	chr14:35615793	KIAA0391	chr14:35591776-35786673:+	0.4	4.52	9.2E-6	Atopic dermatitis	
OV	cis	1	rs77477310	chr14:35615793	PPP2R3C	chr14:35554679-35591679:-	0.39	4.7	4.12E-6	Atopic dermatitis	
OV	cis	1	rs77560201	chr5:158240137	RNF145	chr5:158584419-158637061:-	0.41	3.99	8.4E-5	Hip circumference (psychosocial stress interaction)	
OV	cis	1	rs7756203	chr6:86627707	SNHG5	chr6:86386726-86388451:-	-0.65	-11.02	1.16E-23	Response to antipsychotic treatment	
OV	cis	1	rs7760207	chr6:86721700	SNHG5	chr6:86386726-86388451:-	-0.67	-11.33	1.04E-24	Response to antipsychotic treatment	
OV	cis	1	rs7766645	chr6:86622238	SNHG5	chr6:86386726-86388451:-	-0.66	-11.67	7.28E-26	Response to antipsychotic treatment	
OV	cis	1	rs7770848	chr6:44769237	HSP90AB1	chr6:44214849-44221614:+	-0.55	-4.07	6.23E-5	Asthma (childhood onset)	
OV	cis	1	rs7770848	chr6:44769237	MRPL14	chr6:44081374-44095191:-	-0.58	-4.92	1.47E-6	Asthma (childhood onset)	
OV	cis	1	rs7770848	chr6:44769237	NFKBIE	chr6:44225903-44233525:-	-0.51	-4.05	6.71E-5	Asthma (childhood onset)	
OV	cis	1	rs7770848	chr6:44769237	TMEM151B	chr6:44238480-44275966:+	-0.46	-4.2	3.64E-5	Asthma (childhood onset)	
OV	cis	1	rs7771342	chr6:86631936	SNHG5	chr6:86386726-86388451:-	-0.65	-11.02	1.16E-23	Response to antipsychotic treatment	
OV	cis	1	rs77757126	chr6:36956903	FTSJD2	chr6:37400907-37449282:+	0.56	5.09	6.72E-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	
OV	cis	1	rs7777389	chr7:143744802	ARHGEF35	chr7:143883677-143892736:-	-0.44	-5.67	3.59E-8	Obesity-related traits	
OV	cis	1	rs7777389	chr7:143744802	CTAGE6	chr7:143452184-143454843:-	-0.32	-4.05	6.61E-5	Obesity-related traits	
OV	cis	1	rs7777389	chr7:143744802	OR2A9P	chr7:143991573-143997832:+;chr7	-0.37	-4.52	9.07E-6	Obesity-related traits	
OV	cis	1	rs778758	chr2:61782161	C2orf74	chr2:61372243-61391964:+	0.47	6.54	3.0E-10	Tuberculosis	
OV	cis	1	rs778762	chr2:61782921	C2orf74	chr2:61372243-61391964:+	0.47	6.52	3.28E-10	Tuberculosis	
OV	cis	1	rs778763	chr2:61785639	C2orf74	chr2:61372243-61391964:+	0.48	6.74	9.2E-11	Tuberculosis	
OV	cis	1	rs7794661	chr7:65389730	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs7795242	chr7:65390094	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs7804223	chr7:65664559	CCT6P1	chr7:65216092-65228661:+	-0.33	-3.94	0.000104	Diabetic kidney disease	
OV	cis	1	rs78075821	chr1:171724645	VAMP4	chr1:171669298-171711214:-	0.41	5	1.0E-6	Hippocampal atrophy	
OV	cis	1	rs781142	chr7:65438778	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.22E-5	Diabetic kidney disease	
OV	cis	1	rs781149	chr7:65481284	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs781150	chr7:65480973	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs781156	chr7:65479141	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs781157	chr7:65478311	CCT6P1	chr7:65216092-65228661:+	0.37	4.58	6.95E-6	Diabetic kidney disease	
OV	cis	1	rs78207779	chr14:35506387	KIAA0391	chr14:35591776-35786673:+	0.36	3.93	0.000106	Atopic dermatitis	
OV	cis	1	rs78213404	chr1:171685491	VAMP4	chr1:171669298-171711214:-	0.38	4.75	3.26E-6	Hippocampal atrophy	
OV	cis	1	rs7822232	chr8:145145687	KIAA1875	chr8:145162629-145173218:+	-0.43	-4.49	1.03E-5	Blood metabolite levels	
OV	cis	1	rs7832232	chr8:38469303	ERLIN2	chr8:37594097-37615318:+	-0.29	-3.89	0.000125	Pancreatic cancer	
OV	cis	1	rs78343340	chr4:267437	ZNF718	chr4:53272-156488:+	0.39	4.01	7.71E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs783540	chr15:83254708	AP3B2	chr15:83328034-83378635:-	0.23	3.99	8.61E-5	Schizophrenia	
OV	cis	1	rs7847663	chr9:100544868	FOXE1	chr9:100615537-100618986:+	-0.26	-3.94	0.000105	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
OV	cis	1	rs785464	chr1:46523089	CCDC163P	chr1:45960581-45965646:-	-0.47	-7.01	1.86E-11	Body mass index	
OV	cis	1	rs785471	chr1:46518677	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.89	3.79E-11	Body mass index	
OV	cis	1	rs785479	chr1:46492144	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.97	2.38E-11	Body mass index	
OV	cis	1	rs785481	chr1:46554518	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.16	7.23E-12	Body mass index	
OV	cis	1	rs785485	chr1:46574424	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.07	1.28E-11	Body mass index	
OV	cis	1	rs785488	chr1:46576095	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.17	6.88E-12	Body mass index	
OV	cis	1	rs785489	chr1:46576390	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.17	6.88E-12	Body mass index	
OV	cis	1	rs785491	chr1:46583418	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.17	6.92E-12	Body mass index	
OV	cis	1	rs785492	chr1:46583607	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.08	1.22E-11	Body mass index	
OV	cis	1	rs785494	chr1:46586626	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.14	8.23E-12	Body mass index	
OV	cis	1	rs785495	chr1:46587887	CCDC163P	chr1:45960581-45965646:-	-0.47	-6.97	2.27E-11	Body mass index	
OV	cis	1	rs785503	chr1:46595868	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.17	6.92E-12	Body mass index	
OV	cis	1	rs785520	chr1:46568836	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.16	7.23E-12	Body mass index	
OV	cis	1	rs78803505	chr7:65382572	CCT6P1	chr7:65216092-65228661:+	0.36	4.48	1.1E-5	Diabetic kidney disease	
OV	cis	1	rs7905961	chr10:102297391	SEC31B	chr10:102246403-102289636:-	-0.29	-4.36	1.81E-5	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs791856	chr6:86681841	SNHG5	chr6:86386726-86388451:-	0.68	11.58	1.54E-25	Response to antipsychotic treatment	
OV	cis	1	rs79197732	chr20:33562476	GSS	chr20:33516237-33543601:-	0.43	4.12	5.01E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs79199019	chr14:35581125	KIAA0391	chr14:35591776-35786673:+	0.42	4.54	8.56E-6	Atopic dermatitis	
OV	cis	1	rs79199019	chr14:35581125	PPP2R3C	chr14:35554679-35591679:-	0.38	4.32	2.21E-5	Atopic dermatitis	
OV	cis	1	rs79366248	chr4:266659	ZNF718	chr4:53272-156488:+	0.4	4.1	5.35E-5	Immune response to smallpox vaccine (IL-6)	
OV	cis	1	rs79436302	chr14:35578797	KIAA0391	chr14:35591776-35786673:+	0.42	4.54	8.56E-6	Atopic dermatitis	
OV	cis	1	rs79436302	chr14:35578797	PPP2R3C	chr14:35554679-35591679:-	0.38	4.32	2.21E-5	Atopic dermatitis	
OV	cis	1	rs79548696	chr3:41803385	ULK4	chr3:41288091-42003660:-	0.65	8.57	7.17E-16	Diastolic blood pressure	
OV	cis	1	rs79610916	chr8:69743075	C8orf34	chr8:69243457-69731256:+	-0.39	-4.13	4.72E-5	Obesity-related traits	
OV	cis	1	rs79702597	chr14:35558856	KIAA0391	chr14:35591776-35786673:+	0.42	4.59	6.77E-6	Atopic dermatitis	
OV	cis	1	rs79702597	chr14:35558856	PPP2R3C	chr14:35554679-35591679:-	0.37	4.18	3.99E-5	Atopic dermatitis	
OV	cis	1	rs79716074	chr2:277003	SH3YL1	chr2:218138-264810:-	-0.52	-7.43	1.38E-12	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs79888893	chr14:35510676	KIAA0391	chr14:35591776-35786673:+	0.38	4.1	5.48E-5	Atopic dermatitis	
OV	cis	1	rs8006419	chr14:65500735	CHURC1	chr14:65381140-65411309:+	-0.25	-3.92	0.000111	Red blood cell traits	
OV	cis	1	rs80085676	chr2:242347907	SEPT2	chr2:242254723-242293439:+	0.67	5.77	2.15E-8	Chronic lymphocytic leukemia	
OV	cis	1	rs8010715	chr14:24609147	FAM158A	chr14:24608175-24610797:-	-0.43	-7.37	1.98E-12	IgG glycosylation	
OV	cis	1	rs80109502	chr20:33587596	CPNE1	chr20:34213968-34262539:-	0.43	3.87	0.000138	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs8013540	chr14:35513760	KIAA0391	chr14:35591776-35786673:+	0.39	4.24	3.08E-5	Atopic dermatitis	
OV	cis	1	rs8013540	chr14:35513760	PPP2R3C	chr14:35554679-35591679:-	0.34	3.87	0.000135	Atopic dermatitis	
OV	cis	1	rs8018967	chr14:73976934	ACOT1	chr14:74003928-74042357:+	-0.29	-4.02	7.51E-5	Blood metabolite ratios	
OV	cis	1	rs8018967	chr14:73976934	HEATR4	chr14:73945193-74025651:-	-0.41	-6.51	3.47E-10	Blood metabolite ratios	
OV	cis	1	rs8021692	chr14:104428576	TDRD9	chr14:104394817-104519002:+	0.4	5.51	8.13E-8	Bipolar disorder	
OV	cis	1	rs8029247	chr15:56273446	RFX7	chr15:56379479-56535483:-	0.26	4.18	3.99E-5	Keloid	
OV	cis	1	rs8029247	chr15:56273446	TCF12	chr15:57210323-57580712:+	0.33	5.21	3.7E-7	Keloid	
OV	cis	1	rs8034191	chr15:78806023	IREB2	chr15:78730518-78793798:+	-0.26	-3.93	0.000108	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
OV	cis	1	rs8034191	chr15:78806023	WDR61	chr15:78575580-78591940:-	-0.28	-4.43	1.38E-5	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
OV	cis	1	rs808919	chr12:56647911	CNPY2	chr12:56704217-56710120:-	0.44	4.53	8.66E-6	Psoriasis vulgaris	
OV	cis	1	rs808919	chr12:56647911	CS	chr12:56665483-56694175:-	0.47	4.3	2.38E-5	Psoriasis vulgaris	
OV	cis	1	rs809367	chr10:89741806	ATAD1	chr10:89512875-89577917:-	0.58	6.1	3.48E-9	Parental extreme longevity (95 years and older)	
OV	cis	1	rs809367	chr10:89741806	FAM22A	chr10:88985205-88994731:+	0.4	4.44	1.29E-5	Parental extreme longevity (95 years and older)	
OV	cis	1	rs809367	chr10:89741806	FAM22D	chr10:89102493-89130452:+	0.37	4.17	4.06E-5	Parental extreme longevity (95 years and older)	
OV	cis	1	rs809367	chr10:89741806	FAM35A	chr10:88854953-88951220:+	0.39	4.35	1.94E-5	Parental extreme longevity (95 years and older)	
OV	cis	1	rs809367	chr10:89741806	GLUD1	chr10:88810246-88854623:-	0.45	4.93	1.39E-6	Parental extreme longevity (95 years and older)	
OV	cis	1	rs809367	chr10:89741806	MINPP1	chr10:89264223-89313168:+	0.49	5.42	1.27E-7	Parental extreme longevity (95 years and older)	
OV	cis	1	rs809775	chr1:46538040	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.11	9.91E-12	Body mass index	
OV	cis	1	rs8103622	chr19:18572834	SSBP4	chr19:18530221-18545371:+	-0.35	-4.37	1.73E-5	Breast cancer	
OV	cis	1	rs8105994	chr19:18593553	LSM4	chr19:18417718-18434001:-	-0.28	-4.27	2.64E-5	Breast cancer	
OV	cis	1	rs8105994	chr19:18593553	SSBP4	chr19:18530221-18545371:+	-0.46	-5.89	1.1E-8	Breast cancer	
OV	cis	1	rs8107367	chr19:18564705	SSBP4	chr19:18530221-18545371:+	-0.33	-4.14	4.63E-5	Breast cancer	
OV	cis	1	rs8113263	chr19:13179662	IL27RA	chr19:14142262-14164025:+	0.56	3.91	0.000114	Body mass index	
OV	cis	1	rs8117847	chr20:33642480	CPNE1	chr20:34213968-34262539:-	0.44	4.46	1.17E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs8117847	chr20:33642480	GSS	chr20:33516237-33543601:-	0.38	4.06	6.48E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs8118978	chr20:33574458	CPNE1	chr20:34213968-34262539:-	0.43	4.16	4.18E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs8119827	chr20:33726873	CPNE1	chr20:34213968-34262539:-	0.43	3.98	8.75E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
OV	cis	1	rs812047	chr3:122382074	PARP15	chr3:122296449-122355536:+	0.33	4.03	7.19E-5	Acoustic startle blink response	
OV	cis	1	rs8125868	chr20:25324410	ABHD12	chr20:25275380-25371477:-	-0.4	-6	6.29E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs8125868	chr20:25324410	FAM182B	chr20:25744102-25848786:-	-0.32	-4.87	1.91E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs8181644	chr12:58173466	FAM119B	chr12:58166383-58176323:+	0.35	5.01	9.82E-7	Multiple sclerosis	
OV	cis	1	rs8181644	chr12:58173466	TSFM	chr12:58176536-58191367:+	-0.35	-5.96	7.6E-9	Multiple sclerosis	
OV	cis	1	rs830124	chr12:122395777	WDR66	chr12:122356480-122441830:+	0.42	4.27	2.74E-5	Urinary metabolites	
OV	cis	1	rs832551	chr5:56180112	C5orf35	chr5:56205103-56213010:+	0.71	9.17	1.13E-17	Type 2 diabetes	
OV	cis	1	rs832553	chr5:56114786	C5orf35	chr5:56205103-56213010:+	0.72	9.4	2.14E-18	Type 2 diabetes	
OV	cis	1	rs832554	chr5:56115036	C5orf35	chr5:56205103-56213010:+	0.72	8.34	3.6E-15	Type 2 diabetes	
OV	cis	1	rs832565	chr5:56150803	C5orf35	chr5:56205103-56213010:+	0.71	9.37	2.69E-18	Type 2 diabetes	
OV	cis	1	rs832568	chr5:56153776	C5orf35	chr5:56205103-56213010:+	0.7	9.26	5.9E-18	Type 2 diabetes	
OV	cis	1	rs832569	chr5:56154584	C5orf35	chr5:56205103-56213010:+	0.7	9.26	5.9E-18	Type 2 diabetes	
OV	cis	1	rs832578	chr5:56164223	C5orf35	chr5:56205103-56213010:+	0.7	9.05	2.53E-17	Type 2 diabetes	
OV	cis	1	rs832582	chr5:56177743	C5orf35	chr5:56205103-56213010:+	0.71	9.19	9.83E-18	Type 2 diabetes	
OV	cis	1	rs832583	chr5:56178217	C5orf35	chr5:56205103-56213010:+	0.71	9.22	8.04E-18	Type 2 diabetes	
OV	cis	1	rs832584	chr5:56179212	C5orf35	chr5:56205103-56213010:+	-0.65	-8.81	1.43E-16	Type 2 diabetes	
OV	cis	1	rs854572	chr7:94954696	PON1	chr7:94927671-95025687:-	0.31	4.51	9.39E-6	Paraoxonase activity	
OV	cis	1	rs860580	chr5:56149429	C5orf35	chr5:56205103-56213010:+	-0.72	-9.85	7.9E-20	Type 2 diabetes	
OV	cis	1	rs861283	chr5:56184610	C5orf35	chr5:56205103-56213010:+	0.71	9.22	8.04E-18	Type 2 diabetes	
OV	cis	1	rs863840	chr5:56128999	C5orf35	chr5:56205103-56213010:+	0.71	10.59	3.25E-22	Type 2 diabetes	
OV	cis	1	rs866222	chr5:56184444	C5orf35	chr5:56205103-56213010:+	0.71	9.22	8.04E-18	Type 2 diabetes	
OV	cis	1	rs872863	chr9:126154354	LOC100129034	chr9:127115752-127121461:+	0.34	4.5	9.82E-6	Myopia (pathological)	
OV	cis	1	rs872863	chr9:126154354	NEK6	chr9:127019886-127114722:+	0.37	4.44	1.28E-5	Myopia (pathological)	
OV	cis	1	rs877636	chr12:56480583	RPS26	chr12:56435686-56438005:+	-0.41	-7.45	1.21E-12	Cognitive function	
OV	cis	1	rs882803	chr1:45976147	CCDC163P	chr1:45960581-45965646:-	-0.89	-14.64	2.39E-36	Homocysteine levels	
OV	cis	1	rs882803	chr1:45976147	MMACHC	chr1:45965856-45976737:+	-0.29	-4.08	5.81E-5	Homocysteine levels	
OV	cis	1	rs884613	chr20:25288505	ABHD12	chr20:25275380-25371477:-	-0.39	-5.8	1.84E-8	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs884613	chr20:25288505	FAM182B	chr20:25744102-25848786:-	-0.33	-5.14	5.23E-7	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs884841	chr6:86680300	SNHG5	chr6:86386726-86388451:-	-0.66	-11.06	8.49E-24	Response to antipsychotic treatment	
OV	cis	1	rs886448	chr7:24240165	C7orf30	chr7:23338940-23349182:+	-0.87	-6.94	2.8E-11	Asthma (childhood onset)	
OV	cis	1	rs886448	chr7:24240165	C7orf31	chr7:25174316-25219817:-	-0.6	-4.84	2.15E-6	Asthma (childhood onset)	
OV	cis	1	rs886448	chr7:24240165	C7orf46	chr7:23719749-23742268:+	-0.63	-5.12	5.72E-7	Asthma (childhood onset)	
OV	cis	1	rs886448	chr7:24240165	CCDC126	chr7:23636998-23684326:+	-0.89	-7.1	1.05E-11	Asthma (childhood onset)	
OV	cis	1	rs886448	chr7:24240165	CYCS	chr7:25158277-25164955:-	-0.86	-6.56	2.58E-10	Asthma (childhood onset)	
OV	cis	1	rs886448	chr7:24240165	MPP6	chr7:24613085-24727497:+	-0.73	-5.03	8.82E-7	Asthma (childhood onset)	
OV	cis	1	rs886448	chr7:24240165	OSBPL3	chr7:24836165-25019760:-	-0.73	-5.39	1.48E-7	Asthma (childhood onset)	
OV	cis	1	rs886448	chr7:24240165	TRA2A	chr7:23544402-23571656:-	-0.78	-5.55	6.65E-8	Asthma (childhood onset)	
OV	cis	1	rs891368	chr3:53123273	RFT1	chr3:53122503-53164470:-	-0.34	-4.77	3.0E-6	Height	
OV	cis	1	rs893902	chr15:67014742	DIS3L	chr15:66585633-66626235:+	-0.28	-4.21	3.43E-5	Waist-to-hip ratio adjusted for body mass index	
OV	cis	1	rs893902	chr15:67014742	MAP2K1	chr15:66679211-66783881:+	-0.35	-4.48	1.09E-5	Waist-to-hip ratio adjusted for body mass index	
OV	cis	1	rs893902	chr15:67014742	TIPIN	chr15:66629008-66649054:-	-0.33	-4.52	9.15E-6	Waist-to-hip ratio adjusted for body mass index	
OV	cis	1	rs898225	chr3:48413179	TREX1	chr3:48501186-48509043:+	0.24	4.48	1.08E-5	Longevity	
OV	cis	1	rs906134	chr7:65444288	CCT6P1	chr7:65216092-65228661:+	0.36	4.51	9.47E-6	Diabetic kidney disease	
OV	cis	1	rs910997	chr20:25267301	ABHD12	chr20:25275380-25371477:-	0.41	5.97	7.2E-9	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs910997	chr20:25267301	FAM182B	chr20:25744102-25848786:-	0.32	4.87	1.92E-6	Liver enzyme levels (alkaline phosphatase)	
OV	cis	1	rs919586	chr8:13174671	FAM66A	chr8:12219528-12279968:+	0.43	5.08	6.85E-7	Obesity-related traits	
OV	cis	1	rs919586	chr8:13174671	FAM86B2	chr8:12283126-12293864:-	0.51	5.78	2.0E-8	Obesity-related traits	
OV	cis	1	rs919586	chr8:13174671	LONRF1	chr8:12579406-12612992:-	0.5	5.73	2.68E-8	Obesity-related traits	
OV	cis	1	rs9213	chr2:218386	SH3YL1	chr2:218138-264810:-	-0.51	-7.07	1.27E-11	Spherical equivalent (joint main effects and education interaction)	
OV	cis	1	rs922075	chr3:48489398	TREX1	chr3:48501186-48509043:+	0.25	4.64	5.4E-6	Longevity	
OV	cis	1	rs9283717	chr5:56078659	C5orf35	chr5:56205103-56213010:+	0.7	8.87	9.13E-17	Type 2 diabetes	
OV	cis	1	rs9289275	chr3:125648659	LOC100125556	chr3:125635444-125648865:+	0.53	5.61	4.9E-8	Blood pressure (smoking interaction)	
OV	cis	1	rs9289471	chr3:134230811	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs9289475	chr3:134236459	ANAPC13	chr3:134196547-134204865:-	0.4	5.68	3.37E-8	Height	
OV	cis	1	rs9289476	chr3:134237103	ANAPC13	chr3:134196547-134204865:-	0.38	5.44	1.19E-7	Height	
OV	cis	1	rs9289478	chr3:134268619	ANAPC13	chr3:134196547-134204865:-	0.38	5.38	1.56E-7	Height	
OV	cis	1	rs9291659	chr4:17662360	LAP3	chr4:17578927-17609590:+	-0.27	-4.75	3.28E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs9296504	chr6:46629505	TDRD6	chr6:46655866-46670149:+	-0.27	-4.13	4.73E-5	QRS complex (Sokolow-Lyon)	
OV	cis	1	rs9296617	chr6:49428360	MUT	chr6:49398994-49431031:-	0.27	4.17	4.03E-5	Folate pathway vitamin levels	
OV	cis	1	rs9297216	chr8:34045261	C8orf41	chr8:33330904-33370703:-	0.44	5.01	9.7E-7	Asthma (childhood onset)	
OV	cis	1	rs9297216	chr8:34045261	MAK16	chr8:33342685-33358777:+	0.39	4.29	2.52E-5	Asthma (childhood onset)	
OV	cis	1	rs9297216	chr8:34045261	RNF122	chr8:33405273-33424643:-	0.42	4.78	2.86E-6	Asthma (childhood onset)	
OV	cis	1	rs9304270	chr18:39937509	PIK3C3	chr18:39535199-39661444:+	-0.34	-4.04	6.8E-5	Obesity-related traits	
OV	cis	1	rs9307050	chr4:76905649	NAAA	chr4:76831809-76862166:-	-0.28	-4.8	2.61E-6	Longevity	
OV	cis	1	rs9308910	chr2:240211698	MGC16025	chr2:240115027-240117153:-	0.55	4.06	6.47E-5	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs9309473	chr2:73743982	ALMS1P	chr2:73872046-73912692:+	0.38	5.79	1.95E-8	Metabolite levels	
OV	cis	1	rs9311288	chr3:41804581	ULK4	chr3:41288091-42003660:-	0.66	8.82	1.35E-16	Diastolic blood pressure	
OV	cis	1	rs9311423	chr3:48420308	TREX1	chr3:48501186-48509043:+	-0.26	-4.86	2.01E-6	Longevity	
OV	cis	1	rs934093	chr3:134195885	ANAPC13	chr3:134196547-134204865:-	0.43	6.06	4.53E-9	Height	
OV	cis	1	rs936332	chr12:52640277	LOC283404	chr12:52604714-52617595:+	-0.28	-3.91	0.000117	Diisocyanate-induced asthma	
OV	cis	1	rs937108	chr7:65428452	CCT6P1	chr7:65216092-65228661:+	0.36	4.46	1.17E-5	Diabetic kidney disease	
OV	cis	1	rs9376050	chr6:134910136	HBS1L	chr6:135281517-135376036:-	0.31	4.19	3.83E-5	Melanoma	
OV	cis	1	rs9381784	chr6:49398115	CENPQ	chr6:49431096-49460820:+	0.24	3.92	0.000112	Homocysteine levels	
OV	cis	1	rs9394931	chr6:42873245	PEX6	chr6:42931613-42946981:-	-0.37	-5.62	4.76E-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
OV	cis	1	rs939558	chr3:41976040	ULK4	chr3:41288091-42003660:-	-0.69	-9.21	8.33E-18	Diastolic blood pressure	
OV	cis	1	rs941653	chr14:35592538	KIAA0391	chr14:35591776-35786673:+	0.43	4.65	5.23E-6	Atopic dermatitis	
OV	cis	1	rs941653	chr14:35592538	PPP2R3C	chr14:35554679-35591679:-	0.39	4.41	1.5E-5	Atopic dermatitis	
OV	cis	1	rs9420782	chr10:102235015	SEC31B	chr10:102246403-102289636:-	-0.24	-3.89	0.000126	Palmitoleic acid (16:1n-7) plasma levels	
OV	cis	1	rs9429183	chr1:46524582	CCDC163P	chr1:45960581-45965646:-	-0.48	-7.18	6.32E-12	Body mass index	
OV	cis	1	rs945635	chr1:157670290	FCRL3	chr1:157646278-157670775:-	0.27	4.52	9.31E-6	Type 1 diabetes autoantibodies	
OV	cis	1	rs9463473	chr6:49380121	MUT	chr6:49398994-49431031:-	0.27	4.17	4.05E-5	Folate pathway vitamin levels	
OV	cis	1	rs9463474	chr6:49380199	MUT	chr6:49398994-49431031:-	0.27	4.17	4.05E-5	Folate pathway vitamin levels	
OV	cis	1	rs9463475	chr6:49380899	MUT	chr6:49398994-49431031:-	-0.28	-4.36	1.86E-5	Folate pathway vitamin levels	
OV	cis	1	rs9463477	chr6:49386446	MUT	chr6:49398994-49431031:-	0.27	4.17	4.11E-5	Folate pathway vitamin levels	
OV	cis	1	rs9463479	chr6:49393275	MUT	chr6:49398994-49431031:-	0.27	4.23	3.16E-5	Folate pathway vitamin levels	
OV	cis	1	rs9463480	chr6:49400795	MUT	chr6:49398994-49431031:-	0.28	4.19	3.82E-5	Folate pathway vitamin levels	
OV	cis	1	rs946529	chr1:46485548	CCDC163P	chr1:45960581-45965646:-	-0.46	-6.96	2.4E-11	Body mass index	
OV	cis	1	rs9472819	chr6:46653789	TDRD6	chr6:46655866-46670149:+	-0.29	-3.91	0.000116	Lipoprotein-associated phospholipase A2 activity and mass	
OV	cis	1	rs9473552	chr6:49387154	MUT	chr6:49398994-49431031:-	0.27	4.17	4.11E-5	Folate pathway vitamin levels	
OV	cis	1	rs9473553	chr6:49395977	MUT	chr6:49398994-49431031:-	0.28	4.29	2.43E-5	Folate pathway vitamin levels	
OV	cis	1	rs9473555	chr6:49409487	MUT	chr6:49398994-49431031:-	0.27	4.13	4.78E-5	Folate pathway vitamin levels	
OV	cis	1	rs9473560	chr6:49427918	MUT	chr6:49398994-49431031:-	0.27	4.17	4.03E-5	Folate pathway vitamin levels	
OV	cis	1	rs9473561	chr6:49428755	MUT	chr6:49398994-49431031:-	0.27	4.17	4.03E-5	Folate pathway vitamin levels	
OV	cis	1	rs950027	chr15:45801035	SPATA5L1	chr15:45694519-45713614:+	-0.24	-4.04	7.06E-5	Response to fenofibrate (adiponectin levels)	
OV	cis	1	rs951366	chr1:205685352	PM20D1	chr1:205797154-205819245:-	-0.33	-4.62	5.78E-6	Menarche (age at onset)	
OV	cis	1	rs9527	chr10:104623578	C10orf32	chr10:104613967-104624718:+	-0.39	-5.05	8.02E-7	Arsenic metabolism	
OV	cis	1	rs955196	chr6:86729951	SNHG5	chr6:86386726-86388451:-	0.7	11.64	9.1E-26	Response to antipsychotic treatment	
OV	cis	1	rs955197	chr6:86729675	SNHG5	chr6:86386726-86388451:-	-0.7	-11.46	3.71E-25	Response to antipsychotic treatment	
OV	cis	1	rs9556806	chr13:98378831	FARP1	chr13:98794816-99102016:+	-0.35	-4.7	4.09E-6	Peripheral artery disease	
OV	cis	1	rs957644	chr1:165616157	MGST3	chr1:165600450-165624853:+	0.28	4.8	2.55E-6	Total ventricular volume	
OV	cis	1	rs959617	chr1:165616881	MGST3	chr1:165600450-165624853:+	0.28	4.98	1.13E-6	Total ventricular volume	
OV	cis	1	rs9643597	chr8:69740413	C8orf34	chr8:69243457-69731256:+	0.45	4.92	1.49E-6	Obesity-related traits	
OV	cis	1	rs9643598	chr8:69742300	C8orf34	chr8:69243457-69731256:+	-0.39	-4.21	3.42E-5	Obesity-related traits	
OV	cis	1	rs9647603	chr6:86639341	SNHG5	chr6:86386726-86388451:-	-0.66	-11.67	7.28E-26	Response to antipsychotic treatment	
OV	cis	1	rs9653557	chr2:73795962	ALMS1P	chr2:73872046-73912692:+	0.37	5.85	1.41E-8	Metabolite levels	
OV	cis	1	rs9661504	chr1:205915667	DSTYK	chr1:205111632-205180727:-	0.23	3.86	0.000138	Cystic fibrosis-related diabetes	
OV	cis	1	rs9661596	chr1:171652664	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.37E-6	Hippocampal atrophy	
OV	cis	1	rs9662174	chr1:171652144	VAMP4	chr1:171669298-171711214:-	0.37	4.6	6.37E-6	Hippocampal atrophy	
OV	cis	1	rs9662506	chr1:171655984	VAMP4	chr1:171669298-171711214:-	0.35	4.27	2.65E-5	Hippocampal atrophy	
OV	cis	1	rs9689	chr1:25688276	RHCE	chr1:25688741-25756683:-	0.32	5.15	4.84E-7	Erythrocyte sedimentation rate	
OV	cis	1	rs9689	chr1:25688276	RHD	chr1:25598981-25656935:+	-0.55	-9.92	4.82E-20	Erythrocyte sedimentation rate	
OV	cis	1	rs9783304	chr11:43660255	HSD17B12	chr11:43702143-43878160:+	0.42	6.28	1.34E-9	Forced vital capacity	
OV	cis	1	rs980944	chr3:114929512	ZNF80	chr3:113953478-113956425:-	-0.36	-4	8.21E-5	Type 2 diabetes	
OV	cis	1	rs9809619	chr3:134280948	ANAPC13	chr3:134196547-134204865:-	0.41	5.73	2.63E-8	Height	
OV	cis	1	rs9809843	chr3:48434398	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs9812647	chr3:48448914	TREX1	chr3:48501186-48509043:+	0.27	5.25	3.03E-7	Longevity	
OV	cis	1	rs9813712	chr3:129971101	COL6A4P2	chr3:129931663-129992648:+	0.33	4.33	2.11E-5	Response to amphetamines	
OV	cis	1	rs9813774	chr3:134227100	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs9814567	chr3:134218557	ANAPC13	chr3:134196547-134204865:-	-0.37	-5.2	3.96E-7	Height	
OV	cis	1	rs9815103	chr3:48414215	TREX1	chr3:48501186-48509043:+	-0.25	-4.58	7.17E-6	Longevity	
OV	cis	1	rs9815319	chr3:114792654	ZNF80	chr3:113953478-113956425:-	0.39	4.26	2.79E-5	Type 2 diabetes	
OV	cis	1	rs9815354	chr3:41912651	ULK4	chr3:41288091-42003660:-	0.58	7.15	7.53E-12	Diastolic blood pressure	
OV	cis	1	rs9817615	chr3:48470756	TREX1	chr3:48501186-48509043:+	-0.27	-5.06	7.56E-7	Longevity	
OV	cis	1	rs9818169	chr3:41860599	ULK4	chr3:41288091-42003660:-	0.59	7.5	8.81E-13	Diastolic blood pressure	
OV	cis	1	rs9818982	chr3:45812514	SACM1L	chr3:45730754-45786900:+	-0.36	-4.08	6.01E-5	Blood metabolite levels	
OV	cis	1	rs9819532	chr3:134288644	ANAPC13	chr3:134196547-134204865:-	0.41	5.72	2.73E-8	Height	
OV	cis	1	rs9820192	chr3:41889281	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs9823254	chr3:41894768	ULK4	chr3:41288091-42003660:-	0.6	7.38	1.9E-12	Diastolic blood pressure	
OV	cis	1	rs9824731	chr3:41889698	ULK4	chr3:41288091-42003660:-	0.61	7.51	8.37E-13	Diastolic blood pressure	
OV	cis	1	rs9825741	chr3:41761828	ULK4	chr3:41288091-42003660:-	-0.6	-8.06	2.27E-14	Diastolic blood pressure	
OV	cis	1	rs9826058	chr3:41762062	ULK4	chr3:41288091-42003660:-	0.58	7.74	1.92E-13	Diastolic blood pressure	
OV	cis	1	rs9826195	chr3:48433635	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs9826496	chr3:134224437	ANAPC13	chr3:134196547-134204865:-	0.41	5.75	2.41E-8	Height	
OV	cis	1	rs9827987	chr3:134272621	ANAPC13	chr3:134196547-134204865:-	0.42	5.82	1.62E-8	Height	
OV	cis	1	rs9828398	chr3:41895893	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs9828815	chr3:134265749	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs9829092	chr3:134229866	ANAPC13	chr3:134196547-134204865:-	0.4	5.5	8.48E-8	Height	
OV	cis	1	rs9830064	chr3:41881801	ULK4	chr3:41288091-42003660:-	0.63	8.36	3.05E-15	Diastolic blood pressure	
OV	cis	1	rs9830469	chr3:41762535	ULK4	chr3:41288091-42003660:-	0.58	7.74	1.92E-13	Diastolic blood pressure	
OV	cis	1	rs9830947	chr3:114815878	ZNF80	chr3:113953478-113956425:-	0.36	3.93	0.000108	Type 2 diabetes	
OV	cis	1	rs9832785	chr3:134213070	ANAPC13	chr3:134196547-134204865:-	0.41	5.85	1.4E-8	Height	
OV	cis	1	rs9834098	chr3:41833493	ULK4	chr3:41288091-42003660:-	0.6	7.74	1.87E-13	Diastolic blood pressure	
OV	cis	1	rs9834755	chr3:134206845	ANAPC13	chr3:134196547-134204865:-	0.43	6.05	4.69E-9	Height	
OV	cis	1	rs9835204	chr3:134261342	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs9837038	chr3:156568469	LEKR1	chr3:156544076-156763918:+	-0.39	-6.32	1.04E-9	Multiple sclerosis (severity)	
OV	cis	1	rs9838618	chr3:48487353	TREX1	chr3:48501186-48509043:+	-0.3	-5.75	2.3E-8	Longevity	
OV	cis	1	rs9838965	chr3:41927938	ULK4	chr3:41288091-42003660:-	-0.63	-8.38	2.69E-15	Diastolic blood pressure	
OV	cis	1	rs9839399	chr3:41928044	ULK4	chr3:41288091-42003660:-	-0.63	-8.38	2.69E-15	Diastolic blood pressure	
OV	cis	1	rs9840037	chr3:41827522	ULK4	chr3:41288091-42003660:-	0.6	7.68	2.8E-13	Diastolic blood pressure	
OV	cis	1	rs9840532	chr3:41885697	ULK4	chr3:41288091-42003660:-	0.64	8.48	1.32E-15	Diastolic blood pressure	
OV	cis	1	rs9841212	chr3:134191938	ANAPC13	chr3:134196547-134204865:-	0.43	6.25	1.53E-9	Height	
OV	cis	1	rs984222	chr1:119503843	WARS2	chr1:119573841-119683295:-	-0.29	-4.13	4.78E-5	Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio	
OV	cis	1	rs9842261	chr3:41822708	ULK4	chr3:41288091-42003660:-	-0.61	-8.46	1.54E-15	Diastolic blood pressure	
OV	cis	1	rs9842305	chr3:41998412	ULK4	chr3:41288091-42003660:-	-0.67	-9.11	1.66E-17	Diastolic blood pressure	
OV	cis	1	rs9846634	chr3:41894049	ULK4	chr3:41288091-42003660:-	0.61	7.5	8.47E-13	Diastolic blood pressure	
OV	cis	1	rs9847006	chr3:41755359	ULK4	chr3:41288091-42003660:-	0.6	8.1	1.77E-14	Diastolic blood pressure	
OV	cis	1	rs9847710	chr3:53062661	ITIH4	chr3:52847007-52866554:-	-0.2	-4.12	5.08E-5	Ulcerative colitis	
OV	cis	1	rs9847975	chr3:41786904	ULK4	chr3:41288091-42003660:-	0.6	7.26	3.98E-12	Diastolic blood pressure	
OV	cis	1	rs9848754	chr3:41753647	ULK4	chr3:41288091-42003660:-	0.55	6.76	8.15E-11	Diastolic blood pressure	
OV	cis	1	rs9849509	chr3:48483432	TREX1	chr3:48501186-48509043:+	-0.27	-5.16	4.76E-7	Longevity	
OV	cis	1	rs9850015	chr3:134269541	ANAPC13	chr3:134196547-134204865:-	0.42	5.82	1.62E-8	Height	
OV	cis	1	rs9851441	chr3:134315091	ANAPC13	chr3:134196547-134204865:-	0.38	5.28	2.6E-7	Height	
OV	cis	1	rs9852303	chr3:41759525	ULK4	chr3:41288091-42003660:-	0.61	8.21	8.56E-15	Diastolic blood pressure	
OV	cis	1	rs9854299	chr3:134206728	ANAPC13	chr3:134196547-134204865:-	0.41	5.85	1.37E-8	Height	
OV	cis	1	rs9854833	chr3:41775577	ULK4	chr3:41288091-42003660:-	0.56	7.05	1.45E-11	Diastolic blood pressure	
OV	cis	1	rs9854838	chr3:41805670	ULK4	chr3:41288091-42003660:-	0.66	8.82	1.35E-16	Diastolic blood pressure	
OV	cis	1	rs9855965	chr3:41860508	ULK4	chr3:41288091-42003660:-	0.59	7.5	8.81E-13	Diastolic blood pressure	
OV	cis	1	rs9856088	chr3:41860482	ULK4	chr3:41288091-42003660:-	0.59	7.5	8.81E-13	Diastolic blood pressure	
OV	cis	1	rs9856633	chr3:42013850	ULK4	chr3:41288091-42003660:-	0.69	9.21	8.33E-18	Diastolic blood pressure	
OV	cis	1	rs9856693	chr3:134306913	ANAPC13	chr3:134196547-134204865:-	0.39	5.39	1.52E-7	Height	
OV	cis	1	rs9857175	chr3:41822054	ULK4	chr3:41288091-42003660:-	0.64	8.63	4.76E-16	Diastolic blood pressure	
OV	cis	1	rs9863786	chr3:134247203	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs9863915	chr3:41762002	ULK4	chr3:41288091-42003660:-	0.61	8.21	8.56E-15	Diastolic blood pressure	
OV	cis	1	rs986417	chr14:60858761	C14orf135	chr14:60558629-60635851:+	-0.31	-3.93	0.000107	Gut microbiota (bacterial taxa)	
OV	cis	1	rs9864217	chr3:41762206	ULK4	chr3:41288091-42003660:-	0.56	7.03	1.64E-11	Diastolic blood pressure	
OV	cis	1	rs9864346	chr3:134312352	ANAPC13	chr3:134196547-134204865:-	0.4	5.53	7.41E-8	Height	
OV	cis	1	rs9864371	chr3:48426766	TREX1	chr3:48501186-48509043:+	-0.27	-5	1.02E-6	Longevity	
OV	cis	1	rs9864439	chr3:134298671	ANAPC13	chr3:134196547-134204865:-	0.39	5.34	1.93E-7	Height	
OV	cis	1	rs9864582	chr3:129970462	COL6A4P2	chr3:129931663-129992648:+	0.36	4.71	3.93E-6	Response to amphetamines	
OV	cis	1	rs9865127	chr3:41807448	ULK4	chr3:41288091-42003660:-	0.66	8.82	1.35E-16	Diastolic blood pressure	
OV	cis	1	rs9865780	chr3:41895802	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs9865905	chr3:156649594	LEKR1	chr3:156544076-156763918:+	0.37	6.05	4.67E-9	Multiple sclerosis (severity)	
OV	cis	1	rs9866092	chr3:41895967	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs9866759	chr3:41758418	ULK4	chr3:41288091-42003660:-	0.6	8.1	1.77E-14	Diastolic blood pressure	
OV	cis	1	rs9867627	chr3:41795841	ULK4	chr3:41288091-42003660:-	-0.62	-7.87	7.95E-14	Diastolic blood pressure	
OV	cis	1	rs9869207	chr3:41878661	ULK4	chr3:41288091-42003660:-	0.64	8.5	1.19E-15	Diastolic blood pressure	
OV	cis	1	rs9869282	chr3:41756064	ULK4	chr3:41288091-42003660:-	0.6	8.1	1.77E-14	Diastolic blood pressure	
OV	cis	1	rs9869440	chr3:41763155	ULK4	chr3:41288091-42003660:-	0.6	7.95	4.8E-14	Diastolic blood pressure	
OV	cis	1	rs9869981	chr3:134248801	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs9871305	chr3:134213538	ANAPC13	chr3:134196547-134204865:-	0.4	5.5	8.48E-8	Height	
OV	cis	1	rs9873207	chr3:41884750	ULK4	chr3:41288091-42003660:-	0.61	7.51	8.37E-13	Diastolic blood pressure	
OV	cis	1	rs9874513	chr3:41909508	ULK4	chr3:41288091-42003660:-	0.58	7.15	7.53E-12	Diastolic blood pressure	
OV	cis	1	rs9874517	chr3:53128371	SFMBT1	chr3:52938628-53080070:-	-0.41	-4.04	7.03E-5	Immune reponse to smallpox (secreted IL-2)	
OV	cis	1	rs9875083	chr3:41775786	ULK4	chr3:41288091-42003660:-	0.56	7.05	1.45E-11	Diastolic blood pressure	
OV	cis	1	rs9875107	chr3:41822313	ULK4	chr3:41288091-42003660:-	0.65	8.6	5.92E-16	Diastolic blood pressure	
OV	cis	1	rs9876658	chr3:134179453	ANAPC13	chr3:134196547-134204865:-	-0.4	-5.62	4.66E-8	Height	
OV	cis	1	rs9876781	chr3:48487338	TREX1	chr3:48501186-48509043:+	-0.26	-4.93	1.43E-6	Longevity	
OV	cis	1	rs9876960	chr3:41985812	ULK4	chr3:41288091-42003660:-	-0.67	-9.11	1.66E-17	Diastolic blood pressure	
OV	cis	1	rs9881491	chr3:48487911	TREX1	chr3:48501186-48509043:+	-0.29	-5.58	5.7E-8	Longevity	
OV	cis	1	rs9883753	chr3:134247231	ANAPC13	chr3:134196547-134204865:-	0.38	5.38	1.56E-7	Height	
OV	cis	1	rs9883759	chr3:48463618	TREX1	chr3:48501186-48509043:+	-0.28	-5.26	2.85E-7	Longevity	
OV	cis	1	rs9883927	chr3:48463711	TREX1	chr3:48501186-48509043:+	-0.27	-5.06	7.56E-7	Longevity	
OV	cis	1	rs9884031	chr3:134256500	ANAPC13	chr3:134196547-134204865:-	0.4	5.63	4.45E-8	Height	
OV	cis	1	rs992603	chr2:199027024	BOLL	chr2:198591603-198650938:-	-0.45	-4.86	1.96E-6	Hip bone size	
OV	cis	1	rs9938630	chr16:29837108	MVP	chr16:29831787-29859342:+	-0.26	-4.27	2.67E-5	Multiple sclerosis	
OV	cis	1	rs9968172	chr3:134231251	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.43	1.24E-7	Height	
OV	cis	1	rs9985356	chr3:134232920	ANAPC13	chr3:134196547-134204865:-	-0.32	-4.56	7.83E-6	Height	
OV	cis	1	rs9986596	chr6:28219661	ZNF389	chr6:28129551-28137375:+	-0.41	-4.52	9.13E-6	Depression	
OV	cis	1	rs9989967	chr3:134238964	ANAPC13	chr3:134196547-134204865:-	0.37	5.28	2.58E-7	Height	
OV	cis	1	rs9990351	chr3:134239191	ANAPC13	chr3:134196547-134204865:-	-0.35	-5.1	6.4E-7	Height	
OV	cis	1	rs9991307	chr4:17662408	LAP3	chr4:17578927-17609590:+	-0.27	-4.75	3.28E-6	Parasitemia in Tripanosoma cruzi seropositivity	
OV	cis	1	rs999302	chr2:240213843	MGC16025	chr2:240115027-240117153:-	0.52	4.01	7.68E-5	Perioperative myocardial infarction in coronary artery bypass surgery	
OV	cis	1	rs9995007	chr4:76897791	NAAA	chr4:76831809-76862166:-	-0.28	-4.71	3.9E-6	Longevity	
OV	trans	1	rs10794671	chr1:121168242	NBPF14	chr1:148003643-148346791:-	0.34	6.08	3.88E-9	Hip geometry	
OV	trans	1	rs10903159	chr1:121181997	NBPF14	chr1:148003643-148346791:-	0.34	6.17	2.44E-9	Hip geometry	
OV	trans	1	rs11000019	chr10:73591530	CISD1	chr10:60028895-60049018:+	0.59	6.15	2.75E-9	Asthma (childhood onset)	
OV	trans	1	rs11000019	chr10:73591530	DDX50	chr10:70661034-70706602:+	0.75	6.67	1.36E-10	Asthma (childhood onset)	
OV	trans	1	rs11000019	chr10:73591530	SAR1A	chr10:71909967-71930285:-	0.7	6.08	3.92E-9	Asthma (childhood onset)	
OV	trans	1	rs11249350	chr1:121178446	NBPF14	chr1:148003643-148346791:-	0.34	6.17	2.41E-9	Hip geometry	
OV	trans	1	rs12047116	chr1:121185770	NBPF14	chr1:148003643-148346791:-	0.34	6.27	1.38E-9	Hip geometry	
OV	trans	1	rs1591882	chr1:121183313	NBPF14	chr1:148003643-148346791:-	0.34	6.1	3.49E-9	Hip geometry	
OV	trans	1	rs1856572	chr1:121169579	NBPF14	chr1:148003643-148346791:-	0.34	6.08	3.88E-9	Hip geometry	
OV	trans	1	rs1986111	chr1:121204788	NBPF14	chr1:148003643-148346791:-	0.34	6.1	3.46E-9	Hip geometry	
OV	trans	1	rs2185281	chr1:121179991	NBPF14	chr1:148003643-148346791:-	0.34	6.08	4.01E-9	Hip geometry	
OV	trans	1	rs2292239	chr12:56482180	RPS26P11	chrX:71264259-71264809:+	0.47	7.41	1.5E-12	Cognitive function	
OV	trans	1	rs2381543	chr9:7057850	C20orf177	chr20:58508819-58522559:+	0.6	6.14	2.84E-9	Response to fenofibrate (adiponectin levels)	
OV	trans	1	rs35141484	chr4:39088341	SLC30A9	chr4:41992523-42089550:+	-0.69	-6.16	2.54E-9	Asthma (childhood onset)	
OV	trans	1	rs35141484	chr4:39088341	TMEM33	chr4:41937137-41962824:+	-0.73	-6.04	4.83E-9	Asthma (childhood onset)	
OV	trans	1	rs41433250	chr13:31495835	NUPL1	chr13:25875666-25916560:+	0.66	6.4	6.76E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	trans	1	rs41433250	chr13:31495835	PAN3	chr13:28712643-28869469:+	0.7	7.29	3.31E-12	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	trans	1	rs41433250	chr13:31495835	POMP	chr13:29233241-29253091:+	0.53	6.58	2.32E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	trans	1	rs41433250	chr13:31495835	RFC3	chr13:34392206-34540694:+	0.61	6.29	1.23E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	trans	1	rs41433250	chr13:31495835	SLC7A1	chr13:30083552-30169825:-	0.66	6.06	4.54E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
OV	trans	1	rs4272382	chr8:8433488	AGPAT5	chr8:6565878-6619019:+	-0.62	-6.16	2.53E-9	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	FDFT1	chr8:11653082-11696817:+	-0.58	-6.44	5.32E-10	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	MCPH1	chr8:6264121-6506025:+	-0.65	-6.48	4.17E-10	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	MTMR9	chr8:11142000-11185652:+	-0.64	-7.05	1.41E-11	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	PCM1	chr8:17780366-17887455:+	-0.57	-6.56	2.66E-10	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	PINX1	chr8:10622884-10697299:-	-0.67	-6.94	2.82E-11	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	POLR3D	chr8:22102619-22108679:+	-0.6	-6.39	7.08E-10	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	VPS37A	chr8:17104401-17155532:+	-0.59	-6.06	4.4E-9	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs4272382	chr8:8433488	XPO7	chr8:21777180-21864095:+	-0.62	-6.17	2.38E-9	Response to cytidine analogues (gemcitabine)	
OV	trans	1	rs459745	chr21:28656402	MGC2889	chr3:192959568-192961760:+	0.55	6.1	3.58E-9	Liver enzyme levels (aspartate transaminase)	
OV	trans	1	rs4759229	chr12:56474480	RPS26P11	chrX:71264259-71264809:+	-0.51	-8.29	4.94E-15	Cognitive function	
OV	trans	1	rs4844381	chr1:121184898	NBPF14	chr1:148003643-148346791:-	0.34	6.15	2.71E-9	Hip geometry	
OV	trans	1	rs4844607	chr1:121184059	NBPF14	chr1:148003643-148346791:-	-0.34	-6.09	3.76E-9	Hip geometry	
OV	trans	1	rs4844616	chr1:121171208	NBPF14	chr1:148003643-148346791:-	0.34	6.15	2.63E-9	Hip geometry	
OV	trans	1	rs705696	chr12:56480648	RPS26P11	chrX:71264259-71264809:+	0.5	7.79	1.33E-13	Cognitive function	
OV	trans	1	rs7532615	chr1:121172840	NBPF14	chr1:148003643-148346791:-	-0.34	-6.28	1.27E-9	Hip geometry	
OV	trans	1	rs809367	chr10:89741806	WAPAL	chr10:88195014-88281541:-	0.45	6.17	2.4E-9	Parental extreme longevity (95 years and older)	
OV	trans	1	rs877636	chr12:56480583	RPS26P11	chrX:71264259-71264809:+	-0.49	-7.88	7.3E-14	Cognitive function	
OV	trans	1	rs886448	chr7:24240165	CBX3	chr7:26241099-26252974:+	-0.93	-6.96	2.44E-11	Asthma (childhood onset)	
OV	trans	1	rs886448	chr7:24240165	KLHL7	chr7:23145353-23215036:+	-0.94	-7.65	3.41E-13	Asthma (childhood onset)	
OV	trans	1	rs886448	chr7:24240165	LSM5	chr7:32524945-32534870:-	-0.75	-6.22	1.78E-9	Asthma (childhood onset)	
OV	trans	1	rs886448	chr7:24240165	NUPL2	chr7:23221446-23240629:+	-0.89	-6.45	4.87E-10	Asthma (childhood onset)	
OV	trans	1	rs886448	chr7:24240165	SNX13	chr7:17830386-17980131:-	-0.99	-6.73	9.75E-11	Asthma (childhood onset)	
OV	trans	1	rs886448	chr7:24240165	TOMM7	chr7:22852254-22862421:-	-0.76	-6.56	2.6E-10	Asthma (childhood onset)	
OV	trans	1	rs886448	chr7:24240165	TWISTNB	chr7:19735085-19748660:-	-0.96	-6.24	1.62E-9	Asthma (childhood onset)	
OV	trans	1	rs919586	chr8:13174671	ATP6V1B2	chr8:20054704-20079205:+	0.47	6.15	2.76E-9	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	CNOT7	chr8:17086740-17104387:-	0.6	6.97	2.38E-11	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	ERI1	chr8:8860314-8890849:+	0.6	6.84	5.16E-11	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	KIAA1967	chr8:22462257-22477981:+	0.53	6.59	2.27E-10	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	MCPH1	chr8:6264121-6506025:+	0.6	6.72	1.0E-10	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	MTMR9	chr8:11142000-11185652:+	0.57	6.99	2.04E-11	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	PCM1	chr8:17780366-17887455:+	0.54	7.05	1.42E-11	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	PINX1	chr8:10622884-10697299:-	0.53	6.03	5.34E-9	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	TNKS	chr8:9413445-9639855:+	0.57	7.04	1.52E-11	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	VPS37A	chr8:17104401-17155532:+	0.53	6.05	4.78E-9	Obesity-related traits	
OV	trans	1	rs919586	chr8:13174671	XPO7	chr8:21777180-21864095:+	0.54	6.08	3.88E-9	Obesity-related traits	
OV	trans	1	rs9295695	chr6:26528250	ZNF322B	chr9:99957633-99961910:-	-0.75	-13.93	8.78E-34	Educational attainment	
OV	trans	1	rs9467787	chr6:26556769	ZNF322B	chr9:99957633-99961910:-	0.73	13.73	4.62E-33	Educational attainment	
OV	trans	1	rs9467791	chr6:26562486	ZNF322B	chr9:99957633-99961910:-	-0.73	-13.86	1.49E-33	Educational attainment	
OV	trans	1	rs992137	chr2:31584035	RGPD8	chr2:113125966-113192062:-	0.54	6.11	3.4E-9	Multiple system atrophy	
OV	trans	1	rs992138	chr2:31584321	RGPD8	chr2:113125966-113192062:-	0.54	6.11	3.4E-9	Multiple system atrophy	
